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Thesis Outline 
This thesis will examine monogenetic forms of primary dystonia related to TOR1A, 
THAP1 and GCH1 genes with a focus on genetic and neuropathological 
investigation. Further, this thesis discusses the neuropathology of genetic disorders 
under the neurodegeneration with brain iron accumulation (NBIA) spectrum, Beta- 
propeller protein associated neurodegeneration (BPAN) and neuroacanthocytosis. 
The genetics of spinocerebellar ataxia 8 will be discussed. This thesis also discusses 
the possibility of a common pathology for the lysosomal storage disorders (LSDs) 
impinging on ceramide pathway. 
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Abstracts 
Dystonia 1 (DYT1) abstract 
Early onset primary dystonia, DYT1 is linked to a three base pair deletion (ΔGAG) 
mutation in the TOR1A gene. Clinical manifestation includes intermittent muscle 
contraction leading to twisted movements or abnormal postures. 
Neuropathological studies on DYT1 cases are limited, most showing no significant 
abnormalities. In one study, brainstem intraneuronal inclusions immunoreactive for 
ubiquitin, torsinA and lamin A/C were described. Using the largest cohort of DYT1 
cases reported to date we aimed to identify consistent neuropathological features 
in the disease and determine whether we would find the same intraneuronal 
inclusions as previously reported. Sanger sequencing was used to screen all the 
cases for (ΔGAG) mutation in TOR1A gene. Using immunohistochemistry seven 
DYT1 cases and five age and sex matched controls were studied for the presence of 
ubiquitinated inclusions in the brainstem and other anatomical regions implicated 
in dystonia. The pathological changes of brainstem inclusions reported in DYT1 
dystonia were not replicated in our cohort. Other anatomical regions implicated in 
dystonia showed no disease-specific pathological intracellular inclusions or 
evidence of more than mild neuronal loss. Our findings suggest that the 
intracellular inclusions described previously in DYT1 dystonia may not be a hallmark 
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feature of the disorder. In DYT1, biochemical changes may be more relevant than 
the morphological changes. 
Dystonia 6 (DYT6) abstract 
Mutations in the thanatos-associated protein domain containing, apoptosis 
associated protein 1 gene (THAP1) are responsible for the adult-onset primary 
dystonia (DYT6).  However, no neuropathological descriptions of genetically proven 
DYT6 cases have been reported to our knowledge. We report the clinical, genetic 
and neuropathological features of two DYT6 cases. The two DYT6 cases were 
genetically screened for the THAP1 gene mutations using standard Sanger 
polymerase chain reaction sequencing. A detailed neuropathological assessment of 
the cases was performed using histochemical and immunohistochemical 
preparations. Both DYT6 cases showed no significant neurodegeneration and no 
specific disease-related pathology. This is the first detailed neuropthological 
investigation carried out on adult-onset primary dystonia, DYT6 brains. We did not 
identify any neuropathological features that could be defined as hallmark features 
of DYT6 dystonia. Our study supports the notion that in primary dystonia there is 
no significant neurodegeneration or associated neuropathological lesions.  
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Dopa-responsive dystonia (DRD) abstract 
Autosomal dominant hereditary dopa-responsive dystonia (DYT5) is a rare 
movement disorder which presents typically in childhood with lower limb dystonia 
and subsequent generalization. Mutations in the GCH1 gene on chromosome 14 
q21.1-q22.2 are pathogenic in DYT5. The hallmark of the disease is an excellent and 
sustained response to small doses of levodopa, generally without the occurrence of 
motor fluctuations. The majority of DRD associated mutations lie within the coding 
region of the GCH1 gene, but three additional single nucleotide sequence 
substitutions have been reported within the 5’ untranslated (5’UTR) region of the 
gene. To determine if noncoding mutations in the 5’ upstream region of GCH1 gene 
are pathogenic in DYT5 dystonia Sanger sequencing of the region was carried out in 
a cohort of DRD cases negative for mutation in the coding regions of the GCH1 
gene. Two unrelated cases were identified with both -39C>T and -132C>T 
mutations in the 5’ UTR of GCH1 gene. However, one of the cases has an affected 
sibling without these mutations. Functional study identified negligible effect of 
these two mutations. Hence, in the DRD cohort studied, there is not enough 
evidence to conclude that the two non-coding variants underlie the disease 
manifestation.  
  
 P a g e  | xviii 
Spinocerebellar ataxia type 8 (SCA8) abstract 
SCA8 is characterized by repeat instability and presents as an ataxia with slow 
progression that largely spares brainstem and cerebral function. There is no 
anticipation observed and penetrance is reduced as the expansion can also be 
found in healthy individuals. Potentially pathogenic alleles contain 85 or more 
combined CTA/CTG repeats. However, repeats of this size are surprisingly frequent 
in the general population and also occur in asymptomatic relatives of ataxia 
individuals. This study examined the length of SCA8 repeats in English ataxia 
patients, English controls and in diversity (from 25 different countries) controls. In 
the ataxia cohort investigated, 6 out of 631 cases were in the potentially 
pathogenic range. However, a case out of 631 English controls and 3 cases out of 
1148 individuals in diversity control cohort also fall in the same range.The 
significant difference (p= 0.018) in occurrence of SCA8 repeat expansions in ataxia 
patients compared with English controls but not with the diversity controls 
(p=0.192) suggests that the pathogenicity of SCA8 repeat expansion is not only 
dependent on the repeat size but also on the population, environment and the 
genetic modifiers. This study demonstrates that the presence of a SCA8 expansion 
cannot be used to predict whether or not an asymptomatic individual will develop 
ataxia as the control cases were asymptomatic at the time of study. 
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Beta-propeller protein associated neurodegeneration (BPAN) 
abstract 
Neurodegenerative disorders with high iron in the basal ganglia encompass a single 
gene disorders collectively known as NBIA disorders. NBIA-5 (also known as BPAN) 
is linked to the mutations in the WD repeat domain 45 (WDR45) gene on 
chromosome Xp11.  This study describes the genetic, clinical and neuropathological 
features of a case of BPAN. The clinical history of the case matches to other BPAN 
cases described which is characterized by global developmental delay and 
intellectual deficiency in early childhood then followed by further neurological and 
cognitive regression in early adulthood, with dystonia, and sometimes ocular 
defects and sleep perturbation. A cranial computed tomography (CT) revealed 
generalised brain atrophy and bilateral generalised mineralisation of the globi 
pallidi and substantia nigri that are likely to represent iron deposition on 
subsequent magnetic resonance imaging (MRI). The major pathological findings in 
this case were severe neuronal loss with gliosis affecting the substantia nigra, iron 
deposition in the substantia nigra and globus pallidus, axonal swellings in the 
substantia nigra, gracile nucleus and cuneate nucleus and very extensive phospho-
tau deposition. Tau pathology was in the form of neurofibrillary tangles, pre-tangles 
and neuropil threads and histological studies indicated that many of the tau 
immunoreactive structures contained fibrillary protein (Gallyas silver positive and 
AT100 immunoreactive) and contained both 3-and 4-repeat tau isoforms similar to 
the tau deposits of Alzheimer’s disease. This finding was confirmed by 
immunoblotting of non-dephosphorylated tangle extractions which showed the 
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classical triplet band as observed in AD cases (i.e. 3R+4R). When dephosphorylated, 
the tau isoform composition is almost identical to the AD case with 0N3R, 0N4R, 
1N3R and 1N4R tau-isoforms. This study supports the involvement of beta–
propeller protein (encoded by WDR45 gene) in autophagy as has been documented 
in yeast and mammalian cells. The increased accumulation of LC3-II protein in brain 
tissue of the BPAN case compared to the three control cases implies that the 
autophagosome formation is hindered. BPAN represents the first direct link 
between autophagy mechanism and neurodegeneration. However, the role of iron 
in this process is still elusive. 
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Lewy bodies (LBs) in Lysosomal storage disorders (LSDs)  
Inherited metabolic disorders which have been linked to lysosomal dysfunction 
belong to a family of diseases identified as sphingolipidoses, a class of LSDs. The 
main members of sphingolipidoses are Niemann-Pick disease, Krabbe disease, 
Gaucher disease, Fabry disease, Tay-Sachs disease, Sadhoff diasease and 
Metachromatic leukodystrophy. LSDs occurring due to the enzyme dysfunction in 
ceramide pathway develop Lewy body pathology, for example, Niemann-Pick 
disease, Krabbe disease, and Gaucher disease. This study investigated the 
possibility that LSDs, GM1, Tay-Sachs disease, Sandhoff disease, Fabry disease and 
Metachromatic leukodystrophy which also occur due to the enzyme dysfunction in 
the ceramide pathway may mimic the Lewy body pathology suggesting that this 
may be a common theme for pathogenesis. Small changes in the molecular 
structure of ceramide can regulate its biological function and can contribute in 
development of age-related, neurological and neuroinflammatory disease. The 
negative alpha-synuclein immunohistochemistry observed in each case of LSD 
suggested that Lewy body pathology is not the hallmark of the LSDs in the ceramide 
pathway. However, a possibility is that Lewy bodies are a result of a stress created 
by free ceramides. Cells seek a balance of free ceramides and a slight tilt may be 
pathogenic. 
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Chapter 1. Introduction 
 
1.1. Motor systems 
The ease with which we make most of our movements contradicts the enormous 
sophistication and complexity of the motor system. Much of the brain and nervous 
system is devoted to the processing of sensory input, in order to construct detailed 
representations of the external environment; this is then integrated with the motor 
system to respond. This impact on the countless varieties of actions that make up 
our daily lives, for example: running, walking, expression of our feelings with 
concerted actions of facial muscles, communications through coordinated vocal 
cords and the movements of hands and digits and postural adjustments.  
The sensory information-integrating capabilities of a brain highlight its centralized 
role in the motor systems. A very large proportion of the brain matter is dedicated 
to the motor function in lower mammalian species while in primates, motor areas 
are relatively small due to the huge cortical expansion. The cerebellum, a structure 
heavily involved in motor coordination, alone contains around 80% of the brain 
neurons (1).  
In summary, motor function is supported through the functional integration across 
an extended motor system involving the cortical motor network, the cortico-spinal 
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tracts, the cortico-basal ganglia-thalamo-cortical loops and the cortico-cerebellar 
circuits. Any disorders of the motor system dramatically affect the quality of the life 
of the affected person as it hinders everyday actions that are naturally executed 
smoothly and unconsciously. One motor execution is comprised of many 
components (Figure 1.1) to deliver a precise orchestrated action. When one or 
more components involved in the motor system are subjected to noise, the motor 
output is still possible but slightly variable in response to the changing 
circumstances. 
 
Figure 1.1: Steps in motor system components to execute a motor function (2).  
 
The adaptive nature of the motor system means that there are many potential 
points of fault where motor disturbance and disorders may arise. For example: 
dysfunction of the basal ganglia leads to too little (Parkinsonian features) or 
excessive (dystonia, chorea) movement, abnormal cerebellar activity may lead to 
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unbalanced postures or a release of movement patterns inappropriate to the 
current context, degeneration of neurons and nerves innervating muscles (as can 
occur in diabetes or hereditary neuropathies) or aberrant ion homeostasis 
influencing muscle contractility. 
In this study, I have focused on dystonia and in particular primary dystonia, where 
torsion dystonia is the main clinical symptom with the exception of tremor. 
Dystonia is traditionally believed to be a basal ganglia disorder however; the 
emerging role of cerebellum in dystonia needs consideration.  
1.2. Dystonia overview 
Dystonia is an umbrella term for a range of motor disorders characterised by 
sustained or intermittent muscle contractions causing abnormal, often repetitive, 
movements, postures, or both. These dystonic movements are typically patterned, 
twisting and may be tremulous. Dystonia is often initiated or worsened by 
voluntary action and associated with overflow muscle activation (3–7). The 
prevalence of dystonia is unknown, although it is probably more common than is 
generally appreciated. Total prevalence rates vary from 127 per million to 329 per 
million (8,9). Approximately 70,000 people in the UK are affected by dystonia 
including 8000 children and young adults (10). The prevalence of generalized 
isolated dystonia was reported to be 3.4 per 100,000 individuals in an 
epidemiological study of dystonia in Rochester, Minnesota, (8) and an annual 
prevalence of 15.2 per 100,000 individuals in Europe (11). New 'next generation' 
sequencing technologies have massively increased the speed of genetic discoveries 
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in recent years. Table 1.2 tabulates different dystonia (DYT) genes linked to the 
hereditary forms of dystonia till date.  
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Table 1.1 The current DYT loci with brief description of associated phenotype, gene, locus and 
mode of inheritance (Adapted from(12)) 
 
Locus 
symbol 
Phenotype Gene Locus 
Mode of 
inheritance 
PURE PRIMARYTORSION DYSTONIA 
DYT1 Early-onset generalized limb onset dystonia TOR1A 9q34 AD 
DYT2 
Early-onset generalized dystonia with prominent 
cranio-cervical involvement 
-  
AR 
DYT4 Whispering dysphonia TUBB4a 19p13.12–13 AD 
DYT6 
Generalized cervical and upper-limb-onset 
dystonia 
THAP1 8p11.21 
AD 
DYT7 Adult-onset cervical dystonia - 18p AD 
DYT13 Cervical and upper-limb dystonia - 1p36.32–p36.13 AD 
DYT17 
Segmental or generalized dystonia with prominent 
dysphonia 
- 20p11.2–q13.12 
AR 
DYT21 
Adult-onset generalized or multifocal dystonia, 
often starting with blepharospasm 
- 2q14.3–q21.3 
AD 
DYT23 Adult-onset cervical dystonia CIZ1 9q34 AD 
DYT24 
Cranio-cervical dystonia with laryngeal and upper-
limb involvement 
ANO3 11p14.2 
AD 
DYT25 Adult-onset cervical dystonia GNAL 18p11 AD 
PRIMARY DYSTONIA-PLUS SYNDROME 
DYT5 Dopa-responsive dystonia GCH1 14q22.2 AD 
THD Dopa-responsive dystonia TH 11p15.5 AR 
DYT11 Myoclonus-dystonia SGCE 7q21.3 AD 
DYT12  Rapid-onset dystonia parkinsonism ATP1A3 19q13.2 AD 
DYT15 Myoclonus-dystonia - 18p11 AD 
DYT16 Early-onset dystonia parkinsonism PRKRA 2q31.2 AR 
PAROXYSMAL SYNDROME 
DYT8 Paroxysmal non-kinesigenic dyskinesia (PNKD) MR1 2q35 AD 
DYT9/ 
DYT18 
Paroxysmal dyskinesias with episodic ataxia and 
spasticity/paroxysmal exercise-induced dystonia 
(PED) 
SLC2A1 1p34.2 
AD 
DYT10 Paroxysmal kinesigenic dyskinesia (PKD) PRRT2 16p11.2 AD 
DYT19 Paroxysmal kinesigenic dyskinesia 2 (PKD2) - 16q13-q22.1 AD 
DYT20 Paroxysmal non-kinesigenic dyskinesia 2 (PNKD2) - 16q13–q22.1 AD 
HEREDODEGENERATIVE DYSTONIA SYNDROME 
DYT3 Dystonia parkinsonism TAF1 
16q13–
q22.1 
X-R 
AD, autosomal dominant; AR autosomal recessive: X-R, X linked recessive. *DYT7 locus on chromosome 18p has been 
recently questioned (Winter et al., 2012). 
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The European Federation of Neurological Societies recommended dystonia 
classification scheme based on one of the four major variables: (i) age of onset 
(early versus adult onset); (ii) distribution of affected body parts (focal, multifocal, 
segmental or generalized); (iii) the underlying cause (primary, secondary or 
heredodegenerative); or (iv) special clinical features (paroxysmal, exercise-induced, 
task-specific or DOPA-responsive)(13). This classification scheme was considered in 
this study Table 1.2.  
 
Table 1.2  Classification of dystonia, based on the European Federation of Neurological Societies 
(13) 
 
By aetiology 
Primary dystonia  
1.1 Primary pure dystonia 
Torsion dystonia is the only clinical sign (apart from tremor) and there is no 
identifiable exogenous cause or other inherited or degenerative disease 
1.2 Primary plus dystonia 
Torsion dystonia is a prominent sign but is associated with another 
movement disorder, for example myoclonus or parkinsonism. There is no 
evidence of neurodegeneration. 
1.3 Primary paroxysmal 
dystonia 
Torsion dystonia occurs in brief episodes with normalcy in between. Three 
main forms are known depending on the triggering factor. 
2. Heredodegenerative 
dystonia 
Dystonia is a feature, among other neurological signs, of a 
heredodegenerative disorder, such as Wilson's disease 
3. Secondary dystonia 
Dystonia is a symptom of an identified neurological condition, such as a focal 
brain lesion, exposure to drugs or chemicals, e.g. dystonia because of a brain 
tumour, off-period dystonia in Parkinson's disease. 
By age at onset 
1. Early onset (<30 years of 
age) 
Usually starts in a leg or arm and frequently progresses to involve other limbs 
and the trunk 
2. Late onset 
Usually starts in the neck (including the larynx), the cranial muscles or one 
arm. Tends to remain localized with restricted progression to adjacent 
muscles 
By distribution of affected body parts  
1. Focal Single body region (e.g. writer's cramp, blepharospasm) 
2. Segmental Contiguous body regions (e.g. cranial and cervical, cervical and upper limb) 
3. Multifocal 
Non-contiguous body regions (e.g. upper and lower limb, cranial and upper 
limb) 
4. Generalized Both legs and at least one other body region (usually one or both arms) 
5. Hemidystonia 
Half of the body (usually secondary to a lesion in the contralateral basal 
ganglia) 
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Primary dystonias are the cases where dystonia is the main clinical consequence 
without any evidence of neurodegeneration or any obvious secondary cause (e.g. 
trauma, autoimmune, post-infectious etc). Primary dystonias are further 
categorised into primary pure where torsion dystonia is the only clinical sign (for 
example: DYT1/Oppenheim's Dystonia, DYT6 dystonia); primary plus where torsion 
dystonia is associated with another neurological disorder (for example: DYT11, 
DYT12, DYT16); and primary paroxysmal where torsion dystonia occurs in brief 
episodes (for example: DYT8, DYT10, DYT18). Heredodegenerative dystonia 
comprises a large number of complex neurological disorders of which dystonia can 
sometimes be a significant feature, such as Huntington’s disease and Wilson’s 
disease (7, 8). Secondary dystonia occurs as a downstream consequence of a brain 
injury often resulting in the dysfunction of the basal ganglia, such as stroke, 
tumours or the effect of drugs, toxins or infection (16). 
The age at onset of dystonia varies. Childhood onset cases have a tendency to 
affect the whole body (generalized dystonia) with a more severe course whereas in 
adulthood onset cases, dystonia typically remains focal or segmental (5). Focal 
dystonias generally arise later in life around 40-60 years of age and  affect small, 
discrete muscle groups: for example, focal hand dystonias such as writer’s cramp or 
musician’s dystonia manifest only during writing or playing musical instrument, 
respectively (17,18). Focal dystonias allow the patients a relative normal lifestyle 
(20). Generalised dystonias are of early onset (19), affect nearly all muscle group 
and are strongly enabling.  Generalised dystonias severely reduce the quality of life 
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(21). Environmental factors have been investigated for possible association with 
primary dystonia. Evidence for possible contributions of environmental factors to 
early-onset primary dystonia is limited. However, in specific forms of primary adult 
onset focal dystonia, there is reasonable epidemiological evidence that some 
environmental factors are risk-modifying factors compared to control subjects. 
Namely, eye diseases, sore throat, idiopathic scoliosis, and repetitive upper limb 
motor action seem to be associated with blepharospasm, laryngeal dystonia, 
cervical dystonia, and upper limb dystonia, respectively (22). The pathophysiology 
of dystonia most likely arises due to abnormal processing of motor commands as a 
consequence of brain lesions or dysfunction of motor pathways involving basal 
ganglia and cerebellum (23,24). 
1.3. The Basal Ganglia and their involvement in dystonia 
The basal ganglia are known to be associated with various motor functions (5,25–
28), any disruption of the basal ganglia’s normal function is hypothesized to lead to 
some movement impairment. The basal ganglia are comprised of   the caudate and 
putamen, globus pallidus, substantia nigra and subthalamic nucleus (Figure 1.2). 
The globus pallidus is divided into external segment (GPe), and an internal segment 
(GPi); the substantia nigra is composed of a pigmented region, the substantia nigra 
pars compacta (SNpc) and an unpigmented region, substantia nigra pars reticulata 
(SNpr) (25,28). The basal ganglia have specific input, output and intrinsic nuclei, 
which are modulated by several neurotransmitters. Among these, both the 
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inhibitory gamma-amino butyric acid (GABA) and dopamine are significant to the 
proper functioning of the basal ganglia (5).   
 
Figure 1.2 Organization of the basal ganglia, an ensemble of tightly interconnected sub-
cortical nuclei. In blue are represented the glutamatergic (Glu) structures, in red the 
GABAergic (GABA) nuclei and in yellow the dopaminergic (DA) nucleus. GPe: external part 
of the globus pallidus; GPi: internal part of the globus pallidus; SNr: substantia nigra pars 
reticulata; SNc: substantia nigra pars compacta; dp: direct pathway; ip: indirect pathway. 
Adapted from (28). 
 
The principal region that receives inputs is the striatum. GPi and SNpr are the 
output regions projecting beyond the basal ganglia. The input and output regions 
are connected by two basic pathways: direct and indirect. The former being 
implicated in movement facilitation and the latter in movement inhibition. In the 
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basal ganglia, the putamen receives information from all parts of the cerebral 
cortex. This information projects through an indirect pathway, containing GPe, STN, 
or direct pathway to the GPi. The striatal output of the basal ganglia has an 
ascending component to the thalamic nuclei that in turn are connected with the 
premotor and prefrontal cortical areas, and a descending component to the 
mesencephalon that projects to the lower brainstem and spinal cord (29,30).  
The basal ganglia have been focused on in dystonia research and multiple 
publications have implicated basal ganglia dysfunction in the condition (5,31,32). 
Neuropathological studies showed defects in basal ganglia of individuals with 
secondary dystonia (33,34) well supported by focal lesions observed in putamen in 
neuroimaging studies (35). In total, dystonia occurred in 36% of 240 cases with 
basal ganglia lesions described in literature (36). Abnormalities in the basal ganglia 
have been documented for a wide variety of different forms of dystonia by 
positron-emission tomography (PET) studies of regional metabolic activity detected 
with [18F]-fluorodeoxyglucose (FDG-PET) uptake or regional blood flow, voxel-based 
morphometry (VBM), magnetic resonance imaging (MRI), and diffusion tensor 
imaging (DTI) (37–40). Clinical associations of dystonia with other movement 
disorders have also pointed to the basal ganglia. For example, dystonia often co-
exists with parkinsonism in idiopathic Parkinson’s disease (PD) and several 
Parkinson-plus syndromes (41–44) where the primary pathology involves 
dysfunction of dopaminergic and other basal ganglia pathways (43,45). Dysfunction 
of nigrostriatal pathways is also thought to be responsible for both acute dystonic 
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reactions and tardive dystonia associated with antagonists of dopamine receptors. 
Dystonia similarly co-exists with chorea, for example in Huntington’s disease where 
there is prominent degeneration of the striatum (46). Evidence from deep brain 
stimulation (DBS) of the same region is particularly compelling, since dystonia 
remits when stimulation is turned on, and returns when stimulation is turned off 
(47,48). Benefits are not universal but occur in primary generalized and focal 
dystonias, dystonia-plus syndromes, tardive dystonia, and some developmental or 
degenerative disorders. 
Finally, animal studies frequently have implicated the basal ganglia in dystonia, as 
noted in several reviews (49–51). For example, selective lesions of the nigrostriatal 
dopamine pathway with the toxins 6-hydroxydopamine or MPTP result in dystonic 
movements in both rodents (52) and primates (53,54). Lesions of the striatum with 
the toxin 3-nitropropionic acid similarly cause dystonia in both rodents (55) and 
primates  (56–58). In primates, focal destructive lesions of the posterior putamen 
also result in dystonia (59). In aggregate, these results provide strong converging 
support that the basal ganglia play an important role in dystonia.   
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1.4. The cerebellum and its role in dystonia 
 
 
Figure 1.3 Cerebellum. (a) Macroscopic image of a half brain, cerebellum is located at the 
base of the brain (arrow, from the QSBB repository) (b) cellular layers of the cerebellum. 
 
The cerebellum (Latin ‘Little brain’) plays an important role in motor control by 
modulating the primary motor cortex as well as spinally projecting brainstem 
regions to make movements integrated and seamless. The cerebellum directly 
excites the brainstem reticular formation, the red nucleus and the ventrolateral 
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thalamus to influence and regulate movements (60). The cerebellum is a compact 
structure at the base of the brain which despite its relatively small size comprises 
80% of the neurons in the human brain (1) which are densely arranged in a highly 
ordered fashion (Figure 1.3).  
 In recent years, the cerebellum has emerged as a key player in dystonia. It has 
been reported that in some cases dystonia arises after injury to the cerebellum (61) 
and in some cases of genetic cerebellar degeneration dystonia is the predominant 
disease phenotype (62). In DYT1 mutation carriers, imaging studies revealed 
alterations in metabolic brain activity not only in the basal ganglia but also in the 
cerebellum (63–65). The hypothesis of cerebellar involvement in dystonia is further 
supported by a study in patients with focal dystonia. The patients were found to 
have impaired eyeblink classical conditioning, which is believed to be cerebellum-
dependant (66). During eyeblink classical conditioning (ECC), a tone or light signal is 
repetitively paired with an airpuff to the eye until this unconditioned stimulus itself 
is sufficient to elicit an anticipatory eyeblink. Learning of the association between 
light/tone and airpuff is dependent on the cerebellum (67) but not on the basal 
ganglia: PD patients perform as well as healthy controls (68). Hence, this supports 
cerebellar abnormality to be present in at least some dystonias and rules out basal-
ganglionic pathology in the dystonia patients. It is yet to determine if the aberrant 
cerebellar function is causal or secondary to a dystonic phenotype. Animal model 
provided evidence for a more casual role of abnormal cerebellar activity in 
dystonia: in a genetic mouse model of dystonia, the tottering mouse, 
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pharmacological stimulation of cerebellar structures has been found sufficient to 
elicit dystonia postures (69) and surgical ablation of the cerebellum abolished the 
dystonic phenotype (70). The tottering mice suggests that in this mouse model at 
least, cerebellar involvement is both sufficient and necessary for the generation of 
dystonia. The cerebellum has been suggested to have a prominent role in 
modulating cortical plasticity (71,72) so that developmental structural 
abnormalities in the cerebellum and its outflow pathways may give rise to 
alteractions in cortical activation responses during movement and learning, leading 
to the functional changes seen in dystonia.  
Recently, the anatomical interconnection between the basal ganglia and 
cerebellum were shown using retrogradely transmitted viral tracers (73,74) which 
revealed their capability of directly interacting with each other.  The exact nature of 
this interaction and whether cerebellar activity is casual, correlated or 
compensatory to abnormalities of the basal ganglia in the etiology of dystonia still 
remains unclear. A disynaptic link interconnecting cerebellum and basal gnglia from 
dentate nucleus to striatum and a reciprocal projection from the basal ganglia to 
the cerebellum has also been described which may allow abnormalities of the 
cerebellum to affect the basal ganglia and vice-versa (74).  
The accumulating evidence reviewed above renders traditional models that focus 
on basal ganglia circuits as the central cause for all forms of dystonia obsolete. It is 
becoming increasingly clear that many brain regions contribute to dystonia, 
including the cerebral cortex, cerebellum, thalamus, and midbrain/brainstem. It 
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also is becoming increasingly clear that etiological heterogeneity among dystonias 
is important, as the relative importance of different brain regions seems to vary 
among them. Current challenges are to develop a model for understanding 
physiological interactions for how the different brain regions may contribute to 
different forms of dystonia, whether different dystonias can be subdivided into 
subgroups depending on how these regions are affected, and whether there is a 
final common pathway for all dystonias. 
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1.5. Primary pure dystonia 
(This section will provide a brief review on primary pure dystonia and associated genes, in 
particular TOR1A and THAP1.)  
Primary pure dystonia is usually defined as a syndrome in which dystonia is the only 
clinical feature (except for tremor of the arms or head and neck) without any 
evidence of neurodegeneration or any obvious secondary cause (e.g. trauma, 
autoimmune, post-infectious etc). In United States, the prevalence of generalized 
primary dystonia was reported to be 3.4 per 100,000 individuals and of focal 
primary dystonia, 29.5 per 100,000 individuals (8). In 1999, an epidemiological 
study of dystonia in Europe showed an annual prevalence of 15.2 per 100,000 
individuals with the majority having focal dystonia , 11.7 per 100,000 (ESDE 
Collaborative Group).Genes linked to primary pure dystonia are summarized in 
Table 1.3. 
Table 1.3 Primary pure dystonia genes described in literature (12) 
 
Gene Typical age 
range for onset 
Typical distribution 
of dystonia (at 
onset) 
Generalization 
or progression? 
Clinical clues or other special features 
TOR1A 
(DYT1) 
Childhood 
Legs ≫ arms 
Often 
Generalizes 
Jewish ancestry; dystonia progressing 
to fixed deformity; laryngeal or cranial 
sparing 
THAP1 
(DYT6) 
Adolescence to 
early adulthood 
Laryngeal, cervical 
or brachial 
Generalization 
common 
Laryngeal or brachial onset with 
progression 
CIZ1  Adult Cervical 
No 
generalization 
Only reported in pure focal cervical 
dystonia 
ANO3 
(DYT23) 
Adolescence to 
early adulthood 
Craniocervical or 
brachial 
No 
generalization 
Prominent head, voice or arm tremor 
TUBB4A 
(DYT4) 
Adolescence to 
early adulthood 
Laryngeal, 
craniocervical 
Generalization 
observed 
Ataxic, hobbyhorse gait; extrusional 
tongue dystonia; single family 
GNAL  
Adolescence to 
mid-life 
Craniocervical 
Generalization 
observed 
– 
TOR1A: torsinA ; THAP1: thanatos associated protein domain containing, apoptosis associated protein 1; CIZ1: 
CDKN1A interacting zinc finger protein 1; ANO3: anoctamin 3; TUBB4A: β-tubulin 4; GNAL: Guanine nucleotide-
binding protein G(olf) subunit alpha  
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1.5.1. TOR1A Mutations (DYT1/Oppenheim's Disease) 
Genetics and clinical features  
DYT1 dystonia is the most common inherited form of early onset primary dystonia. 
The symptoms typically present in childhood or adolescence with only a few cases 
in adulthood and it has an autosomal dominant mode of inheritance (75).  
In 1911, Oppenheim proposed the term 'dystonia musculorum deformans' to 
describe a syndrome in children with twisting or jerking movements, muscular 
spasm, and gait abnormalities that often progressed to a fixed postural deformity. 
The hereditary nature of the condition was subsequently recognized and in 1990, 
the disease was linked to chromosome 9q32-34 and designated with the first 
dystonia locus (DYT1) (76). It was quickly realized that this locus was associated 
with a significant proportion of all childhood-onset dystonia, particularly in 
Ashkenazi Jews (76,77). Seven years later the gene responsible for the condition 
was identified and named TOR1A (78).  
The most frequent genetic cause of early-onset, generalized dystonia is a GAG 
deletion in exon 5 of the DYT1 gene leading to deletion of a glutamic acid residue in 
the gene product torsinA (78). This mutation has been shown to be responsible for 
~80% of all primary, early-onset dystonia in Ashkenazi Jewish populations and up to 
50% of primary, early-onset dystonia in non-Jewish populations (79,80). Only two 
other missense variants (p.A288G and p.F205I) and one frameshift, 4-base pair 
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deletion (c.934_937delAGAG) in this gene have since been reported to cause 
dystonia, though their pathogenicity is by no means certain (81,82). Phenotypic 
presentation can vary widely within families (83) and between ethnic groups, with 
increased prevalence and severity found in the Ashkenazi Jewish population. 
Common clinical features include dystonic muscle contractions causing posturing of 
a foot, leg, or arm and in most cases this evolves to generalized dystonia with 
severe disability (84). 
The penetrance of the GAG deletion is notably low, with current estimates 
somewhere within the region of 30–40% (76,79). In manifesting carriers, the 
spectrum of severity of the symptoms is wide, ranging from mild focal dystonia to 
severe and disabling generalized dystonia. The exact mechanism underlying this 
variability remains unclear, but is presumed that other genetic or environmental 
modifiers must exist that influences the penetrance and presentation of the 
disease. 
Clinically, DYT1-related dystonia typically presents in childhood with dystonic 
posturing of the foot or leg and evolves to generalized dystonia with fixed 
deformities. However, late-onset or much milder forms of the disorder are 
recognized (80). There is generally a family history consistent with autosomal 
dominant inheritance, albeit with reduced penetrance, but apparently sporadic 
early and late onset cases are also seen (85). In general, symptoms of early-onset 
generalized dystonia can include: 
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 Twisted postures, for example in the torso or limbs  
 Turning in of the foot or arm  
 Unusual walking with bending and twisting of the torso  
 Muscle spasms, with or without pain  
 Rapid, sometimes rhythmic, jerking movements (often ‘myoclonic jerks’)  
 Progression of symptoms leading to areas of the body remaining in 
sustained or fixed postures 
TorsinA 
The DYT1/TOR1A gene encodes a protein torsinA, a member of the AAA+ family of 
ATPases which resides in the lumen of the endoplasmic reticulum and nuclear 
envelope (78,86). However, when the mutant form of torsinA, torsinAΔE, is 
overexpressed, it concentrates in the perinuclear space of the nuclear envelope, 
forming inclusions in both neuronal and nonneuronal cells (Figure 1.4) (33,87–89).  
It is believed to be involved in maintenance of both structural integrity and/or 
normal protein processing and trafficking (90–92).  Molecular chaperone-like 
activities of torsinA have been reported using in vitro or in vivo protein aggregation 
models. Overexpression of torsinA prevents aggregation of luciferase in vitro (93), 
accumulations of α-synuclein in cultured mammalian cells (94), and polyglutamine-
repeat proteins in Caenorhabditis elegans (95), suggesting torsinA has molecular 
chaperone activities.  
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Figure 1.4: Putative mechanism by which mutant torsinA asserts dystonic movements. 
Mutant torsinA acts like a substrate trap and accumulates that in the nuclear membrane. 
The impaired tosinA function leads to neuronal dysfunction. Further environmental insults 
or genetic modifiers can then lead to the development of dystonia. (Adapted from (96)). 
 
Of the four torsins that are encoded in the human genome (TorsinA, TorsinB, 
Torsin2A, Torsin3A), torsinA is by far the best characterized (97). TorsinA has a 
highly homologous family member torsinB, which is encoded by TOR1B located 
adjacent to TOR1A on human chromosome 9q34 (98) sharing 61% amino acid 
identity. TorsinA is expressed throughout the central nervous system in humans, 
but is found at particularly high levels in the dopaminergic neurons of substantia 
nigra pars compacta, locus coeruleus, Purkinje cells, cerebellar dentate nucleus, 
basis pontis, thalamus, hippocampal formation, oculomotor nuclei and frontal 
cortex (Figure 1.5  (99–101)). Since the discovery of the TOR1A gene, a number of 
cellular processes have been associated with torsinA, albeit the specific molecular 
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mechanism through which mutated torsinA leads to DYT1 dystonia remains 
unclear. There is accumulating data to suggest that torsinA has an important role in 
several cellular compartments and pathways, including the cytoskeleton, the 
nuclear envelope, the secretory pathway and the synaptic vesicle machinery (102–
105). Recently a new function for torsinA in endoplasmic reticulum-associated 
degradation has been reported (106). 
 
 
Figure 1.5: TOR1A gene expression pattern in different brain regions of neuropathologically 
confirmed healthy controls (HEX databse). Of the regions studied, TOR1A expression is 
highest in the temporal cortex. 
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Models of DYT1 dystonia 
Several murine models of DYT1 dystonia have been developed, and characterized 
to various degrees. These models include DYT1 knock-out (102), cortex-specific 
DYT1 knock-out (107), torsinA knock-down (108), transgenic overexpression of 
mutant and wild-type torsinA (109,110) and DYT1 ΔGAG knock-in (102,111) mouse 
models. Whereas common features exist among some of these models, 
inconsistencies have been noticed. Morphological studies of TOR1A knock-out and 
homozygous TOR1A ΔGAG knock-in revealed that they are embryonically lethal 
(103,111). The heterozygous ΔGAG knock-in mice showed abnormal motor 
behaviours in 6-month old males with ubiquitin and torsin A positive aggregates in 
neurons of the pontine nuclei (111). Similar findings were reported in a cortex-
specific DYT1 knock-out model (107). Dystonic movement of limbs with self-
clasping, circling behavior, and hyperactivity was reported in 40% of the transgenic 
mouse models along with ubiquitin and torsinA-positive inclusions in the 
pedunculopontine nucleus, periaqueductal grey matter and pons (109,110). Prion 
protein promoter was reported to affect the torsinA expression in another DYT1 
transgenic mouse model (110). Recently, mice that lacked the TOR1A gene in the 
entire central nervous system were generated and observed to develop striking 
abnormal twisting movements indicative of dystonia (112). In a genetic mouse 
model of dystonia, the tottering mouse, pharmacological stimulation of cerebellar 
structures has been found sufficient to elicit dystonia postures (69) and surgical 
ablation of the cerebellum abolished the dystonic phenotype (70) suggesting that in 
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this mouse model at least, cerebellar involvement is both sufficient and necessary 
for the generation of dystonia. 
Alteration in the normal cytoplasmic localization to a perinuclear inclusion 
morphology was reported when mutant porcine torsinA was overexpressed  in 
neuroblastoma cells (105). A similar observation was reported where transfection 
of mutant torsinA into cells resulted in re-distribution of the wild-type protein to 
the nuclear envelope (102). Severe abnormalities were also observed in the 
neurons from both torsinA null and homozygous disease mutant knockin mice (50). 
These observations suggest that DYT1 dystonia may be one of a group of diseases 
associated with defects in nuclear membrane structure and function (89).  
DYT1 in vitro studies suggested that torsinA interacts with several proteins within 
the endoplasmic reticulum/nuclear envelope space, including lamina-associated 
polypeptide 1 (LAP1), luminal domain-like LAP-1 (LULL1), nesprins, and printor 
(113–116). Recent study has shown physical interaction of TOR1A with LAP1 and 
LULL1 where overexpression of these cofactors profoundly changes the subcellular 
localization of torsinA (117).  
 
Neuropathology of DYT1 cases 
 
Neuropathological studies of dystonia are sparse, partly due to the low availability 
of post-mortem tissue from these patients and the labour intensive nature of 
exploratory neurological examination of the entire human brain. Only a few studies 
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have examined neuropathological abnormalities in a handful of dystonia patients, 
providing limited information regarding the relationship between 
functional/structural brain changes and underlying neuropathology. However, 
neuropathological research has been unrewarding in providing information on 
disease processes.  
Despite the studies implicating the caudate, putamen and globus pallidus in 
dystonia (36,118,119) neuropathological investigation of primary pure dystonia has 
not provided consistent evidence of neurodegeneration affecting these structures. 
There are relatively few published neuropathological studies of primary pure 
dystonia and the major contributors to the literature have been summarized in 
Table 1.4. Early studies lack genetic investigation and are based only on clinical 
classification of patients. The majority of primary pure dystonia cases that have 
undergone neuropathological investigation showed no abnormalities (120,121). 
Meige syndrome (a condition characterized by blepharospasm with facial, 
mandibular, oral, lingual, and laryngeal spasms) has been associated with neuronal 
loss in brainstem nuclei including the substantia nigra and with brainstem LB 
pathology (122,123). In one Meige syndrome case rod-shaped intranuclear 
inclusions were observed in neurons in the midbrain tectum. However, the nature 
of these inclusions is uncertain as immunohistochemical staining was not available 
at that time and the finding does not appear to have been replicated in more 
recent studies (122) . Decreased dopamine turnover in the substantia nigra, 
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striatum and nucleus accumbens, similar to that found in PD, was also described in 
one of the cases with Meige syndrome associated with Lewy bodies (LBs) (123).  
Histopathological changes of neurofibrillary tangles (NFTs) with mild neuronal loss 
in the locus coeruleus and occasional NFTs identified by Congo red and 
Bielschowsky silver stains in the substantia nigra, pedunculopontine nucleus and 
dorsal raphe nucleus were reported in the brain of a 29 year old male with onset of 
dystonia at the age of 14 years. He had sustained a head injury aged 23 and 
additional neuropathological findings included old contusions in frontal and 
temporal lobes (121). NFTs have been described in the hippocampal formation and 
neocortex of patients as young as 27 years following a single episode of head 
trauma, however, brain stem regions have not been studied in such cases and it is 
therefore uncertain whether the brain stem NFTs could relate to the episode of 
trauma in this case (124).  Neurofibrillary tangle pathology does not seem to be a 
consistent finding in dystonia, although in a series of 6 cases aged 65 – 84 years 
neurofibrillary tangle pathology and amyloid-β peptide deposition were observed 
in patients corresponding to the diagnosis of intermediate-high likelihood of 
Alzheimer’s disease (AD). These changes were regarded as incidental and related to 
age rather than representing the pathology underlying dystonia (125). No 
significant neuropathological abnormalities were reported for clinical cases with 
spasmodic torticollis, blepharospasm with oromandibular dystonia (44) and 
oromandibular dystonia with torticollis  (121,126). one of the cases with Meige 
syndrome associated with LBs (123).  
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Neuropathological examination of genetically confirmed DYT1 cases was 
disappointing as no evidence of neuronal loss, inflammation or altered localization 
of torsinA could be identified  (101,120,127,128) (Table 1.4). Evaluation of a single 
DYT1 case demonstrated a modest reduction in dopamine content in the rostral 
putamen and caudate (127). A further study, which described 3 cases of DYT1 
dystonia, also demonstrated a reduction in striatal dopamine, but this was not 
statistically significant when compared with controls. These authors were able to 
demonstrate evidence of increased dopamine turnover and a trend towards 
reduced D1R and D2R binding (128). A study of 5 DYT1 cases showed no apparent 
loss of pigmented neurons in the substantia nigra, however, using a semi-
quantitative approach to estimate the size of pigmented neurons it was suggested 
that these may show an increase in size. Detailed morphometric analysis would be 
required to validate this observation (101).  
One of the most interesting neuropathological studies of DYT1 dystonia described 
the novel finding of neuronal cytoplasmic inclusions (NCIs) immunoreactive for 
ubiquitin, torsinA and lamin A/C in the periaqueductal grey matter, cuneiform and 
pedunculopontine nuclei. These inclusions were identified in four genetically 
confirmed DYT1 dystonia cases and were absent from normal controls. Tau 
immunoreactive inclusions likely to represent age-related NFTs were also observed 
in the substantia nigra and locus coeruleus (129). In the light of current functional 
studies suggesting that torsinA interacts with nuclear membrane proteins, the 
presence of both torsinA and lamin A/C in the DYT1-associated intracytoplasmic 
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inclusions is of considerable interest (129,130). Although this report represents the 
most significant neuropathological observation in DYT1 dystonia to date, the 
findings have never been replicated due to the shortage of cases available for post-
mortem investigations. Support for these observations has been provided by 
reports of similar inclusions in some DYT1 mouse models produced by expression 
of transgenic human torsinA (92,109).  
Current treatments for DYT1 dystonia 
Early diagnosis and start of treatment for dystonia, though not proven to alter its 
course or increase the likelihood for remission, may improve quality of life and 
alleviate the disability of patients with dystonia. Anticholinergic drugs, dopamine 
modulators, baclofen, muscle relaxants, and other pharmacologic agents have been 
used for a long time to treat dystonia. The introduction of botulinum toxin and DBS 
clearly revolutionized the symptomatic treatment of this neurological movement 
disorder (131). Therapy of dystonia can be divided into the following categories: (1) 
physical, supportive, and ancillary therapy; (2) pharmacologic treatment; (3) 
chemodenervation with botulinum toxin; and (4) peripheral and central surgery 
such as DBS. Anticholinergics block the neurotransmitter acetylcholine and have 
been shown moderately effective in patients with either generalized or focal 
dystonia (132,133). A second treatment modality involves injection of botulinum 
toxin directly into affected muscle regions. Botulinum toxin acts to block neuronal 
signals that tell the muscles to contract, thereby allowing the hypercontracted 
muscles of DYT1 patients to relax. Though shown to be quite effective for treating 
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focal dystonia, it is not practical for generalized dystonia and effects are transient, 
lasting 3-6 months.  
The final treatment option shown to be effective is DBS of the globus pallidus, a 
nucleus within the basal ganglia, particularly for severe cases of generalized 
dystonia (134,135). Electrode leads are placed within the brain and the patient 
receives electrical impulses to the targeted region of the brain. The mechanism by 
which DBS operates is not currently understood. Some drawbacks of this treatment 
include the invasive nature of the surgery and variable effectiveness between 
patients. 
Although several treatments are currently available for DYT1 patients, none of 
them are universally effective or curative and are associated with potentially severe 
and sometimes poorly characterized adverse effects. Given these limitations 
further therapies should be investigated. 
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Table 1.4 Summary of neuropathological studies in primary dystonia in literature 
Refer-
ences 
Cases 
Diagnostic 
method 
Clinical phenotype 
Age at 
death, years 
Sex 
 
Neuropathology reported 
 
(136) 1  Clinical Spasmodic torticollis 65 F No abnormality observed. 
(121) 1  
 
Clinical Dystonia musculorum defomans 29 M Numerous NFTs and mild neuronal loss in the LC. Occasional NFTs in the 
SNpc, pedunculopontine nucleus & dorsal raphe nucleus 
 2  
 
Clinical Meige syndrome  68 M Moderate to severe neuronal loss in brainstem nuclei including the SNpc, 
LC, raphe nuclei & pedunculopontine nucleus. 
3  Clinical Dystonia musculorum defomans 10 M No abnormality observed. 
4 Clinical Spasmodic torticollis 50 F No abnormality observed. 
(126) 1  
 
Clinical Cranial dystonia (blephararospasm 
& oromandibular dystonia) 
67 M No abnormality observed. 
2  
 
Clinical Cranial dystonia (blephararospasm 
& oromandibular dystonia) 
68 M No abnormality observed. 
3  
 
Clinical Cranial dystonia (blephararospasm 
only) 
73 M Angioma in dorsal pons involving the central tegmental tract (represents 
secondary dystonia). 
4  
 
Clinical Oromandibular dystonia with 
retrocollis 
68 F No abnormality observed. 
(122) 1 
 
Clinical Meige syndrome 72 M Mild to moderate cell loss in the SNpc & LC, midbrain tectum & dentate 
nucleus. Frequent LBs in SN & LC. Rod-shaped intranuclear inclusions in 
neurons in midbrain tectum. 
(123) 1 
 
Clinical Meige syndrome 69 M LB pathology in the nucleus ambigus, LC, SN & nucleus basalis of Meynert. 
Mild neuronal loss in SN & LC. 
M= male, F = female; Meige syndrome (focal adult onset torsion dystonia variant with cranial dystonia), SN-substantia nigra, SNpc-substantia nigra par compacta, LC-locus coeruleus, CN-cuneiform nucleus, PAG- 
periaqueductal gray matter, LB-Lewy body, DA- dopamine 
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Table 1.4 Summary of neuropathological studies in primary dystonia in literature continued... 
 
Refer-
ences 
Cases  
Diagnostic 
method Clinical phenotype 
Age at 
death, years 
Sex 
 
Neuropathology reported 
 
(120) 1 Genetic, DYT1 Generalized dystonia 33 M No abnormality in localization of torsinA, no other significant 
pathological changes. 
2  Clinical, DYT1-ve Cervical & possible brachial dystonia 68 N/A No abnormality observed. 
3  Clinical, DYT1-ve Cranial segmental dystonia 72 N/A No abnormality observed. 
4  Clinical, DYT1-ve Cranial segmental dystonia 45 N/A Occasional pyknotic neurons in putamen & thalamus. 
(101) 1 Genetic, DYT1 Dystonia musculorum defomans 83 F No difference in the pattern of torsinA immunoreactivity between 
dystonia & control brains. No loss of pigmented neurons in the SN 
but increased neuronal size suggested by semiquantative analysis. 
Cases 1, 2,4,5,7 & 8 used for IHC. Cases 4, 5 & 6 are DYT1 negative. 
2  Genetic, DYT1 Focal non-progre-ssive dystonia 86 M 
3  Genetic, DYT1 Dystonia musculorum defomans 29 M 
4  Genetic, DYT1 Dystonia musculorum defomans 78 M 
5  Genetic, DYT1 Spastic dysphonia 80 F 
6  Genetic, DYT1 Torsion dystonia 67 F 
7  Genetic, DYT1 Dystonia musculorum defomans 78 M 
8  Genetic, DYT1 Torsion dystonia 67 F 
(127) 1  
 
Genetic, DYT1 Generalized dystonia 10 M No pathological abnormalities, normal content of dopamine with 
exception of a modest reduction in the rostral putamen & caudate. 
(128) 1  Genetic, DYT1 Early onset generalized dystonia 67 F Normal content of DA, changes in DA metabolites suggestive of 
increased DA turnover. Case 4 showed neuronal loss in the SN with 
no LBs. Mutation in parkin gene was excluded 
2  Genetic, DYT1 83 F 
3  Genetic, DYT1 86 M 
4  Genetic, DYT1 Parkinsonism 79 F 
M= male, F = female; Meige syndrome (focal adult onset torsion dystonia variant with cranial dystonia), SN-substantia nigra, SNpc-substantia nigra par compacta, LC-locus coeruleus, CN-cuneiform nucleus, PAG- 
periaqueductal gray matter, LB-Lewy body, DA- dopamine 
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Table 1.4 Summary of neuropathological studies in primary dystonia in literature continued.. 
 
Refer-
ences 
Case
s  
Diagnostic 
method Clinical phenotype 
Age at 
death, years 
Sex 
 
Neuropathology reported 
 
(129) 1 Genetic, DYT1 Dystonia musculorum defomans 83 F Ubiquitin, laminA/C & torsinA positive inclusions within neurons 
in the brainstem, including the pedunculopontine nucleus, CN & 
the PAG. Tau & ubiquitin positive inclusions likely to represent 
NFTs noted in pigmented neurons in the SN & LC. 
2 Genetic, DYT1 Focal non-progre-ssive dystonia 86 M 
3 Genetic, DYT1 Dystonia musculorum defomans 78 M 
4 Genetic, DYT1 Generalized dystonia 33 M 
(125)  
 
1 Clinical, DYT1-ve Blepharospasm, subsequent right arm 
dystonia (late onset) 
84 F Neuronal inclusions were not identified in brainstem nuclei. No 
apparent neuronal loss in the striatal striosome compartment. 
Case 2: Frequent neuritic plaques, Braak & Braak stage IV tau 
pathology & brainstem predominant LB pathology. 
Cases 1, 3 & 5: minor degree of Alzheimer pathology. 
Cases 3, 4 & 5: small vessel disease, severe in case 3 with infarct 
in caudate nucleus. 
2 Clinical Retrocollis, facial dystonia (late onset) 72 M 
3 
 
Clinical, DYT1-ve Torticollis, dystonic head & hand tremor, later 
jaw opening dystonia (late onset) 
79 F 
4 Clinical Axial dystonia, later laryngeal dystonia  
(late onset) 
65 M 
5 Clinical, DYT1-ve Torticollis (late onset) 80 F 
6 Clinical Blepharospasm (late onset) 78 F 
M= male, F = female; Meige syndrome (focal adult onset torsion dystonia variant with cranial dystonia), SN-substantia nigra, SNpc-substantia nigra par compacta, LC-locus coeruleus, CN-cuneiform nucleus, PAG- 
periaqueductal gray matter, LB-Lewy body, DA- dopamine 
 P a g e  | 32 
1.5.2. THAP1 mutations (DYT6) 
Genetics and clinical features  
Another distinct form of primary pure dystonia is dystonia 6 (DYT6). Affected 
individuals, who were negative for TOR1A mutations, tend to have an older age of 
onset during adolescence. Cases presented clinically with predominantly cranio-
cervical or focal dystonia affecting the upper limbs. 
The DYT6 locus was localized to chromosome 8p21-q22  by linkage analysis in two 
Mennonite families (137,138) and linked to mutations in the DYT6 gene, also 
known THAP1 (thanatos-associated domain-containing apoptosis-associated 
protein 1) in a non-Amish-Mennonite German family with primary torsion dystonia 
(138). DYT6/THAP1 mutations are either missense or out of frame deletions, usually 
non-recurrent and have now been reported across many ethnicities (138). 
Inheritance is autosomal dominant with reduced penetrance. The disease 
penetrance was found to be 60% in three Amish-Mennonite families (75,137,139) 
but this may not be true of all populations or mutations (139).  
The clinical spectrum of THAP1 mutations is wide. Presentation with 
oromandibular, cranio-cervical and laryngeal dystonia is common, but 
presentations with focal dystonia of the limbs, segmental or generalised dystonia 
are also described in the literature (5,140).  
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THAP1 
The THAP1 protein is a 213 amino acid protein characterized by an N-terminal 
THAP domain (amino acids 1 to 81) with DNA binding properties, followed by a  
proline-rich region (amino acids 90 to 110) and a nuclear localization signal (amino 
acids 146 to 162) (141). The THAP domain is conserved in both vertebrates and 
invertebrates (142). It has DNA binding properties and is thought to be involved in 
the regulation of transcription, either on its own or in concert with other proteins. 
Thus, one possible mechanism by which mutations in THAP1 might cause dystonia 
is by dysregulated transcription of key genes. THAP1 protein is also known to 
interact with the prostate apoptosis response protein 4 (PAR-4), which is a 
transcription regulator involved in apoptosis (143). Under conditions of cellular 
stress or toxicity, this protein is rapidly upregulated and it has been linked to 
neurodegeneration in a number of disease models (144–146). Two spliced 
messenger ribonucleic acid (mRNA) variants that produce functional proteins have 
been reported (THAP1a: CCDS6136 and THAP1b: CCDS6137)(147). The first 2.2Kb 
isoform contains 3 exons, whereas the second corresponds to an alternatively 
spliced isoform that lacks exon 2 (2 kb mRNA). This second isoform encodes a 
truncated THAP1 protein without the C-terminus of the THAP domain (Figure 1.6). 
The two isoforms are expressed in many tissues suggesting that THAP1 has a 
widespread, although not ubiquitous, distribution in humans.  
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Figure 1.6: THAP1 gene expression pattern in different brain regions of neuropathologically 
confirmed healthy controls (HEX databse). 
 
 
One intriguing finding has been that THAP1 may regulate transcription of TOR1A by 
binding to one of the two sites in its promoter region suggesting a link via 
transcriptional regulation of other dystonia genes (148). Mutations in THAP1 have 
been shown to disrupt binding to the TOR1A promoter and decrease TOR1A-driven 
luciferase expression, thus suggesting that under some conditions TOR1A is 
negatively regulated by THAP1 protein and that mutations in THAP1 may lead to 
abnormally high levels of torsinA (149). Although these data come from 
experimental cell lines and thus are of uncertain physiological significance, this 
does at least raise the possibility that the disease mechanisms in DYT1 and DYT6 
dystonia may be linked. However, if this is the case, the question arises as to how 
to link this mechanistically with the prevailing idea that the GAG-deletion in TOR1A 
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leads to a loss of function of the protein (103). One possibility is that TOR1A 
expression must be maintained within a set range in relation to its binding partners 
and that dysfunction may result from either increased expression or loss of 
function (150). Indeed, transgenic mice overexpressing wild-type TOR1A have been 
shown to display evidence of neurohistological, neurochemical and behavioural 
abnormalities, which may provide some support for this hypothesis (110). It has 
also been suggested that if there is a link between two monogenic forms of 
dystonia, mutations or other sequence variations in THAP1 might influence the 
penetrance of DYT1 dystonia (151). 
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1.5.3. THAP1/DYT6 and TOR1A/DYT1 interaction 
(This section reviews the emerging role of THAP1 protein. We aim to ifentify the 
interaction between two primary pure dystonia genes, TOR1A and THAP1 thereby 
predicting a common pathology in primary dystonia.) 
 
 
 
 
Figure 1.7: THAP1 Protein interaction prediction model generated by SIFT software predicting 
TOR1A interaction. Prediction based on Neighbourhood, Gene fusion, Co-occurance, Co-expression, 
Experiments, Data-bases, Text-mining, and Homology. 
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The phenotypic variability of primary dystonia suggests genetic heterogeneity. 
However clinical overlaps, not only in early-onset but also with the more common 
focal/segmental dystonias, suggest that common pathogenic mechanisms may be 
involved. Indeed, recent functional studies have demonstrated that THAP1 and 
TOR1A interact in a common pathway (148,149). 
Torsion dystonias are mostly associated with dysfunction in CNS regions controlling 
movement. The precise nature of this dysfunction is unclear, although it is believed 
that it may involve imbalances in neurotransmission within certain circuits, 
particularly in the basal ganglia, sensorimotor cortex, brainstem, and cerebellum 
(5,152). THAP1 is a nuclear transcription factor that can regulate endothelial cell 
proliferation (153) but its function in the brain is still unknown. In vitro studies have 
shown that THAP1 physically interacts with TOR1A and represses torsinA 
expression by binding to the TOR1A promoter; this interaction is abolished by 
pathogenic mutations, leading to a decreased repression (149). However, the role 
of THAP1 as a major genetic modifier in DYT1-dystonia has been recently 
questioned (154). Molecular analysis of THAP1 as a genetic modifier for DYT1 has 
shown no sequence variation in coding regions and untranslated regions of the 
THAP1 gene among affected and non-manifesting carriers of the DYT1 GAG 
deletion carriers (155). In line with this, THAP1 is predicted to regulate several 
other gene targets, including the TAF1 gene implicated in DYT3 dystonia (156). 
THAP1 has been reported to co-localise with the apoptosis response protein 
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PAWR/PAR-4 in promyelocytic leukemia (PML) nuclear bodies, and function as a 
proapoptotic factor that links PAWR to PML nuclear bodies (143) Figure 1.7.  
Although, the sequences and predicted functional domains of the two proteins 
causing DYT1 and DYT6 do not reveal obvious relationships among them, the 
mutations produce overlapping clinical phenotypes. In DYT1 symptoms starts 
before the age of 28 (157,158). Onset most often begins in legs and in the majority 
of the cases, symptoms spread to involve multiple body regions with segmental, 
multifocal or generalized dystonia (75). In DYT6 onset occurs across a much broader 
span, ranging from 10 to 80 years. The arm is the most common site of onset for 
DYT6, with subsequent spread to craniofacial muscles, leg, and neck (159). A 
common feature of DYT6 is laryngeal dystonia, producing severe speech defects, 
which is not often seen in DYT1 (157,159). 
The initial efforts to map torsinA expression in human brain found particularly high 
mRNA levels in dopaminergic nigrostriatal neurons (160,161). However, no 
pathologic lesions were detected (33) in DYT1 in dopaminergic cell bodies in the 
substantia nigra, or in any other regions in CNS region, although one study reported 
apparent enlargement of dopaminergic neurons in DYT1 brains relative to controls 
(101). Inconsistent results were obtained from the multiple DYT1 mouse models 
and similarly monitored striatal tissue content of dopamine and metabolites (108–
111,162–164). However, inconsistent results were obtained even in the same 
mouse model when analyzed by separate labs (162,164). Although a recent report 
describing a specific interaction between torsinA and tyrosine hydroxlase (163,165) 
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indicates this may still be a possibility. Moreover, a particularly striking finding is 
that even greater reductions in D2R availability were apparent in brains of DYT6 
patients compared to controls than for the DYT1 patients, independent of clinical 
disease status (166). These data provide one of the first direct links between DYT6 
and a potential dopamine-related defect, while further suggesting that D2R 
availability may be a critical factor in both DYT1 and DYT6 dystonias. in 
promyelocytic leukemia (PML) nuclear bodies, and function as a proapoptotic 
factor that links PAWR to PML nuclear bodies (143).  
A recent hypothesis linking DYT1 and DYT6 is that THAP1 may regulate transcription 
of torsinA (148,149). In vivo method using human epithelial cervical cancer (HeLa) 
and neuroblastoma cells (SH-SY5Y) demonstrated the interaction between THAP1 
and TOR1A promoter (149). Cell lines overexpressing THAP1 was transfected with a 
plasmid containing a 977bp TOR1A promoter/exon1 fragment litigated to a 
reporter gene.  A THAP1-mediated dose dependent decrease in activity of the 
promoter construct was reported; however failed to replicate the same effect in a 
more direct experiment. A small interfering RNA (siRNA)-mediated repression of 
THAP1 did not have any effect on the cellular level of TOR1A mRNA. THAP1 and 
TOR1A interaction was also demonstrated by electrophoretic mobility shift assay 
(EMSAs) using nuclear extracts from the cells overexpressing wild-type THAP1 
which bound to the TOR1A promoter sequences, whereas multiple DYT6 mutant 
forms did not (148). Human umbilical vein endothelial cells (HUVECs) and T98G 
glioblastoma cell lines were used for the purpose. THAP1 modulation of TOR1A 
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expression in lymphoblast cell lines derived from subjects with THAP1 mutations, in 
293T cells, or in HUVEC cells was not demonstrated. Thus, it is possible that the 
THAP1/TOR1A interaction is important in the CNS only. in promyelocytic leukemia 
(PML) nuclear bodies, and function as a proapoptotic factor that links PAWR to PML 
nuclear bodies (143).  
Hence the recent hypothesis that THAP proteins most likely function as 
transcriptional repressors contrasts markedly with the prevailing DYT1 
pathogenesis which proposes that TOR1A mutation results in a loss of torsinA 
function (96,103) as DYT6 mutations which decrease its DNA binding could 
theoretically lead to abnormally high levels of torsinA protein. 
However, in studies of torsinA's role in trafficking of the DA transporter (DAT), 
overexpression of wild-type torsinA decreased surface expression of DAT, 
presumably by trapping it within the endoplasmic reticulum (113). In addition, 
phenotypic abnormalities were observed in transgenic mice overexpressing either 
mutant human torsinA or wild-type torsinA, indicating that at high expression 
levels, the wild-type protein may also interfere with protein processing (110). A 
potential hypothesis would then be that torsinA expression levels must be 
maintained within a certain stoichiometry relative to its binding partners and that 
perturbations in either direction might lead to imbalances that cause dysfunction. 
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1.6. Primary plus dystonia, Dopa-responsive dystonia (DYT5) 
(This section reviews dopa-responsive dystonia with mutations in GCH1 gene. This project 
aims to identify if non-coding mutations in the 5’UTR of the gene are pathogenic in dopa 
responsive dystonia.) 
To date, three genes have been convincingly shown to cause DOPA-responsive 
dystonia (DRD): GCH1 (guanosine triphosphate cyclohydrolase 1 gene), TH (tyrosine 
hydroxylase) and SPR (sepiapterin reductase) (167–169). All three genes are bound 
together aetiologically by their connection to the endogenous pathway for the 
synthesis of dopamine, which accounts for their shared clinic characteristic of an 
improvement in symptoms in response to treatment with oral l-DOPA.  We discuss 
GCH1 gene in relation to dopa responsive dystonia in detail hereafter as mutations 
in GCH1 gene are the commonest cause of dopa-responsive dystonia (DYT5). 
Genetics and clinical features 
DYT-5 dystonia is an autosomal dominant hereditary DRD (170), a rare movement 
disorder which presents typically in childhood with lower limb dystonia and 
subsequent generalization (171). DYT5 is linked to the mutations in the GCH1 on 
chromosome 14 q21.1-q22.2 (167,172). More than 200 mutations have been 
reported in the gene (refer The Human Gene Mutation Database [HGMD]: 
http://www.hgmd.cf.ac.uk/ac/gene.php?gene = GCH1 for a complete published list 
of mutations). The hallmark of the disease is an excellent and sustained response to 
small doses of levodopa, generally without the occurrence of motor fluctuations. 
(170–173).  
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Clinical presentation is typically with lower limb dystonia and gait disturbance in 
the first decade of life, which occasionally leads to misdiagnosis as cerebral palsy or 
spastic paraparesis (174). Diurnal fluctuation in the severity of the dystonia is 
common, though this may abate with age. With time there is usually gradual 
generalization, and parkinsonism and dystonic tremor are possible complications of 
the condition (175,176). In a subgroup of patients, the dystonia is mild, progresses 
only very slowly and may require no treatment (177). Infrequently, patients may 
present later in life with a dystonic tremor or akinetic-rigid Parkinsonism (172,177). 
There is some evidence that subtle neuropsychiatric features may be associated 
with mutations in this gene. In one recent study of 18 patients, major depressive 
and sleep disorders occurred in about half of those over 20 years of age, whereas 
obsessive–compulsive disorder was found in 25% of cases (178). In terms of 
treatment, the response even to low doses of l-DOPA is generally excellent (70–
100% improvement in clinical symptoms), sustained and is not generally associated 
with the late-onset dyskinesias that often accompany prolonged use of l-DOPA in 
other conditions, such as PD (179). Diagnosis can be confirmed on the basis of 
reduced cerebrospinal fluid levels of pterins, dopamine and serotonin metabolites 
(180), or an abnormal phenylalanine loading test (181,182). 
Inheritance is usually autosomal dominant with reduced penetrance. Mutations in 
this gene account for ~60–80% of autosomal dominant DRD (183). Penetrance is 
incomplete and lower for males (~40–50%) than females (~80%)(184). Autosomal 
recessive mutations in GCH1 have also been reported, resulting in no detectable 
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enzyme activity in the liver. As might be expected the phenotype is generally 
distinct and much more severe, with complex neurological dysfunction, including 
developmental delay, spasticity, seizures and physiological 
hyperphenylalaninaemia, which is generally picked up on routine screening of 
newborn infants (185). DRD shares some similarities with primary torsion dystonia 
such as frequent onset in childhood and initial involvement of lower limbs. 
Noncoding mutations have also been reported spanning the 5’ upstream region of 
GCH1 gene. One subject had 2 mutations, -39C>T and -132C>T and another had a 
single mutation, -22 C>T. One family of Irish/French-Canadian ethnicity with DRD 
was studied where -22 C>T mutation segregate in the family with disease affected 
status (181,186). This makes it likely that the -22 C>T mutation is pathogenic and 
results in DRD. Of the above three mutations only -22 C>T mutation is 
evolutionarily conserved between human, rat and mouse (Figure 1.8).
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Figure 1.8: Alignment of the human, mouse and rat 5’ upstream GCH1 region. Nucleotides are numbered from the transcription start site (+1) as previously identified for 
the human, rat and mouse GCH1 genes. Substitutions identified to date is shaded and the nucleotide substitution is shown beneath the sequence.(Adapted from (187)). 
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 GTP cyclohydrolase 1 (GTPCH) 
GCH1 gene encodes the enzyme guanosine triphosphate cyclohydrolase 1 gene, the 
enzyme controlling the first and rate-limiting step of the biosynthesis of 
tetrahydrobiopterin, essential cofactor for the ativity of tyrosine hydroxylase, and 
for dopamine production in nigrostriatal cells (188).  
Neuropathology 
Neuropathological examination, in a limited number of dystonia cases, revealed 
marked reduction of melanin pigment and dopamine content in nigrostriatal 
neurons, but no evidence of nigral cell loss or degeneration (189). 
1.7. Genetics of Spinocerebellar ataxia type 8 (SCA8) 
The autosomal dominant inherited ataxias (ADCA) constitute a clinically and 
genetically heterogeneous group of neurodegenerative diseases (190). ADCA is 
commonly denoted as Spinocerebellar ataxias (SCAs) and numbered chronologically 
following publication date from SCA1 found in 1993 (191) up to SCA35 and SCA36 
described in 2011 (192,193) and SCA37 described in 2013 (194). SCAs are a group of 
late-onset neurodegenerative disorders characterized by slowly progressive ataxia 
that eventually leads to severe gait, speech, coordination and sensory loss (190). 
Polyglutamine expansion (a type of trinucleotide repeat expansion) in the encoded 
protein is the main mutational mechanism behind SCA1-3, SCA6-7 and 
Dentatorubral-Pallidoluysian Atrophy (DRPLA). However, trinucleotide repeat 
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expansions in the non-translated region of the genes causes gait ataxia in SCA8, 10, 
12, 31 and 36 (192,195).  
Identification of the SCA8 CTG/CAGrepeat expansion mutation 
SCA8 is a dominantly inherited, slowly progressive neurodegenerative disorder 
caused by expression of a CTG/CAG repeat expansion mutation from opposite 
strands producing CUG expansion transcripts (ATXN8OS) and a polyglutamine 
expression protein (ATXN8) in the 3’ UTR of the SCA8 gene (196). SCA8 has been 
classified into a new class of degenerative disorder in which microsatellite repeat 
expansion within a non-coding region of the gene results in an altered RNA product 
with a deleterious effect. The mutation for SCA8 was initially identified in 1999 as a 
CTG/CAG expansion mapping to chromosome 13q21 (197). The initial sequence 
analysis of the SCA8 CTG/CAG repeat region identified no likely open reading 
frames in the CTG or CAG direction but it was demonstrated that the SCA8 repeat 
mutation was transcribed in the CTG direction and that transcripts containing the 
CAG repeat were primarily expressed in the CNS and cerebellum (197). The 
CTG/CAGrepeat is adjacent to a CTA/TAG repeat that is highly polymorphic but 
stable when transmitted from one generation to the next (197–199). Although the 
SCA8 repeat is conserved in chimpanzees, gorillas, and orang-utans the genomic 
region containing the SCA8 repeat is not conserved in the mouse (200–202). 
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Evidence for SCA8 CTG expansion causing ataxia 
It has been suggested that the CTG/CAG expansion is not involved in the SCA8 
disease process and is simply a non-pathogenic polymorphism in linkage 
disequilibrium with another mutation that causes ataxia (203,204). However, using 
RAPID cloning  SCA8 CTG/CAG expansion was isolated directly from the DNA of a 
single ataxia patient (197,205). Similar SCA8 expansions were subsequently found 
in additional ataxia families including a seven generation Amish-mennonite (MN-A) 
family (197,206). This study allowed 92 family members to genetically confirm that 
the mutation and the clinical disease map to the same locus (197,205,207). The 
relationship between repeat length and disease was observed in MN-A family 
members having longer CTG repeat tract (mean 116) than 21 asymptomatic 
expansion carriers (mean 90). The high frequency of SCA8 expansion was observed 
among apparently unrelated ataxia families worldwide with an incidence of 2-5% 
(197,208–212). SCA8 transcripts are primarily expressed in CNS tissue, including 
cerebellum (197,206). 
Clinical features of SCA8 
SCA8 presents as an ataxia with slow progression that largely spares brainstem and 
cerebral function (197,206–209,213,214). In the MN-A family, disease onset ranges 
from 13-60 years of age with the most frequently reported symptom being gait 
incoordination. Disease progression is relatively slow with significantly limited 
mobility occurring approximately 20 years after the initial symptoms, but without 
shortening life expectancy. Moderate to severely affected patients present with 
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dysarthric speech and commonly manifest oculomotor deficits (206,213,215). 
Severely affected individuals can present with hyperflexia and occasionally present 
mild myoclonic finger and arm jerks. Mild sensory loss is observed as indicated by 
decreased vibratory perception (206,213). 
MRI analysis shows atrophy of the cerebellar hemispheres and vermis in affected 
SCA8 individuals (206,214,216), with little or no involvement of the brainstem, 
cerebral hemispheres and basal ganglia. Results from MRI studies are variable but 
generally show little change in affected individuals over decades of life, being  
consistent with the slowly progressive disease course (206). Analysis of a carrier of 
a SCA8 expansion, who is clinically unaffected, showed cerebellar atrophy 
indicating that asymptomatic individuals with the SCA8 mutation may have mild 
cerebellar atrophy (216).  
Reduced Penetrance in SCA8 
The SCA8 mutation is transmitted in an autosomal dominant pattern with reduced 
penetrance. The linkage data and the biological relationship between the repeat 
length and disease status in the MN-A family have supported the hypothesis that 
CTG/CAG repeat length is directly associated with ataxia. Affected members of the 
large MN-A family have significantly longer expansions (110-127, mean=119) than 
unaffected MN-A expansion carriers (73-104, mean=90) (206), indicating 
penetrance is influenced by CTG/CAGrepeat length (197,206). 
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A more complex pattern of inheritance emerges in other SCA8 families with more 
individuals that are carriers for the SCA8 expansion being asymptomatic 
(197,206,214,216,217). In small families with multiple affected individuals, the 
repeat mutation co-segregates with ataxia but far fewer expansion carriers develop 
ataxia (197,206,213,214,216–218). Additionally, the tight correlation between 
repeat size and pathogenesis found in the MN-A family has not been found in other 
reported SCA8 ataxia families with unaffected expansion carriers commonly having 
repeat sizes that exceed the pathogenic threshold observed in the MN-A family 
(218). These findings, and others, demonstrate that SCA8 expansions cannot be 
used to predict ataxia in asymptomatic expansion carriers (199,204,218). 
SCA8 allele sizes 
The precise number of the pathogenic (CTG)n repeat is technically difficult to 
determine due to its localization adjacent to a non-pathogenic but highly 
polymorphic, stably transmitted (CTA)n repeat (198).  Therefore the current 
reference ranges are based on the total number of both the (CTA)n and (CTG)n 
repeats. Normal alleles: In general population, more than 99% of the alleles have 
16-37 combined repeats (197). Expanded alleles: The reduced penetrance is found 
for SCA8 repeats of all sizes (219). The combined repeat length of the alleles with 
ataxia ranges from 68  to >1000 repeats, mostly 85-130 (203,218). Although the 
length of the repeat tract does not correlate with the age of onset, severity, 
symptoms or disease progression, within the repeat range 85-130, affected 
individuals tend to have longer repeat tracts than asymptomatic individuals. 
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However large SCA8 repeat allele has been reported in healthy controls and in non-
ataxia neurological and neuropsychiatric patients (203,204,217,220,221). 
1.8. Neurodegeneration with brain iron accumulation (NBIA) 
(Neurodegeneration with brain iron accumulation (NBIA) brain is a movement disorder with a 
hallmark feature of iron deposition in the basal ganglia observed in magnetic resonance imaging.   
Neuroacanthocytosis (NA) is progressive movement disorder where presence of acanthocytes, spiky 
red cells with a poorly-understood membrane dysfunction in blood is a hallmark feature. The 
neuropathology of these two disorders, NBIA and NA will be discussed.)    
Neurodegenerative disorders with high levels of iron in the basal ganglia 
encompass a group of single gene disorders collectively known as NBIA 
(neurodegeneration with brain iron accumulation) disorders. NBIA is a group of 
heterogeneous disorders primarily characterized by progressive extrapyramidal 
deterioration and excess iron accumulation in the basal ganglia (222). The hallmark 
clinical manifestations of NBIA are progressive dystonia, dysarthria, spasticity and 
parkinsonism.  To date there are nine genes associated with the NBIA disorders 
(Table 1.5). Despite important differences, several genetically diverse forms of NBIA 
share common features in addition to iron deposition, such as the presence of 
neuroaxonal spheroids suggesting axonal dysfunction (223). Also reported are tau 
or α-synuclein pathology (223). Beta-propeller protein (WDR45) will be the focus of 
this chapter. 
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Table 1.5 Types of NBIA (224) 
Disease name Gene Inheritance Pattern of iron deposition Other key features 
Pantothenate kinase-associated 
neurodegeneration (PKAN) (225) 
 
PANK2 
AR GP, SN Eye-of-the-tiger sign in GP 
PLA2G6-associated neurodegeneration (226) 
 
PLA2G6 
AR 
Variable GP, SN (some cases have no iron 
accumulation) 
Cerebellar atrophy 
Mitochondrial membrane protein-associated 
neurodegeneration (227,228) 
 
C19orf12 AR GP, SN 
Cerebellar and cortical atrophy; on T2-weighted images hyperintense 
streaking of the medial medullary lamina between the globus pallidus 
interna and externa 
Beta-propeller protein-associated 
neurodegeneration (229) 
WDR45 XLD GP, SN 
T1-weighted signal hyperintensity with a central band of hypointensity 
in the SN; SN iron > GP iron 
Fatty acid hydroxylase-associated 
neurodegeneration (230) 
FA2H AR GP, SN Pontocerebellar atrophy 
Kufor-Rakeb syndrome (231) ATP13A2 AR 
Variable GP, putamen, caudate (some cases 
have no iron accumulation) 
Cerebral, cerebellar, and brain stem atrophy 
Neuroferritinopathy (232) FTL AD GP, putamen, caudate, dentate, thalamus Cystic cavitation; mild cortical and cerebellar atrophy 
Aceruloplasminemia 
(233) 
CP AR GP, putamen, caudate, thalamus, RN, dentate Cerebellar atrophy 
Woodhouse-Sakati syndrome (234) DCAF17 AR GP No additional key features 
 
COASY protein-associated neurodegeneration 
(CoPAN) (235) 
COASY AR GP, SN 
T2-weighted images: hyperintense caudate, putamina, medial and 
posterior thalami in early disease; GP calcifications 
GP: globus palligus; SN: substantia nigra; RN: red nucleus 
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1.8.1. Beta-propeller protein associated neurodegeneration (BPAN)  
Mutations in the WD repeat domain 45 (WDR45) gene  on chromosome Xp11 are 
linked to BPAN, a type of NBIA (229). Previously referenced as “SENDA” (static 
encephalopathy of childhood with neurodegeneration in adulthood), BPAN has X-
linked inheritance and is characterized by global developmental delay in early 
childhood that is essentially static, with slow motor and cognitive gains until 
adolescence or early adulthood (229). In young adulthood, affected individuals 
develop progressive dystonia, parkinsonism, extrapyramidal signs and dementia 
resulting in severe disability. Brain MRI shows iron accumulation in the globus 
pallidus and substantia nigra. A characteristic finding is T1-weighted hyperintensity 
surrounding a central band of hypointensity in the substantia nigra. Cerebral and 
cerebellar atrophy are also observed (229,236).  
Genetics 
All BPAN cases reported to date harboured de novo mutations in the WDR45 gene 
encoding a beta-propeller protein.  In a study of 20 unrelated patients (17 females 
and 3 males) with BPAN, 19 different hemizygous or heterozygous de novo 
mutations in the WDR45 gene were identified located throughout the coding 
sequence, most of the mutations were truncating but 2 were missense mutations 
affecting highly conserved residues (229). Another study identified 5 different de 
novo heterozygous truncating mutations in the WDR45 gene in 5 unrelated women 
with NBIA5 (236). Although molecular analysis has shown it to be X-linked 
dominant, both affected males and females exhibited a homogeneous phenotype 
(236). Since WDR45 is on the X chromosome, the males must be somatic mosaic for 
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the mutation (229). Presumably, males with germline WDR45 mutations are 
nonviable. Females may either harbor germline or somatic mutations, and several 
affected females had evidence of skewed X-inactivation. All of these factors may 
contribute to disease manifestations. 
Neuropathology 
Macroscopic features reported in a single BPAN case were mild cerebellar atrophy, 
thinned cerebral peduncles and a dark grey-brown appearance of substantia nigra 
and, to a much lesser extent, the globus pallidus. Microscopic findings included that 
the globus pallidus and substantia nigra stained strongly for iron and demonstrated 
numerous large axonal spheroids, siderophages, reactive astrocytes and severe 
neuronal loss. Axonal spheroids were seen also in the pons, medulla and thalamus 
but were fewer in number. The putamen and thalamus showed gliosis and mild 
neuronal loss. Significant loss of Purkinje cells with axonal ‘torpedoes’ was evident. 
Numerous tau-positive NFTs were seen in the hippocampus, neocortex, putamen, 
and hypothalamus, with fewer seen in remaining neurons in globus pallidus, 
substantia nigra, pons and thalamus. No amyloid-β plaques or LBs were observed 
(237). 
Iron 
Iron participates in a wide array of cellular functions including cytokinesis, 
myelination, electron transport, antioxidant enzyme activity and biogenic amine 
metabolism. It is essential for normal neuroembryogenesis (238). In normal human 
brain, iron is regionally distributed and is highest in the globus pallidus, substantia 
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SNpr, dentate nucleus, and red nucleus. Though very little iron is typically stored in 
neurons, and since neuronal iron is transported along axons and dendrites, iron 
overload may cause both neuronal cell death and axonal degeneration (239). In 
NBIA iron accumulates abnormally in the brain regions that are typically iron-rich, 
substantia nigra and globus pallidus (240). The electronic properties of this 
transition metal enable iron to take part in chemical reactions that may be injurious 
to neural and other cellular substrates. Owing to iron’s ability to donate electrons 
to oxygen, increased iron levels can lead to the formation of hydroxyl radicals and 
hydroxyl anions via the Fenton Reaction (Fe2+ + H2O2 → Fe
3+ + OH· + OH−).  
Increased iron levels also can generate peroxyl/alkoxyl radicals due to Fe2+-
dependent lipid peroxidation (241). These reactive-oxygen species (ROS) can 
damage cellular macromolecules including proteins, lipids, and DNA. Under normal 
conditions, several detoxification systems and antioxidant defence mechanisms 
exist to prevent this damage; for example, catalase and glutathione peroxidase 
quickly convert H2O2 to water, helping to ensure that ROS-induced damage is 
minimal in the brain (242). However, when the formation of ROS exceeds the cells’ 
detoxification/antioxidant systems, the cell experiences oxidative stress. Iron-
induced oxidative stress is particularly dangerous because it can cause further iron 
release from iron-containing proteins such as ferritin (Ft), heme proteins, and iron-
sulfur (Fe-S) clusters, forming a destructive intracellular positive-feedback loop that 
exacerbates the toxic effects of brain iron overload (246). Iron has been shown to 
progressively accumulate in the brain with normal aging, and  iron-induced 
oxidative stress can also cause neurodegeneration (243). However, the brain iron 
 P a g e  | 55 
uptake and the cellular and intercellular iron transport mechanisms in the central 
nervous system are still poorly understood. In NBIA, where iron deposition is 
considered as the biomarker, it is yet to be understood if the iron directly 
contributes to the functional consequences, for example, tissue damage or is solely 
an epiphenomenon.  
Beta-propeller protein and autophagy 
In the case of BPAN,  the WDR45 gene is postulated to have an important role in 
the autophagy pathway, which is the major intracellular degradation system by 
which cytoplasmic materials are packaged into autophagosomes and delivered to 
lysosomes for degradation in autophagy (236). WDR45 is the first NBIA gene 
directly linked to autophagy.  
Beta-propeller protein encoded by the WDR45 gene is one of the four mammalian 
homologs of yeast Atg18, an important regulator of autophagy. Its involvement in 
autophagy has been documented in yeast and mammalian cells, where it interacts 
with ATG2 (244), and in C. elegans, where its deletion leads to accumulation of 
early autophagosome (245). In lymphoblast cells from BPAN patients, accumulation 
of LC3-II protein and its co-localization with ATG9a in enlarged membrane 
structures was observed suggesting autophagosome formation is hindered at an 
early stage (236). Hence, BPAN represents the first direct link between the 
autophagy mechanism and neurodegeneration. Further functional studies may 
provide a link between iron homeostasis and autophagy as neuronal autophagy is 
essential for the elimination of accumulated and aggregating proteins.  
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1.8.2. Neuroacanthocytosis 
Neuroacanthocytosis (NA) encompasses a group of genetically heterogeneous 
disorders characterized by neurologic signs and symptoms associated with 
acanthocytosis, an abnormality of red blood cells in which a certain percentage of 
erythrocytes (typically 10-30%) have an unusual starlike appearance with spiky- or 
thorny-appearing projections (246,247). Neurologic problems usually consist of 
either movement disorders or ataxia, personality changes, cognitive deterioration 
(248,249), axonal neuropathy, and seizures (250).  
The first form of NA to be well described in the medical literature is Bassen-
Kornzweig disease, or abetalipoproteinemia  which is an autosomal recessive 
abnormality of lipoprotein metabolism resulting in ataxia combined with 
acanthocytosis (246). Bassen-Kornzweig disease was compared with a better 
known condition, Friedreich ataxia. The two are rather similar except that patients 
with Bassen-Kornzweig disease have acanthocytosis. The second type of 
neuroacanthocytosis was described in two separate North American kindreds 
known as Levine-Critchley syndrome (251,252). Levine-Critchley syndrome 
resembled Huntington disease with prominent choreiform or choreoathetoid 
movements, progressive dementia, and, in the original descriptions, autosomal 
dominant inheritance. 
The first recognised neurological association was a result from inherited 
abetalipoproteinaemia and sometime referred to as hereditary acanthocytosis 
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(246). However, casaes with acanthocytosis and neurological impairment have 
been reported without lipoprotein abnormalities (253). 
Genetics  
The inheritance of NA has been described as autosomal recessive, autosomal 
dominant and as part of an X-linked disorder called McLeod syndrome (MLS). The 
autosomal recessive type, called chorea-acanthocytosis (ChAc), is the most 
common form of NA and is linked to the mutations in VPS13A gene 
(251,252,254,255). The VPS13A gene spans a 250kb region on chromosome 9q21 
and consists of 73 exons encoding chorein (255,256). Chorein is believed to be 
involved in protein trafficking at the trans-golgi network for maintenance of the 
plasma membrane (255,257). The localization of chorein has been demonstrated in 
wild-type mice by western blot (WB) and immunohistochemical (IHC) analyses 
(258).  
Neuropathology 
The degeneration of the basal ganglia is a consistent feature of NA. On autopsy of 
NA cases, the cerebral cortex appears unaffected. Macroscopically, bilateral 
atrophy of the caudate nucleus, the putamen and the globus pallidus was 
observed. This corresponds to neuronal loss and gliosis, which was particularly 
severe in the caudate and less so in the putamen and the external and internal 
pallidum (259–261). Pronounced neuronal loss in the substantia nigra was the likely 
neuropathological correlate of Parkinsonism. Gliosis and extraneuronal melanin 
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pigment without LBs were reported in the substantia nigra. The locus coeruleus, 
inferior olives, and cerebellum appeared unaffected. Loss of spinal cord anterior 
horn cells, a correlate of neurogenic muscle atrophy, was seen in some of the 
autopsies of individuals with ChAc. Gliosis may also occur in the thalamus.  
Acanthocyte 
Acanthocytic deformation of red cells is an intriguing feature and may possibly 
provide an essential clue for the understanding of their pathophysiology. The 
acanthocytic protrusion of parts of the cell membrane appears to be the result of 
disorganized membrane-cytoskeleton interactions due to defective endosomal 
trafficking and sorting, autophagic flux and autolysosomal degradation in late stage 
erythropoiesis. The protrusions and thorns of acanthocytes could perhaps be 
viewed as an arrested state among a multitude of continuously changing states of 
membrane deformation, thus potentially providing insights into basic mechanisms 
of cell biology (262).
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1.9. Lewy bodies (LBs) in Lysosomal storage disorders (LSDs)  
Classically, the approach taken to the study of genetic forms of diseases has relied 
on the clinical features associated with each genetic locus. A great deal of attention 
has been focused on the assignment of the locus on the clinical basis. However, to 
identify the pathways of pathogenicity for a given disorder, arguably, one should 
start by analyzing the genetics of disease based on pathology. We are more likely to 
find a common pathway if there is a common pathology rather than common 
clinical characteristics. In this regard, LB diseases sharing the common role in 
ceramide metabolism are discussed based on Figure 1.9. 
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Figure 1.9: Ceramide pathway with lysosomal storage disorders (highlighted in red) along the 
pathway. The defective enzymes are in bold. Adapted from (263). 
Ceramide 
Ceramide, the precursor of all complex sphingolipids, is a potent signaling molecule 
that mediates key events of cellular pathophysiology. In the nervous system, the 
sphingolipid metabolism has an important impact on neural tissue. All sphingolipids 
are synthesized from ceramides and are hydrolyzed to ceramides using specific acid 
exohydrolases. Deficiency or malfunctioning of one of these enzymes results in 
accumulation of the corresponding lipid substrate in the lysosomal compartment 
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leading to cellular enlargement, dysfunction and death. Their abnormal storage and 
slow turnover results in severe dementia and mental retardation. Ceramides are 
able to induce apoptosis by changing the phospholipid membrane properties, 
increasing the membrane permeability leading to an efflux of lysosomal proteases 
and inhibits the mitochondrial respiratory chain (264–266). Appropriate lipid 
membrane homeostasis is crucial for lysosomal, mitochondria and myelin sheath 
arrangement. Lysosomes are linked to iron in the cell, as they degrade cytosolic 
ferritin and its disruption would damage cellular iron recycling (267). In turn the 
free iron would overload phagocytosing cells and increase reactive oxygen species. 
Oligodendrocytes contain the highest iron content of all the brain cells; they are 
highly energy and lipid demanding. Disruption of these supplies may lead to 
dysfunction of myelin production or maintenance (268).  
Levels of cellular ceramide are regulated by the de novo pathway and the recycling 
pathway (269). The former relates to the synthesis of ceramide through the 
condensation of palmitate and serine in a series of reactions that are ultimately 
dependent on Co-Enzyme A. The latter pathway is slightly more intricate, since 
several outcomes are possible depending on the enzymes involved (269). 
LSDs 
Lysosomes are acidic intracellular compartment that provide inherent protein, 
nucleic acid and pathogen degrading activities for the cell. They receive their 
substrates from endocytosis, phagocytosis and autophagy and are active 
participants in bulk degeneration of metabolic waste products (270). Lysosomal 
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activities are rate-limiting, induced under stress and the major force in clearance of 
damaged or aggregated proteins. The autophagy-lysosomal pathway is essential for 
maintaining protein and energy homeostasis (271).  
Inherited metabolic disorders which have been linked to lysosomal dysfunction 
belong to a family of diseases identified as sphingolipidoses, a class of LSDs 
(272,273). The main members of the sphingolipidoses are NPC disease, Krabbe 
disease, Gaucher disease, Fabry disease, Tay-Sachs disease, Sandhoff disease and 
metachromatic leukodystrophy. They are generally inherited in an autosomal 
recessive fashion, but notably Fabry disease is X-linked. Taken together, 
sphingolipidoses have an incidence of approximately 1 in 10,000, but substantially 
more in certain populations such as Ashkenazi Jews. Enzyme replacement therapy 
is available to treat mainly Fabry disease and Gaucher disease, and people with 
these types of sphingolipidoses may live well into adulthood. The other types are 
generally fatal by age 1 to 5 years for infantile forms, but progression may be mild 
for juvenile- or adult-onset forms (274). 
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Table 1.6 Comparison of the main sphingolipidoses 
Disease (reference) Inheritance Deficient enzyme Accumulated products Clinical symptoms Treatment 
Niemann-Pick (275) 
Autosomal 
recessive 
 
Sphingomyelinase 
Sphingomyelin in brain & red blood cell 
 
Mental retardation, spasticity, seizures, 
hepatosplenomegaly, thrombocytopenia, ataxia 
Limited, usually fatal by the age of approx 
1.5years 
 
Fabry disease (276) X-linked α-galactosidase A 
Glycolipids, particularly ceramide 
trihexoside, in brain, heart, kidney 
Ischemic infarction in affected organs, 
acroparesthesia, angiokeratomas hypohidrosis 
Enzyme replacement therapy (but 
expensive), life expectancy among males of 
approximately 60 years 
Krabbe disease (277) 
Autosomal 
recessive 
Galactocerebrosida-
se 
Glycolipids, particularly 
galactocerebroside, in 
oligodendrocytes 
Spasticity, neurodenegeration(leading to death), 
hypertonia, hyperreflexia, decerebration-like 
posture, blindness and deafness 
Limited, generally fatal before age 2 for 
infants 
Gaucher disease (278) 
Autosomal 
recessive 
 
Glucocerebrosidase 
Glucocerebrosides in red blood cells, 
liver and spleen 
Hepatosplenomegaly, pancytopenia, bone pain, 
erlenmeyer flask deformity 
Enzyme replacement therapy (but 
expensive), may live well into adulthood 
Tay-Sachs disease (279) 
Autosomal 
recessive 
Hexosaminidase A GM2 gangliosides in neurons 
Neurodegeneration, developmental disability, 
early death 
Death by approximately  4 years for infantile 
Tay–Sachs 
Sandhoff disease (280) 
Autosomal 
recessive 
Hexosaminidase A + 
B 
Globosides in neurons and spinal cord 
 
Developmental disability, seizures, ataxia, speech 
problems, early death 
Infantile Sandhoff usually live only into early 
childhood 
Metachromatic 
 leukodystrophy (MLD) 
(277) 
Autosomal 
recessive 
Arylsulfatase A or 
prosaposin 
Sulfatide compounds in neural tissue, 
demyelinisation in  central and 
peripheral nervous system 
Mental retardation, motor dysfunction, ataxia, 
hyporeflexia, seizures 
Death by approximately  5 years for infantile 
MLD 
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Niemann-Pick type C (NPC) disease is an autosomal recessive lipid storage disorder 
characterized by progressive neurodegeneration with a highly variable clinical 
phenotype. Patients with the 'classic' childhood onset type C usually appear normal 
for 1 or 2 years with symptoms appearing between 2 and 4 years. They gradually 
develop neurologic abnormalities which are initially manifested by ataxia, seizures, 
and loss of previously learned speech. Spasticity is striking and seizures are 
common (281). Approximately 95% of cases are caused by mutations in the NPC1 
gene, referred to as type C1. This gene encodes a putative integral membrane 
protein containing motifs consistent with a role in intracellular transport of 
cholesterol to post-lysosomal destinations. Cells from NPC subjects show a 
decrease in acid sphingomyelinase activity, leading to the accumulation of 
sphingomyelin (282). Since one of the pathways for ceramide recycling is the 
sphingomyelin pathway, it is conceivable that associated to the accumulation of 
sphingomyelin, a decrease of ceramide may also be present. Some cases of NPC1 
were described as having LBs (283). 
Krabbe disease is an autosomal recessive disorder caused by deficiency of the 
enzyme galactocerebrosidase.  The disease most often affects infants, with onset 
before age 6 months, but can occur in adolescence or adulthood.  The build up of 
undigested fats affects the growth of the myelin sheath and causes severe 
deterioration of mental and motor skills.  Other symptoms include muscle 
weakness, hypertonia, myoclonic seizures, spasticity, irritability, unexplained fever, 
deafness, optic atrophy and blindness, paralysis, and difficulty when swallowing. In 
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infants, the disease is generally fatal before age 2.  Patients with a later onset form 
of the disease have a milder course and live significantly longer. 
Galactocerebrosidase is responsible for the liposomal hydrolysis of galactolipids 
formed during white matter myelination. The pathologic changes in the peripheral 
and CNS (globoid cell formation and decreased myelin) appear to result from the 
toxic nature of accumulated psychosine (galactosylsphingosine) and 
galactocerebroside (galactosylceramide) that cannot be degraded because of the 
galactocerebrosidase deficiency. In vitro assays demonstrated that psychosine, the 
neurotoxic sphingolipid accumulated in Krabbe brain, accelerated the fibrillization 
of α-synuclein. Hence, the occurrence of neuronal deposits of fibrillized proteins 
including α-synuclein, identified Krabbe disease as a new α-synucleinopathy 
(277,284). 
Gaucher disease is the most common form of the sphingolipidoses caused by a 
homozygous or a compound heterozygous mutation in the glucocerebrosidase 
gene (GBA). The gene GBA encodes a lysosomal enzyme, glucocerebrosidase, that 
catalyses the breakdown of the glycolipid glucosylceramide to ceramide and 
glucose (285). Over 200 mutations have been described in GBA, most of which are 
known to cause Gaucher disease, in the homozygous or compound heterozygous 
condition (286). Manifestations may include an enlarged spleen and liver, liver 
malfunction, skeletal disorders and bone lesions that may be painful, severe 
neurologic complications, swelling of lymph nodes and (occasionally) adjacent 
joints, distended abdomen, a brownish tint to the skin, anemia, low blood platelets 
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and yellow fatty deposits on the sclera (287,288). Gaucher patients typically present 
enlarged macrophages resulting from the intracellular accumulation of 
glucosylceramide. The fact that these patients show increased levels of the 
enzyme’s substrate indicates that pathogenic variants act as loss-of-function 
mutations. GBA mutations, in addition to causing Gaucher disease when 
homozygous, have recently been established to act as a risk factor for PD (289,290) 
and for LB disorders (291). 
Fabry disease, also known as alpha-galactosidase-A deficiency, causes a build-up of 
glycolipids in the autonomic nervous system, eyes, kidneys, and cardiovascular 
system.  Fabry disease is the only X-linked lipid storage disease.  Onset of 
symptoms is usually during childhood or adolescence.  Neurological signs include 
burning pain in the arms and legs and the build up of excess material in the clear 
layers of the cornea.  Glycolipids storage in blood vessel walls may impair 
circulation, putting the patient at risk for stroke or heart attack.  Other 
manifestations include heart enlargement, progressive kidney impairment leading 
to renal failure, gastrointestinal difficulties, decreased sweating, fever and 
angiokeratomas.   
The gangliosidoses are comprised of two distinct groups of genetic diseases, 
monosialoganglioside 1 (GM1) and 2 (GM2).  Both are autosomal recessive and affect 
males and females equally. The GM1 gangliosidoses are caused by a deficiency of 
the enzyme beta-galactosidase, resulting in abnormal storage of acidic lipid 
materials particularly in the nerve cells in the central and peripheral nervous 
 P a g e  | 67 
systems.  GM1 gangliosidosis has three clinical presentations:  early infantile, late 
infantile, and adult.  Symptoms may vary with the age at onset but mainly include 
neurodegeneration, seizures, liver and spleen enlargement, coarsening of facial 
features, skeletal irregularities, joint stiffness, distended abdomen, muscle 
weakness, gait ataxia, dementia, angiokeratomas and difficulties with speech, 
muscle atrophy, corneal clouding in some patients, and dystonia. 
The GM2 gangliosidoses represent a heterogeneous autosomal recessive group of 
disorders caused by deficiency of the lysosomal enzyme beta- hexosaminidase. The 
resulting accumulation of ganglioside GM2 occurs primarily in neuronal cells and 
coincides with a progressive broad spectrum of neurologic deterioration (292,293). 
The GM2 disorders include: 
Tay-Sachs disease (also known as GM2 gangliosidosis-variant B) and its variant forms 
are caused by a deficiency in the enzyme hexosaminidase A.  The incidence is 
particularly high among Eastern European and Ashkenazi Jewish populations, as 
well as certain French Canadians and Louisianan Cajuns (294).  Affected children 
appear to develop normally for the first few months of life.  Symptoms begin by 6 
months of age and include progressive loss of mental ability, dementia, decreased 
eye contact, increased startle reflex to noise, progressive loss of hearing leading to 
deafness, difficulty in swallowing, blindness, cherry-red spots in the retinas, and 
some paralysis.  Seizures may begin in the child’s second year and often die by age 
4 from recurring infection. A rarer form of the disorder, called late-onset Tay-Sachs 
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disease, occurs in patients in their twenties and early thirties and is characterized 
by unsteadiness of gait and progressive neurological deterioration.  
Sandhoff disease (variant AB) is a severe form of Tay-Sachs disease.  Onset usually 
occurs at the age of 6 months and is not limited to any ethnic group.  Neurological 
signs may include progressive deterioration of the CNS, motor weakness, early 
blindness, marked startle response to sound, spasticity, myoclonus (shock-like 
contractions of a muscle), seizures, macrocephaly (an abnormally enlarged head), 
and cherry-red spots in the eye.  Children generally die by age 3 from respiratory 
infections.  
Metachromatic leukodystrophy (MLD) is an autosomal recessive deficiency 
comprised of several allelic disorders. The variant with cerebroside sulfate 
deficiency results in accumulation of the myelin lipid sulfatide in oligodendrocytes 
and Schwann cells (295). Patients are normal up to age one or two years, and then 
develop progressive peripheral neuropathy, psychomotor retardation, and 
blindness. Signs of white matter involvement (spasticity, brisk tendon reflexes, 
extensor plantar responses) are prominent. Less severe variants cause adult onset 
dementia, psychiatric disorders, and neuropathy (295). 
LBs 
Intracellular proteinaceous inclusions called LBs and Lewy neurites are the common 
pathological features in the brainstem and cortical areas in PD and dementia. 
Alpha-synuclein is the major component of LBs and diseases with mutations in 
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SNCA gene have extensive LBs since these mutations are known to increase 
aggregation of the protein (296,297). Alpha-synuclein may also be involved, albeit 
in a more indirect manner, in the ceramide pathway. It has been shown that 
deletion of the gene decreases brain palmitate uptake (298) and that the presence 
of palmitic acid increases the de novo synthesis of ceramide significantly (299). 
However, known pathogenic mutations in SNCA gene are likely gain-of-function 
mutations, suggesting that, in these cases, the mutations drive the aggregation of 
α-synuclein, while in cases where ceramide metabolism is affected, LB inclusions 
may be a cellular response to this altered ceramide metabolism. Also connecting 
the ceramide pathway to α-synuclein deposition is the recent description of an 
increase in alpha-synuclein inclusions in C. elegans when LASS2, a ceramide 
synthase, is knocked-down (300). This result should obviously be taken with some 
caution, since it was obtained in a non-mammalian organism, but nevertheless it 
further connects ceramide to synuclein deposition. 
LSDs occurring due to the enzyme dysfunction in the ceramide pathway also 
develop Lewy body pathology, for example, NPC, Krabbe disease, and Gaucher 
disease. Hence, a possibility is that LSDs, GM1, Tay-Sachs disease, Sandhoff disease, 
Fabry disease and metachromatic leukodystrophy which occur due to enzyme 
dysfunction in the ceramide pathway may mimic the Lewy body pathology 
suggesting that this may be a common theme for pathogenesis. 
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1.10. Thesis Aims and objectives 
This primary aim of this thesis is to significantly contribute to the field of 
neuroscience by identifying causes of the neurodegenerative diseases via classical 
methods. In this regard genetics and neuropathology of dystonia, NBIA, SCA 8 and 
LSDs in ceramide pathway were investigated.  
The specific aims include: 
A) To investigate genetic and neuropathological aspects of primary dystonia 
cases and provide a detailed neuropathological study on primary pure 
dystonia through a unique resource of genetically confirmed 7 DYT1 cases 
and 2 DYT6 cases. The approach taken is to provide a clinical-genetic-
pathological description of these cases.  
B) To investigate interaction between two primary pure dystonia genes, 
TOR1A and THAP1, thereby determining whether there is a common 
mechanistic pathway in primary dystonia. The approach taken is from 
genetic to pathophysiological prediction. 
C) To investigate whether the non coding mutations in the 5’UTR region of 
GCH1 gene is pathogenic in dopa responsive dystonia. The approach taken 
is from genetic to clinical correlation. 
D) To investigate the trinucleotide repeat expansion length for SCA8 in ataxia 
patients to determine whether the repeat length is directly related to the 
disease pathogenesis. The approach taken is from repeat length to clinical 
and pathogenicity prediction. 
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E) To investigate the neuropathology of NBIA cases, neuroacanthocytosis and 
WDR45 case. The approach taken is from clinical to genetic and pathological 
description.  
F) To investigate if disease with an enzyme dysfunction in a specific pathway 
may have a shared pathology. In this regard, LSDs in the ceramide pathway 
were investigated for LB pathology. This approach taken is from 
neuropathology to genetic and clinical description. 
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Chapter 2. Materials and method 
 
2.1. Research cohorts 
Dystonia cohort 
This project was approved by the Joint Local Research Ethics Committee of the 
National Hospital for Neurology and Neurosurgery and the UCL Institute of 
Neurology. Autopsy specimens were received from the Brain and Tissue Banks for 
Developmental Disorders, Baltimore (BTBDD), Queen Square Brain Bank (QSBB) at 
University College London, and Harvard Brain Bank (HBB) and stored with 
appropriate consent. Ethical consent was also approved from all the participants. 
The research cohort consisted of 89 clinically diagnosed generalized dystonia 
patients (Table 2.1). Brain tissue samples were collected for 57 patients from 
BTBDD, 7 from HBB and 14 from QSBB. Genomic DNA was received for 11 patients 
from National Hospital for Neurology and Neurosurgery (NHNN-lab).  
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Table 2.1 Dystonia cases received from different brain banks 
Source UMB# 
 
Sex 
 
Age at death 
 
Disease Onset 
 
Clinical diagnosis 
 
NICHD-BTB 187 M 83 Adolescence Dystonia, Generalized, Familial 
NICHD-BTB 593 F 57 Adolescence Dystonia, Meige Syndrome, Focal 
NICHD 741 F 52 N/A Dystonia, Spasmodic Torticollis 
NICHD 785 M 69 Adulthood Dystonia, Generalized 
NICHD 837 F 52 N/A Dystonia 
NICHD 842 F 79 Adulthood Dystonia, Spasmodic Torticollis 
NICHD 851 M 70 N/A Dystonia, Spasmodic Torticollis 
NICHD 855 M 80 Adulthood Dystonia, Blepharospasm 
NICHD 903 F 68 Adulthood Dystonia, Meige Syndrome, Focal 
NICHD 999 F 79 N/A Dystonia, Spasmodic Torticollis 
NICHD 1017 F 84 Adulthood Dystonia, Spasmodic Torticollis 
NICHD 1019 M 44 Adulthood Dystonia 
NICHD 1020 M 71 Childhood Dystonia 
NICHD 1048 F 44 N/A Dystonia, Medication Induced 
NICHD 1099 F 75 Adult onset Dystonia, Blepharospasm 
NICHD 1125 F 77 Adult onset Dystonia,  Familial Tremor 
NICHD 1141 F 82 Childhood Dystonia, Generalized, Familial, 
NICHD 1162 F >90 N/A Dystonia, Meige Syndrome 
NICHD 1187 M >90 N/A Dystonia , Myoclonic Dystonia 
NICHD 1235 F 87 Adult onset Dystonia, Blepharospasm 
NICHD 1353 M 78 Childhood Dystonia, Acquired, Post Traumatic 
NICHD 1457 M 72 N/A Dystonia 
NICHD 1458 M 62 N/A Dystonia 
NICHD 1481 F 62 Late Dystonia 
NICHD 1513 F 81 Adulthood Dystonia, Spasmodic Torticollis 
NICHD 1554 F 59 Adulthood Dystonia 
NICHD 1559 F 78 Adulthood Dystonia, Spasmodic Torticollis 
NICHD 1629 F 73 N/A Dystonia, Blepharospasm, Meige Syndrome 
NICHD 1688 F 81 N/A Dystonia, Spasmodic Torticollis 
NICHD 1705 F >90 N/A Dystonia, Blepharospasm 
NICHD 1716 F >90 N/A Dystonia, Spasmodic Dysphonia 
NICHD 1837 F 81 N/A Dystonia, Meige Syndrome 
NICHD 1850 F 50 Adult onset Dystonia 
NICHD 1899 M 81 Adult onset Dystonia, Generalized, Meige Syndrome 
NICHD 4518 F 82 N/A Dystonia, Spasmodic Torticollis 
NICHD 4520 F 68 N/A Dystonia, Blepharospasm 
NICHD 4635 M 76 Adult onset Dystonia, Familial 
NICHD 4690 F >90 N/A Dystonia, Spasmodic Dysphonia 
NICHD 4700 F 75 Early onset Dystonia, Spasmodic Torticollis 
NICHD 4763 F 60 N/A Dystonia, Meige Syndrome 
NICHD 4835 M >90 Adult onset Dystonia, Meige syndrome,  Familial 
NICHD 4880 F 44 N/A Dystonia, Generalized 
NICHD 4881 M 70 Adult onset Dystonia, Generalized/Dementia 
NICHD 4897 F 49 N/A Dystonia, Generalized 
NICHD 5145 F 84 Adult onset Dystonia 
NICHD 5154 F >90 N/A Dystonia 
NICHD 5155 F 86 N/A Dystonia, Spasmodic Torticollis 
NICHD 5159 F 85 N/A Dystonia, Spasmodic Torticollis 
NICHD 5221 F 61 Late onset Dystonia 
NICHD 5281 F 32 N/A Dystonia, Spasmodic Torticollis 
NICHD 881 F 67 Childhood Dystonia, Generalized 
NICHD 1512 F 89 N/A Dystonia, DYT1 
NICHD 1619 F 87 Adult onset Dystonia, DYT1 
NICHD 4628 F 77 Childhood Dystonia, DYT1 
NICHD 4877 F >90 Late onset Dystonia, DYT1 
NICHD 4896 F >90 N/A Dystonia, DYT1 
NICHD 5200 F 88 N/A Dystonia, DYT1 
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 Table 2.1 Dystonia cases received from different brain banks continued... 
Source Case 
 
Sex 
 
Age at death 
 
Disease Onset 
 
Clinical diagnosis 
 
HBB HB1 M 30 N/A Dystonia 
HBB HB2 F 57 N/A Dystonia 
HBB HB3 F 79 N/A Dystonia 
HBB HB4 M 58 N/A Dystonia 
HBB HB5 M 56 N/A Dystonia 
HBB HB6 M 88 N/A Dystonia 
HBB HB7 M 57 N/A Dystonia 
QSBB QS1 M 69 Adulthood Dystonia 
QSBB QS2 F 76 Adulthood Dystonia 
QSBB QS3 F 76 Childhood Dystonia 
QSBB QS4 F 74 Adulthood Dystonia 
QSBB QS5 F 70 Late Dystonia 
QSBB QS6 F 77 Childhood Dystonia 
QSBB QS7 M 91 Late Dystonia 
QSBB QS8 M 79 Adulthood Dystonia 
QSBB QS9 F 81 Late Dystonia 
QSBB QS10 F 86 Late Dystonia 
QSBB QS11 F 84 Late Dystonia 
QSBB QS12 F 76 Adulthood Dystonia 
QSBB QS13 M 61 N/A Dystonia 
NHNN NH1 N/A N/A N/A Dystonia 
NHNN NH2 N/A N/A N/A Dystonia 
NHNN NH3 N/A N/A N/A Dystonia 
NHNN NH4 N/A N/A N/A Dystonia 
NHNN NH5 N/A N/A N/A Dystonia 
NHNN NH6 N/A N/A N/A Dystonia 
NHNN NH7 N/A N/A N/A Dystonia 
NHNN NH8 N/A N/A N/A Dystonia 
NHNN NH9 N/A N/A N/A Dystonia 
NHNN NH10 N/A N/A N/A Dystonia 
NHNN NH11 N/A N/A N/A Dystonia 
 
The dystonia cohort for the gene interaction project consisted of 6 DYT1 and 2DYT6 
cases along with 5 age and sex matched controls. Brains regions available and used 
for the study are summarized in Table 2.2. 
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Table 2.2 Dystonia cohort for gene interaction study 
Cases Frontal 
cortex 
Superior  
temporal  
gyrus  
Cerebellum Globus 
pallidus  
Caudate Putamen  Medulla Pons  Hippo- 
campus 
Midbrain 
DYT1 X          
DYT1 X x X x  x  x   
DYT1 X x         
DYT1 X x X x  x x x  x 
DYT1 X x X     x   
DYT1 X x X x  x x x  x 
DYT6 X x X x x x x   x 
DYT6 X x X x x x x  x  
Ctrl x x X x x x x x x x 
Ctrl x x X    x x x x 
Ctrl x  X     x x x 
Ctrl x  X  x x x x x  
Ctrl x  X  x   x x x 
 
DYT1 and DYT6 cohorts for neuropathological study  
Table 2.3 DYT1 and DYT6 cohorts for neuropathological study 
UMB# Sex Age at death Brain regions available 
DYT1 cases 
1512 F 89 
Frontal cortex , basal ganglia, Superior temporal gyrus , motor 
cortex BA4,  cerebellum with dentate nucleus 
1619 F 87 
Frontal cortex, basal ganglia, superior temporal gyrus, pons with 
locus coeruleus, cerebellum with dentate nucleus 
4628 F 77 
Frontal cortex, basal ganglia, superior temporal gyrus, motor 
cortex BA4,  pons with locus coeruleus, cerebellum with dentate 
nucleus 
4877 F 90 
Frontal cortex, basal ganglia, superior temporal gyrus, motor 
cortex BA4,  midbrain/pons, medulla, cerebellum with dentate 
nucleus 
4896 F 90 
Frontal cortex, basal ganglia, superior temporal gyrus, motor 
cortex BA4,  midbrain/pons, cerebellum with dentate nucleus 
5200 F 88 
Frontal cortex, basal ganglia, superior temporal gyrus, motor 
cortex BA4,  cerebellum with dentate nucleus 
DYT6 cases 
1020 M 71 
Frontal cortex , basal ganglia, superior temporal gyrus , medulla,  
cerebellum with dentate nucleus 
HB5 M 56 Multiple brain regions 
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DRD cohort 
The DRD cohort consisted of 192 clinically diagnosed DRD cases. These cases were 
negative for mutations in the coding regions of GCH1 gene. The dystonia cohort 
described above was also screened for mutations in the GCH1 coding regions and 
the promoter region. 
Ataxia cohort 
Written consent was obtained from all the patients to perform molecular studies. 
The ataxia cohort comprised 630 cases of clinically diagnosed sporadic cases with 
progressive cerebellar ataxia from the NHNN. 
English control cohort 
English cohort consisted of 631 normal individuals of English origin obtained from 
Wellcome trust. 
Human genome diversity project (HGDP) control cohort 
HGDP of worldwide control cases consisted of 1148 control individuals of diverse 
ethnicities (including individual from China, India, Pakistan, South Africa, Brazil etc) 
and was obtained from The Foundation Jean Dausset-Centre d'Etude du 
Polymorphisme Humain (CEPH).  
Neuroacanthocytosis case  
Paraffin blocks representing multiple brain regions from a post mortem case of NA 
were obtained from QSBB. 
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Neurodegeneration with brain iron accumulation -BPAN case 
Paraffin blocks representing multiple brain regions from a post mortem case of 
BPAN were obtained from QSBB. 
Lewy body in LSDs  
To investigate if LBs are hallmark feature of LSDs in ceramide pathway, the cohort 
consisted of the following cases: 
Table 2.4 LSD cohort to access Lewy body pathology 
Disease UMB# Age/Sex Ethnicity Fixed tissue available 
Leukodystrophy, 
Metachromatic 
1231 60M Caucasian frontal cortex, hippocampus, 
substantia nigra, pons  
Sandhoff Disease 1814 1M Caucasian frontal cortex, hippocampus 
 
Fabry's Disease 4299 50M Caucasian frontal cortex, hippocampus, 
substantia nigra, pons 
Tay-Sachs 
Disease 
5094 27M Caucasian frontal cortex, hippocampus, 
substantia nigra, pons 
Gangliosidosis, 
GM1 
5384 19M Caucasian frontal cortex, hippocampus, 
substantia nigra, pons 
     
     
 
2.2. Genetics 
2.2.1. Extraction of nucleic acids 
Genomic deoxyribonucleic acid (DNA) was extracted from brain tissues using 
DNeasy kit. Genomic DNA was extracted from peripheral blood leucocytes by 
standard method at the NHN-lab where only blood samples were available for the 
study.  DNA concentration was measured using Nanodrop and diluted to 
(~20ng/uL) for use in the polymerase chain reaction (PCR).  
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2.2.2. Candidate Gene Screening 
All exons and exon‐intron boundaries were PCR amplified using primers already 
published. The target genomic DNA sequence was amplified by using a PCR and gel 
electrophoresis was done for quality control. PCR amplified fragments were 
purified using PCR Cleanup Filter Plates (Millipore, MA, USA) and a direct dye 
terminator sequencing (BigDye v3.1; Applied Biosystems, CA, USA) was performed 
as per the manufacturer’s instructions. The resulting reactions were cleaned with 
PCR Cleanup Filter Plates (Millipore, MA, USA) before processing on a 3730xl DNA 
Analyzer 84 (Applied Biosystems, CA, USA) and analysed with Sequencher™ 
software (version 4.1.4; Gene Codes Corporation, MI, USA). The dystonia cohort 
was screened for the 3‐bp ΔGAG mutation in exon 5 of TOR1A, three exons in 
THAP1, twelve exons in GNAL, seventeen exons in CIZ1 and two exons in PRRT2 
using direct sequencing as described above. The DRD cohort was sequenced for five 
exons in GCH1 gene and a promoter region. 
2.2.3. PCR amplification 
PCR were performed on Eppendorf thermocycler. Typical volumes of PCR 
amplification reactions are as follows: 
TOR1A conditions, Exons 3, 4 and 5 PCR reagents for each reaction are as follows: 
12μl Roche mix, 2μl forward/reverse primer (5μM), 3μl dH20, 1μl DNA (~20ng/ul). 
PCR was run on a 62 touchdown 57 programme. 
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THAP1 conditions, Exon1 PCR reagents for each reaction are as follows: , 2.5μl x10 
PCR buffer, 5μl x5 Q buffer mix, 2.5μl DNTPs (2mM), 3μl forward/reverse primer 
(5μM), 0.5μl Taq polymerase,0.8μl DMSO, 6.2μl ddH20, and 1μl DNA (~20ng/ μl).  
PCR was run on a 62.5 touchdown 55 programme. Exons 2 and 3 PCR reagents for 
each reaction are as follows: 12μl Roche mix, 2μl forward/reverse primer (5μM), 
2μl dH20, 2μl DNA (~20ng/ul). PCR was run on a 60 touchdown 50 programme. 
CIZ1 conditions, Exons 2-17 PCR reagents for each reaction are as follows: 12μl 
Roche mix, 2μl forward/reverse primer (5μM), 2μl dH20, 2μl DNA (~20ng/ μl). Exon 
1 PCR reagents for each reaction are as follows: 12μl Roche mix, 2μl 
forward/reverse primer (5μM), 1.2μl dH20, 0.8μl DMSO, 2μl DNA (~20ng/ul). PCR 
was run on a 65 touchdown 55 programme. Primers used were published 
before(301). 
GNAL conditions, Exons 2-12 PCR reagents for each reaction are as follows: 12μl 
Roche mix, 2μl forward/reverse primer (5μM), 2μl dH20, 2μl DNA (~20ng/ μl). PCR 
was run on a 60 touchdown 50 programme. Primers used were published before 
(302). 
TUBB4a conditions, Exons 1-4 PCR reagents for each reaction are as follows: 12µl 
FastStart Mastermix (Roche), 1µl (10pM) forward and reverse primers, 1µl DMSO, 
4µl PCR grade water, 1µl DNA (30ng/µl). Primers used were published before (303).  
GCH1 conditions, Exons 1-5 PCR reagents for each reaction are as follows: 12μl 
Roche mix, 2μl forward/reverse primer (5μM), 2μl dH20, 2μl DNA (~20ng/ μl). PCR 
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was run on a 60touchdown50 programme. Promoter region PCR reagents for each 
reaction is as follows: 2.5μl x10 PCR buffer, 5μl x5 Q buffer mix, 3μl DNTPs (2mM), 
5μl forward/reverse primer (5μM), 0.2μl Taq polymerase, 1.3μl ddH20, and 3μl 
DNA (~20ng/ μl).  PCR was run on a 60 touchdown 50 programme. 
SCA8 conditions, PCR reagents for each reaction are as follows: 12μl Roche mix, 2μl 
forward/reverse primer (5μM), 0.8 μLDMSO, 1.2μl dH20, 2μl DNA (~20ng/ μl). PCR 
was run on a 60 touchdown 50 programme. Primer set used was published before 
(197). 
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Table 2.5 Primers used for sequencing and fragment analysis 
Primary Antibody Forward Reverse Primary Antibody Forward Reverse 
TOR1A_exon5 AAGGAGCTGATTGATGGC GGGTGCAGGATTAGGAAC CIZ1_exon15 GATATGGGAGGGTCATGTGG TGGAAATCAAGGGGATTCTG 
THAP1_exon1 GCTTCCCAGGAAACGTACC TTCCAGGAGCGCGAGAAAC CIZ1_exon16 ACCCGAATCAGCTTGGATTA TGGTACAGCGCGTGAGTGGCT 
THAP1_exon2 TAAGATATTTCCTAAGCTGG CCAGGCACATTTATTCTC CIZ1_exon17 TGGGAACTGCACAGCCAAACTACC CAGAGAGGCCGAGTGCATCACGCA 
THAP1_exon3 TAGGATTATAGGCATGAGC AATGAAACTCCTTTACAGG GNAL_exon1-2 AAACGCCTGCTCTGAATCGGAA ACTCTGGGAGAGAGACGAAGTTT 
CIZ1_exon1 GCATCCCAGTCCCTAGAAGA CCGCCATCCCTGTCTTAGTC GNAL_exon3-4 AACCTTTGCAGATGTCTTGG CCTCTTATGCATTTAGAGAGCTGG 
CIZ1_exon2 TCCGAGACATGGGTCTGAGT AGCAGGCCTGACTTATGGTG GNAL_exon5 TCACACTAAACATAGAGTAGGTGCAT TTATTCATTCCTTGCACTCAAG 
CIZ1_exon3 GTGGCTGTGTGGAGTTGAGA CTTGGGGAAGAAGGAAGGTC GNAL_exon6 ACTCACTTCAGCTTCTTGGCCT ATGACCAATCCACRCACACACA 
CIZ1_exon4 AGCTTCTTTTTGCCAACCAA GGGGGATGGATGTTTTATGG GNAL_exon7 ATGCTCGGCCAATGTTGGTT TGGGCCATGCAGCTCTTAACAA 
CIZ1_exon5 GGCATAAAGGGAGTGTGACC TGCCTGACCCTACCTTCTGC GNAL_exon8 ATGTGTGAACGCTGGAACCT GCAGTGCTGAGTGTTAGAATTCAC 
CIZ1_exon6 TGCCTCTATCACCTGCTGACCC GGGTGGGTATTGGATGTCAA GNAL_exon9 TGCAGGCTGATCTGTGACT AGAGATACTTCGTACGGTTCTGG 
CIZ1_exon7 TAAGGCCTTCCTCCAAATCA CCCATCTCTTGGAGGTCAGA GNAL_exon10 ACAGATGGAATGAGGATACTGGTG GGGATCCAATTACAAATAGGACCTTG 
CIZ1_exon81 ACCCAGTCAGGGGAGGAAT GCAAACACAGACCTCTCCAG GNAL_exon11 GCTGGGAATATACAGCAGTCTAACA TGAAGTCTAGCCCATCCAAG 
CIZ1_exon82 CTGTGTGTGGACCTGTGGAT GGGCCTCTTTGAAGACATGA GNAL_exon12 TGCATTGAGACCATTCCTGCCT GGGAGGCTGTATTCAATGACAACA 
CIZ1_exon9 GACGCACAACAGCAAGAGG ACGGAGAAGGCAGCTCTTG GCH1_exon1 CCGGGCCATAAAAAGGAG CGCCAAAAGTGAGGCAACTC 
CIZ1_exon10 GAGGGCAGGCTGGGCATTCCACGC GGCTGGCCCACTATAAGTACA GCH1_exon2 TTAACGTTCGTTTATGTTGACTGTC ACCTGAGATATCAGCAATTGGCAGC 
CIZ1_exon11 TGTTACAGGCAGGGAAAACTG CCTTGCCCACTGTTCTGG GCH1_exon3 AGATGTTTTCAAGGTAATACATTGTCG TAGATTCTCAGCAGATGAGGGCAG 
CIZ1_exon12 AACTGGGGCTCTGTGTTGTC TGTCTTTCTGGCGTCACATT GCH1_exon4 GTCCTTTTTGTTTTATGAGGAAGGC GGTGATGCACTCTTATAATCTCAGC 
CIZ1_exon13 GGGCTGGGATAAACCTCAAC GTGCTAGTCAGGGGGCTTG GCH1_exon5 CTCTGTGGCCCAGTCAGC AGGCTCAGGGATGGAAATCT 
CIZ1_exon14 GCACTTCACAGTAATCAGTTGTGGC CAAGGCTGTGTAGCAAGTTGAGGTTTA GCH1_exon6 CATTTGTGTAAGAAGGGATATTTCG AGTGACAAGGAATAAAGTTCACATC 
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2.2.4. Gel electrophoresis 
Amplified products were run on an agarose gel to ensure that PCR amplification 
efficiency and fragment size. Red dye was added to the gel to enable visualization 
and orangeG was used as a loading buffer (5μl product +5μl OrangeG). Gel 
electrophoresis was done in a 1.5% agarose gel along with a corresponding 
molecular weight standard (100bp ladder) to estimate the size of the DNA 
fragments. The electrophoresis was run at 100V for 40 mins in 1x TBE buffer. Gels 
were visualised using a UV transilluminator and images were taken with Syngene 
Bioimaging System.  
2.2.5. PCR Clean Up  
 Samples were centrifuged briefly for 30secs to collect condensation formed during 
PCR. ddH20 was added up to a total of 100μl and diluted PCRs transferred to the 
MultiScreen-PCR 96 filter plates (Millipore). The filter plate was placed under 
vacuum until all fluid was removed (20-25inHg). Further 20μl ddH20 water was 
added to each well to reconstitute the PCR and placed on a shaker for 10mins. The 
purified PCR products were transferred to a clean 96-well reaction plate and stored 
at -20°C until further use. 
2.2.6. Sanger Sequencing 
DNA sequencing reactions were performed based on the principle of the chain 
termination method. Sequencing reagents for each 10μl reaction are as follows: 2μl 
Big dye buffer 5X, 0.5μl Big Dye v3.1, 0.5μl forward/reverse primer (5μM), 5μl clean 
PCR product, 2μl ddH20. The sequencing reaction was run on Eppendorf 
 P a g e  | 83 
thermocycler and a big dye termination programme used is as follows: Initial 
denaturation 96°C x5mins, denaturation 96°C x10secs, primer annealing 50°C 
x5secs, extension 60°C x 4mins.  
2.2.7. Sequencing cleanup 
Samples were centrifuged briefly for 30secs to collect condensation formed during 
sequencing reaction. Double distilled water was added up to a total of 100μl and 
diluted sequencing reaction was transferred to the MultiScreen-PCR 96 filter plates 
(Millipore). The filter plate was placed under vacuum until all fluid was removed 
(20-25inHg). Further 20μl ddH20 water was added to each well to reconstitute the 
sequencing reaction and placed on a shaker for 10mins. The purified sequencing 
products were transferred to a clean 96-well reaction plate and processed on a 
3730xl DNA Analyzer 84 (Applied Biosystems, CA, USA) and analysed with 
Sequencher™ software (version 4.1.4; Gene Codes Corporation, MI, USA). 
2.2.8. Fragment analysis 
Fragment analysis was carried out to determine the SCA8 repeats. The 5’ terminal 
of SCA8 forward primer was labeled with FAM™ fluorescent dye. PCR amplification 
and gel electrophoresis was carried out as described above. GeneScan™ Liz-500 
(Applied Biosystems) was used as a size standard. Amplified PCR products were 
visualised by automated fragment size analysis on an ABI 3730XL Genetic 
Sequencer (Applied Biosystems). Each reaction consisted of 12 μl L Formamide,0.3 
μl Liz marker 500 and 7 μl of amplified PCR product. The fragment size data was 
collected and analysed using GENESCAN™672 Data Collection Software version 
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1.2.1 (Applied Biosystems). The alleles were sized manually in relation to a 
fluorescent-labelled size standard in a GeneMapper version 3.7 software.  
2.3. Neuropathology 
2.3.1. Tissue processing  
Paraffin-wax embedded blocks were requested from Maryland brain bank for the 
genetically confirmed DYT1 and DYT6 cases. Formalin fixed half brain received for a 
DYT6 case from Harvard Brain Bank was processed and embedded in paraffin wax 
at Queen Square brain bank using routine protocols. Paraffin-wax embedded blocks 
were also obtained from age-matched neurologically normal control individuals 
from QSBB. 
2.3.2. Histology stains Dewaxing and rehydration of sections 
procedure 
Eight-micrometer-thick sections were cut, deparaffinized in three changes of xylene 
(10mins, 5mins and 5mins respectively) and then rehydrated using graded alcohols 
(100, 95, and 70%) for 2mins in each.  Sections were washed for 2mins in running 
water before proceeding for appropriate immunohistochemical procedure. The 
procedure is reversed to dehydrate section to xylene. 
2.3.3. Haematoxylin and Eosin (H&E) Staining  
Deparaffinized and rehydrated sections as described above were placed in Gills 
haematoxylin for 5mins, rinsed under running water until excess dye has cleared, 
and quick dips in 1% acid-alcohol until tissue appeared red/purple in colour. 
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Sections were washed under cold running water to ‘blue’ tissue and incubated in 
eosin for 5mins. After a brief wash in water, sections were rehydrated as described 
above and mounted in DPX and cover. Haematoxylin is a basic dye, highlights 
nuclei. Eosin is an acidic dye, highlights cytoplasmic components of the cell. 
2.3.4. Immunohistochemistry (IHC) on Formalin-fixed-paraffin-
embedded (FFPE) tissue  
Eight-micrometer-thick sections were deparaffinised and rehydrated as described 
above. Endogenous peroxidase activity was blocked using 0.3% peroxide in 
methanol for ten minutes, followed by several washes in distilled water. 
Pretreatment was carried out according to the appropriate IHC protocol for each 
antibody used. Sections were then placed in 10% non fat milk for 30 min at room 
temperature (RT) to reduce non-specific binding, followed by incubation in the 
primary antibody. After washes in PBS, the sections were incubated with secondary 
antibodies (dilution of 1:200) for 30 min at RT. The secondary antibody was washed 
off then the sections were incubated in the avidin-biotin complex solution for 30 
min at RT. After washes in PBS, they were treated in the diaminobenzidine (DAB) 
solution for 2-5 min. The DAB solution was washed off and the tissues were 
counterstained in Mayer’s hematoxylin for 30 sec. The tissue sections were then 
dehydrated in graded alcohol (70%, 90%, and absolute alcohol), cleared in three 
changes of xylene, and then mounted with DPX mounting medium. Primary 
antibodies with pre-treatment conditions, dilutions and incubation times are 
described below (Table 2.1).  
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2.3.5. Gallyas silver staining  
Sections were dewaxed and rehydrated as described above. Sections were placed 
in several changes of distilled water, incubated in 5% periodic acid for 5mins, 
washed in several changes of distilled water, incubated in alkaline silver iodide 
solution for 1min and then washed in 0.5% acetic acid for 5mins. Further sections 
were incubated in developer solution until the sections turned dark brown/black 
(5-45mins), wash again in 0.5% acetic acid for 5mins, followed by a 5min wash in 
distilled water. Sections were ‘toned’ in 0.2% gold chloride until the excess dark 
colour has disappeared, washed again in distilled water, fixed in 1% sodium 
thiosulphate solution and finally washed in distilled water. Sections were then 
counterstained in Mayer’s haematoxylin for 1min and excess dye was washed off in 
the running water. Finally, the sections are dehydrated, cleared and mounted as 
previously described. This technique highlights NFTs, plaques neurites, and neuropil 
threads as black. 
2.3.6. Luxol Fast Blue/ cresyl violet (LFB/CV) procedure  
Thirteen-micrometer-thick sections were cut and require longer time in xylene 
(30mins) to clear the wax. Sections were incubated in filtered LFB solution 
overnight at 60°c.  Sections were then rinsed briely in 95% IMS, rinsed again in 
distilled water, differentiated in lithium carbonate solution for 30secs, followed by 
30secs in 70% IMS and rinsed in distilled water. Sections were counter stained with 
prewarmed (60°C) cresyl violet for 20mins, rinsed in distilled water, followed by a 
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final 5mins incubation in 95% IMS. Finally, the sections are dehydrated, cleared and 
mounted as previously described. 
2.3.7. Evaluation of IHC 
Neuronal loss, gliosis and concomitant pathologies: tau, beta-amyloid (Aβ), LBs, 
cerebral amyloid angiopathy (CAA), TAR DNA-binding protein 43 (TDP-43), and 
small vessel disease (SVD) were assessed in a semi-quantitative manner according 
to published criteria (304–307) and summarized in Table 2.6. A score scale of 0 - +3 
was used to indicate increasing pathology.  
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Table 2.6 Semi-quantitative scale 
Parameter Scale 
GCI and NCI 
burden 
0  Absent 
+1 1-5 inclusions 
+2 6-19 inclusions 
+3 ≥20 inclusions 
Neuronal loss 0  No neuronal loss  
+1 Slight neuronal loss 
+2 Moderate neuronal loss 
+3 Severe neuronal loss 
Gliosis 0   No gliosis  
+1 Astrocytes around blood vessels and sub-pial 
+2 Astrocytes around blood vessels and sub-pial and 
extending into intervening parenchyma 
+3 Greater burden than ++’ 
CAA 0  No amyloid 
+1 Scattered vessels in leptomeninges or cortex with 
patchy deposition 
+2 As ‘+’ with occasional vessels having circumferential 
deposition 
+3 Widespread circumferential deposition 
+4 Severe deposition of amyloid accompanied by 
projection of amyloid into the adjacent parenchyma 
SVD 0  Vessels normal 
+1 Occasional vessels affected 
+2 A significant proportion of small vessels affected with 
few or no sequelae noted 
+3 A significant proportion of the small vessels affected 
with obvious sequelae 
   
   
   
   
2.3.8. Western blot (WB) 
Research cohorts 
Human brain lysates were extracted from normal human controls available at QSBB 
for optimizing the antibodies. Mouse and cell lysates used in antibody optimization 
were kindly given in the lab. For tau-blot cohort, cases included were: WDR45, AD 
and Pick’s disease. For LC3-blots, cohort consisted of WDR45 case and 3x age and 
sex matched control human brains. 
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Preparation of homogenates/extractions 
For immunoblotting, the frontal cortex was homogenised in 50mMTris-HCl pH7.5, 
150mM NaCl, 5mM EDTA, 1%tritonX-100, 2% SDS, complete protease inhibitor and 
Phosphatase inhibitor (Roche). Lysates were obtained after centrifugation of 
homogenised samples at 10000g for 15 min.  Protein concentration was 
determined using Bio-RAD protein assay kit.  
Tau extraction: Sarkosyl-insoluble tangle phosphorylated (PHF) tau was isolated 
from brain samples as previously described (308). Insoluble PHF-tau was enriched 
from frontal cortex of the cases as previously described (309,310). For Sarkosyl-
insoluble tangle PHF-tau preparation, tissue samples (frontal cortex) were weighed 
and homogenized in 10 volumes of homogenization buffer (NP-40 lysis buffer 
supplemented with protease inhibitors (Complete Mini Protease inhibitors, Roche). 
The homogenized samples were spun at 15,000 rpm for 20 min; the supernatants 
were collected; and aliquots were resuspended in 5X sample buffer (32% 1M Tris, 
pH6.8, 5% SDS, 50% glycerol, and 1% β-mercaptoethanol) for analysis as the 
starting material. The rest of the sample was used for extraction of PHF-tau using 
the sarkosyl extraction of insoluble material (309). Briefly, the supernatants of the 
brain homogenates were centrifuged at 35,000 rpm for 1 hr at 23°C; the resulting 
pellets were resuspended in 1% sarkosyl (Fisher Scientific) in TBS and incubated on 
shaker for 30 min at RT, and then centrifuged at 35,000 rpm for 1 hr at 23°C. 
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WB run 
Gel samples were prepared by the addition of 5x sample buffer (0.625 M Tris-HCl, 
pH 6.8, 50% glycerol, 10% (w/v) SDS, bromophenol blue and 10% b-
mercaptoethanol). Samples were denatured in at 98°C for 10 minutes and 20ug of 
protein was loaded.  Proteins were then separated on 6% SDS gels and transferred 
to PVDF membrane. Membranes were blocked with PBS/0.1% Tween 20 (PBS-T) 
containing 10% milk for 30mins to 1 hour, washed briefly in PBS-T and then 
incubated overnight at 4°C. The membranes were washed five times in PBS-T and 
then incubated at room temperature for 60mins with secondary antibody in PBS-T 
with 1% milk. Membrane were then washed in PBS a further five times and 
developed in Odyssey scanner.  
 P a g e  | 91 
 
 
 
 
 
Table 2.7 Primary and secondary antibodies used in IHC staining and WB 
Primary Antibody Species Company Pre-treatment Dilution Usage Incubation time 
Glial fibrillary acidic protein (GFAP) Rabbit DakoCytomation, Denmark (M0872) Proteinase K 1/1000 IHC 1 hour 
CD68 Mouse Dako Citrate Buffer 1/150 IHC 1 hour 
Ubiquitin Rabbit Dako Citrate Buffer 1/200 IHC 1 hour 
Tau (AT8) Mouse Source Bioscience, UK (90206) Citrate Buffer 1/600 IHC 1 hour 
P62 Mouse Bio Sciences Citrate Buffer 1/100 IHC 1 hour 
AT100 tau Mouse Autogen bioclear Citrate Buffer 1/1000 IHC 1 hour 
β-Amyloid (Aβ) Mouse DakoCytomation,Denmark (M0872) Formic acid and Citrate Buffer 1/100 IHC 1 hour 
α-synuclein Mouse VectorLaboratories, (VP A106) Formic acid and Citrate Buffer 1/50 IHC 1 hour 
α-synuclein Mouse BD transduction (610787) Formic acid  1/1000 IHC Overnight 
TAR DNA-binding protein 43 (TDP-43) Rabbit Protein Tech  (12892-1-AP) Citrate Buffer 1/2000 IHC 1 hour 
TDP-43 phosph Rabbit Protein Tech Citrate Buffer 1/2000 IHC 1 hour 
α-internexin Mouse  Citrate Buffer 1/75 IHC 1 hour 
Tau (rabbit  anti-human) Rabbit DakoCytomation,Denmark (A0024) - 1:20000 WB Overnight 
αβ crystalline Mouse  Citrate Buffer 1:300 IHC 1 hour 
SMI31 Mouse Sternberger Citrate Buffer 1:5000 IHC 1 hour 
Neurofilament cocktail Mouse  - 1:20 IHC 1 hour 
Amyloid precursor protein (APP) Mouse  Citrate Buffer 1:100 IHC 1 hour 
Microtubule-associated protein 1A/1B light 
chain 3 (LC3) 
Rabbit Novus Biologicals - 
1:2000 WB Overnight 
Β-actin Mouse Sigma - 1:10000 WB Overnight 
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Table 2.7 Primary and secondary antibodies used in IHC staining and WB continued..  
Secondary Antibody Species Company Dilution Usage Incubation time 
Biotinylated rabbit anti-mouse IgG Goat DakoCytomation, Denmark (E0354) 1:200 IHC 1 hour 
Biotinylated swine anti-rabbit IgG Goat DakoCytomation, Denmark (E0353) 1:200 IHC 1 hour 
IRDye800CW Donkey anti-Rabbit IgG (H+L) Donkey Li-Cor(926-32213) 1:10000 WB 1 hour 
IRDye800CW Goat anti-Rabbit IgG (H+L) Goat Li-Cor 1:15000 WB 1 hour 
IRDye680CW Donkey anti-Mouse IgG (H+L) Donkey Li-Cor 1:15000 WB 1 hour 
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2.4. RNA - Quantitative real-time PCR (qPCR)  
2.4.1. RNA Extraction   
RNA was extracted using Qiagen RNEasy kit www.qiagen.com/hb/rneasymini. 700 
µL of QIAzol was added to the tissue sample, which was then disrupted and 
homogenized using TissueRuptor (Qiagen). The homogenized sample was then left 
at RT for 5 min. To the homogenized sample, 140 µL of chloroform was added, 
vortexed for 30 sec, incubated at RT for 2-3 min and centrifuged at 12000g at 4°C 
for 15 min. The aqueous phase (upper layer) was then transferred to a sterile 2 mL 
RNase free tube, added 100% ethanol (1.5x the volume of the aqueous phase) and 
mixed with pipette to precipitate the RNA. Samples were then purified into the spin 
column (including any precipitate) and centrifuged at 10000 rpm at RT for 1 min. 
The flow-through was discarded. The samples were washed for salt traces and 
impurities by adding 700µL of the RWT solution and centrifuged at 10000 rpm at RT 
for 1 min. The flow-through was discarded. 500µL RPE solution was added to the 
column and centrifuged at 10000 rpm at RT for 1 min. The flow-through was 
discarded. The washing step was repeated. The flow-through was discarded and 
500µL RPE solution was added to the column and centrifuged at 10000 rpm at RT 
for 2 min. The column as transferred to a new 1.5 mL RNase free tube. 15µL RNase-
free water was added to the column and let to stand for 1-2 min at RT, then 
centrifuged at 10000 rpm at RT for 1 min. The elute is the extracted RNA. RNA 
quality and concentration was assessed using the nanodrop and Agilent Bioanalyser 
2100. RNA samples with 260/280 ratio > 1.9 were used for reverse transcription -
PCR. 
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2.4.2. Reverse transcription  
This procedure is carried out to convert total RNA to first strand DNA. RNA is 
reverse transcribed to form cDNA using SuperScript® VILO™ cDNA Synthesis Kit 
(Invitrogen, UK). According to manufacturer’s instructions, following components 
are mixed for each reaction: 4 μl 5X VILO Reaction Mix, 2 μl 10X SuperScript 
Enzyme Mix, RNA (up to 2.5 μg), DEPC-treated water to make up 20 μl total 
reaction volume. After gently mixing the tube contents, incubation was done at 
42°C for 60 min followed by termination at 85°C for 5 min. Samples were stored -
20°C until further use. For multiple reactions, a mater mix was prepared without 
RNA. cDNA was then diluted 1:10 for use in qPCR. 
2.4.3. Primer design  
Primers were designed to detect the most common isoforms for THAP1 and TOR1A 
genes and where possible primers were used from rt-primer database 
(http://www.rtprimerdb.org/). Careful primer design is necessary in SYBR green 
detection is of utmost importance because of the sensitivity of real-time detection. 
Primers were designed across exon-exon boundary, reducing contamination 
through amplification of genomic DNA. Housekeeping genes (RPLP0, UBC, GAPDH, 
and beta-actin) were used to ensure reliability of the experiment and for 
adjustment of relative expression data. Real-time PCR was performed on 
Stratagene MX3000p (Agilent technologies, CA) using Power SYBR Green Master 
Mix (Applied Biosystems). In addition to the software output, qPCR products were 
also checked by running them on agarose gels. Primers used are listed in Table 2.8. 
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Table 2.8 Primers used in qPCR 
Housekeeping genes: Genes of interest: 
GAPDH (amplicon 120 bp) TOR1A_q1 (amplicon 117 bp) 
GAPDH_q1F: GAAATCCCATCACCATCTTCCAGG  TOR1A_q1F: TACAGTTGTGGATTCGAGGCA 
GAPDH _q1R: GAGCCCCAGCCTTCTCCATG  TOR1A_q1R: AATAGTCGAGGAAAGGCTTGATG 
Rplp0 (amplicon 130 bp) TOR1A_q2 (amplicon 113 bp) 
Rplp0_q1F: GCTGCTGCCCGTGCTGGTG TOR1A_q2F: GCACAGCAGCTTAATTGACCG 
Rplp0_q1R: TGGTGCCCCTGGAGATTTTAGTGG TOR1A_q2R: CATAGCCTCGGGACTGCATT 
UBC (amplicon 133 bp) THAP1_q1 (amplicon 95 bp) 
UBC_q1F: ATTTGGGTCGCGGTTCTTG THAP1_q1F: TGCAAGAACCGCTACGACAA 
UBC_q1R: TGCCTTGACATTCTCGATGGT THAP1_q1R: CTGACAGCTGCCTCCCATTC 
ATCB (amplicon 107 bp) THAP1_q2 (amplicon 117 bp) 
ATCB_q1F: ATGTGGCCGAGGACTTTGATT THAP1_q2F: GCAGTCCTGCTCCGCCTACG 
ATCB_q1R: AGTGGGGTGGCTTTTAGGATG THAP1_q2R: CTGACAGCTGCCTCCCATTC 
 
2.4.4. Validation of primers and efficiency of the qPCR 
The standard curve was created using a cDNA pool with the primers listed above to 
determine the efficiency of the primers for genes of interest and housekeeping 
genes using conventional PCR method. Each PCR reaction contained 12/ uL 
5xRoche mix, 2uL of each primer (5uM), 2ul of ddh20 and 2ul of cDNA template 
(~30ng/uL).  The cycling conditions were as follows: Initial denaturation 95°C 
x5mins; 40 cycles of denaturation 95°C x15secs, primer annealing 60°C x60secs, 
extension 72°C x 45secs; and the final extension at 72°C x 10mins. The PCR product 
was purified with Millipore plate and verified on 1% agarose gel run at 100V for 1 
hr. The purified product was quantified with Nanodrop spectrophotometer and 
diluted to the first working standard 108. The stock is then diluted serially from 101 
– 107. The serial dilutions are used as a template for qPCR to generate a standard 
curve.  
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2.4.5. qPCR  
SYBR Green is a dye that fluoresces upon intercalation with double-stranded DNA. 
It is used to detect the threshold cycle (Ct) during PCR when the level of 
fluorescence gives a signal over the background and is in the linear portion of the 
amplified curve. The Ct value is responsible for the accurate quantification of the 
PCR. The PCR amplification mixture for each 20 L reaction was prepared as 
follows: 10 L Power SYBR Green PCR Master Mix, 1 L forward primer (500nM), 1 
L  reverse primer (500nM), 3 L molecular biology grade water and 5 L cDNA 
(1:15 dilution). Cycling conditions: : Initial denaturation 95ºC 10min; denaturation 
95ºC 15secs, primer annealing 60ºC 1min for 40 cycles. Melting curve analysis: 
Initial denaturation 95°C x5mins, denaturation 95°C x30secs, primer annealing 60°C 
x45secs, extension 72°C x 45secs and the final extension at 72°C x 10mins. The PCR 
was run for 40 cycles and kept at -20 and away from light.  
2.4.6. ∆∆Ct method 
Semi-quantitative real-time PCR was used in this study to determine a fold change 
of gene expression levels. The relative expression of mRNA is calculated by 
measuring the cycle in the log phase of PCR, at which amplified DNA reaches a 
significant fluorescence threshold (Ct) and was determined for each sample using 
Maxpro software. Due to technical variability between experiments the Ct needs to 
be normalised against the housekeeping genes. Comparing the normalised 
expression (ΔCt) of three conditions (in this case THAP1, TOR1A and control) it was 
possible to calculate the fold change of the gene expression (2^-ΔΔCt). The fold 
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change is the expression ratio: a positive changes means a gene is upregulated, a 
negative fold change represents a downregulation (Livak and Schmittgen 2001). 5 
healthy age and sex matched controls were used as a calibrator.  
Fold change (2^-ΔΔCt) = 2 exp {∆Ct sample (target gene- reference gene) -∆Ct 
calibrator (target gene – reference gene)} 
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Chapter 3. Genetics of primary dystonia 
 
3.1. Background 
The dystonias are a heterogenous group of movement disorders, characterized by 
involuntary sustained muscle contractions affecting one or more sites of the body, 
which lead to twisting and repetitive movements or abnormal postures of the 
affected body part. It is the third most common movement disorder worldwide (3–
6). Approximately 70 000 people are affected by dystonia in the UK alone, including 
some 8000 children and adolescents (311). Affected individuals can suffer 
considerable physical and psychosocial distress, which has been demonstrated to 
have a significant impact on their quality of life (12). New 'next generation' 
sequencing technologies have massively increased the speed of genetic discoveries 
in recent years and this has made itself felt in the field of dystonia research as in 
many others. To date, genes associated with primary pure dystonia are 
TOR1A/DYT1 (torsinA), THAP1/DYT6 (thanatos associated protein domain 
containing, apoptosis associated protein 1), CIZ1 (CDKN1A interacting zinc finger 
protein 1), ANO3/DYT23 (anoctamin 3), TUBB4A/DYT4 (β-tubulin 4) and GNAL (α-
activating activity polypeptide, olfactory type). Dystonia gene, ANO3 is not included 
in this study (Chapter1, 1.2).  
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3.2. Aims and Hypothesis 
Hypothesis 
 Primary pure dystonia is caused by a mutation in one of the primary 
dystonia genes described in literature: TOR1A, THAP1, CIZ1, TUBB4, or GNAL  
 The nature of the mutation will influence the clinico-pathological phenotype  
Aims 
 To locate and obtain clinically diagnosed primary dystonia cases 
 Investigate clinical and genetic correlation 
3.3. Methods 
Primary dystonia genes were screened using Sanger sequencing (described in 
Chapter 2). 
3.4. Results 
Tissues were initially requested from cases clinically diagnosed as primary dystonia 
from Maryland Brain Bank, Baltimore, USA, Queen Square Brain Bank and Harvard 
Brain Bank. Consent for research was obtained from all the participants. A cohort of 
90 patients clinically diagnosed as primary dystonia was screened for primary pure 
dystonia genes, TOR1A, THAP1, CIZ1, GNAL and TUBB4. Dystonia cohort was not 
screened for ANO3. The cohort was also sequenced for PRRT2. 
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The disease onset in the cohort varied from early to adult onset and was in the 
ratio of 1:4. Age at death ranged from 32 to 91 years old and male to female ratio 
was 1:3. 
3.4.1. Genetic screening and mutation analysis 
DNA was extracted using the Qiagen Tissue extraction kit. All exons in each of the 
genes were amplified using polymerase chain reaction and Sanger sequencing was 
carried out to identify the mutations. Mutations identified are summarized in the 
Table 3.1. 
 
Figure 3.1 The location of the recurring 3basepair deletion (ΔGAG) mutation in exon 5 of TOR1A. 
 
Figure 3.2 Structure of THAP1 protein and location of THAP1 mutations in the cases studied. 
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Ten cases were identified with heterozygous mutation p.303-/Glu304 in exon 5 of 
the TOR1A/DYT1 gene (Figure 3.1). This mutation is a recurring mutation in DYT1 
cases and has been described as pathogenic in human and animal studies 
(background information on the mutation in chapter 1).  
Two cases were identified with heterozygous mutations, p.Arg29Gln or p.R29Q and 
p.Ser21Phe or p.S21F respectively, in the coding region of THAP1/DYT6 gene 
(Figure 3.2). p.R29Q mutation variant predicted to be damaging by Mutation taster 
(score: 43), Polyphen (score: 0.867) and SIFT (score: 0.004). This mutation has 
previously been described as pathogenic in dystonia (312,313). Case 2 had a novel 
variant p. S21F, predicted to be disease causing by Mutation taster (score: 155), 
Polyphen (score: 0.981) and SIFT (score: 0.01). A pathogenic mutation in the amino 
acid 21 was reported before but involving a different nucleotide than reported 
above. Both amino acids are conserved across several species (chimpanzee, 
Table 3.1  Mutations identified in the cohort 
Case Mutation Clinical diagnosis 
 TOR1A THAP1 CIZ1 GNAL TUBB4  
1  p.303-/Glu304 - - - - Dystonia, DYT-1 GAG deletion carrier 
2  p.303-/Glu304 - - - - Dystonia, DYT-1 GAG deletion carrier 
3  p.303-/Glu304 - - - - Familial congenital Dystonia, generalized, 
childhood onset 
4  p.303-/Glu304 - - - - Dystonia, DYT-1 GAG deletion carrier 
5  p.303-/Glu304 - - - - Dystonia, generalized 
6  p.303-/Glu304 - - - - Dystonia, DYT-1 GAG deletion carrier 
7  p.303-/Glu304 - - - - Dystonia,  DYT-1 GAG deletion carrier 
8  p.303-/Glu304 - - - - Dystonia,  DYT-1 GAG deletion carrier 
9  - p.Arg29Gln - - - Dystonia, childhood onset 
10  - p.Ser21Phe - - - Dystonia 
11  p.303-/Glu304 - - - - Dystonia 
12  p.Lys275Glu - - - - - 
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monkey, mouse, chicken, zebrafish and xenopus). Mutations identified are 
summarized in Table 3.1. 
3.4.2. Clinical details 
Case1: This Caucasian female (ΔGAG mutation carrier) was 89 years old at death. 
Despite having a strong family history of dystonia she was clinically unaffected. Her 
grandson had primary dystonia and torticollis. Her sister (case 2) and niece were 
positive for the ΔGAG mutation. She had a medical history of hypertension, 
coronary artery disease, arteriovascular insufficiency involving left arm and 
developed cognitive impairment.  
Case 2: A Caucasian woman (ΔGAG mutation carrier) who died at the age of 87 
years had a past medical history of hypertension, hyperlipidemia, coronary artery 
disease, pulmonary embolism, hypothyroidism, osteoarthritis and dementia. 
Although unaffected herself, she had a strong family history of dystonia. Her sister 
(case 1) and niece were both positive for ΔGAG mutation. She died following a right 
middle cerebral artery infarction confirmed prior to death by imaging studies 
Case 3: This Caucasian female, positive for ΔGAG mutation, had a clinical diagnosis 
of congenital dystonia with life-long disability. Dystonic symptoms started at the 
age of 9 or 10 and were slowly progressive. She had a similarly affected sibling but 
no other family history was available. By 73 years of age she was weak bilaterally in 
the upper and lower limbs and wheelchair bound. Abnormal involuntary 
movements affected both upper extremities. She complained of progressive 
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bilateral hearing loss and episodic problems with her vision and speech. 
Neurological examination reported no facial asymmetry, weakness in the both 
upper and both lower extremities, more severe proximally than distally. Deep 
tendon reflexes were diminished in the upper extremities, but symmetrical. 
Sensory evaluation showed intact pinprick and vibration sensation in both hands 
and right foot but these were absent in the left leg. No obvious cerebellar 
dysfunction was reported. She died at the age of 77.  
Case 4: A Caucasian female (ΔGAG mutation carrier) of Jewish ancestry died at the 
age of 90 years. She had been well until the age of 89 when she developed left 
sided weakness, expressive aphasia and dysphagia secondary to cerebrovascular 
accident. She also had intermittent confusion and paranoia. MRI reportedly showed 
an infarct involving the right internal capsule, thalamus and white matter.  She did 
not have a history of movement disorder; however, her grandson had a diagnosis 
of dystonia.   
Case 5: A Caucasian female with a clinical diagnosis of dystonia died at the age of 
90 years. Her son had a confirmed ΔGAG mutation. No further medical history was 
available. 
Case 6: This Caucasian female was a ΔGAG mutation carrier and died aged 88 years. 
No further medical history was available.  
Case 7:  This Caucasian male (ΔGAG mutation carrier) was unaffected by dystonia 
and died at the age of 75. No further clinical history was available.   
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Case 8: This Caucasian female, positive for ΔGAG mutation had a clinical diagnosis 
of torsion dystonia. The symptoms initially started at approximately 12-15 years of 
age but diagnosed as a psychiatric condition. Diagnosis of dystonia was made when 
she was 34 years old and narrowed down to torsion dystonia when she was 
approximately 57 years old. The symptoms largely took the form of tremors of the 
body, not of the neck or head and were described as a mild case of cerebral palsy. 
At the end of her life, 67 years old dystonia did not get any worse and no other 
treatments were offered. 
Case 9: This Caucasian male with p.Arg29Gln mutation in THAP1/DYT6 gene had a 
history of multi-infarct dementia, chronic obstructive pulmonary disease with 
severe dystonia and incontinence. He was negative for DYT1 dystonia and the onset 
of the dystonic symptoms was at the age of 17. He developed absence seizures late 
in life, at approximately, the onset of his Alzheimer’s symptoms. He died of two 
violent seizures three hours apart at the age of 71.  
Case 10: This Caucasian male with p.Ser21Phe mutation in THAP1/DYT6 gene, was 
59 years old at death with clinical diagnosis of dystonia. No further clinical details 
were available. 
Case 11 and 12 were with clinical diagnosis of dystonia. No further clinical details 
were available. 
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3.5. Discussion 
New 'next generation' sequencing technologies have massively increased the speed 
of genetic discoveries in recent years. Till date, 25 different loci for dystonia are 
reported in literature. The genes involved in monogenic forms of dystonia reflect 
the clinical heterogeneity. Although the genes identified to date are diverse and at 
present, the underlying functions of most of these genes and how they lead to 
dystonia remain elusive, their identification has fostered basic research 
(development of animal and cellular models) aimed at understanding the 
pathophysiology of dystonia. 
There is an accumulating evidence for genetic and clinical heterogeneity in primary 
dystonia. However, due to extremely reduced penetrance of primary dystonia mild 
cases may remain undiagnosed. A recurring mutation (ΔGAG) in the TOR1A gene 
causes the loss of an amino acid, glutamic acid, in the torsinA protein which is 
responsible for primary dystonia DYT1. Several heterozygous mutations along the 
coding regions of THAP1 gene are linked to primary dystonia DYT6.  
In total, 90 cases clinically diagnosed as primary dystonia were screened for 
primary dystonia genes TOR1A, THAP1, CIZ1, TUBB4 and GNAL. The disease onset in 
the cohort varied from early to adult onset and was in the ratio of 1:4. Age at death 
ranged from 32 to 91 years old and male to female ratio was 1:3. TOR1A mutations 
were identified in ten cases (11.1%) (9 cases with recurring mutation p.303-/Glu304 
and a case with p.Lys275Glu) and two cases (2.2%) have mutation in the THAP1 
gene (p.Arg29Gln and p.Ser21Phe). p.303-/Glu304 is a recurring mutation in DYT1 
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dystonia. The THAP1 mutations observed in cases 9 and 10 are predicted to be 
pathogenic by prediction softwares. One of the DYT1 cases has also a mutation in 
CIZ1 gene.  
Among the ten cases presented here, medical records and brain tissues were not 
available for cases 9 and 10 hence excluded from further study. Of the 8 cases, 
three cases (cases 3, 5, 8) are symptomatic and five of them are carriers for DYT1 
dystonia (cases 1, 2, 4, 6, and 7). Monogenic inheritance is most often seen in early-
onset cases, where a family history can often be elicited. Among eight cases in our 
cohort, cases 1, 2 and 8 belong to a same family tree. However, the reduced 
penetrance of DYT1 mutation means that many apparently sporadic cases may also 
fall into this category.  
Although the clinical phenotype associated with DYT1 dystonia can vary from 
severe dystonic storm to mild writer’s cramp, a typical phenotype has been 
described across ethnic groups characterized by early (mean age at onset, 13 years; 
with the majority before 26 years) limb (arm or leg is affected first in 90% of cases) 
onset, progressing to generalized/multifocal (65%) involvement, with spread to 
cranial muscles less common (15%–20%) (75). Symptomatic cases in the dystonia 
cohort: case 3 had no family history of dystonia, disease onset was in childhood 
affecting limbs (arms and leg) and progressed to generalized involvement; case 5 
had no clinical details available; case 8 had no family history of dystonia, disease 
onset was in childhood in the form of tremors of the body. Cases 1, 2, 4, 6, and 7 
are DYT1 mutation carriers where dystonic symptoms were absent.   
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Comparing clinical symptoms in mutation carriers, a typical DYT6 phenotype is 
characterized by early onset (mean, 16 years; range, 5–62 years); onset most often 
in an arm (50%), followed by cranial muscles (about 25%) or the neck (about 25%). 
In the dystonia cohort, a DYT6 symptomatic case (case 9) with a THAP1 mutation 
had onset at 17 years with severe dystonia and incontinence.  
Mutations in primary dystonia genes TUBB4, GNAl and CIZ1 are rare. Sanger 
sequencing of the primary dystonia genes mentioned above suggest that GNAL, 
TUBB4 and CIZ1 mutations do not represent a common cause of dystonia (in at 
least US and UK population) and that the frequency of mutations may vary with the 
population under consideration.  
Recent international consensus has proposed a new classification system for 
dystonia to address an increased understanding of the various clinical 
manifestations and etiologies (7). Owing to the serious shortcomings with assigning 
the DYTn loci based on statistical associations (314), the new classification system 
highlights the importance of biological phenomenon in understanding the 
disorders. The classification system is based on two axes: (a) clinical characteristics: 
age at onset, body distribution, temporal pattern, associated features (isolated or 
combined with another movement disorder), (b) etiology: nervous system 
pathology and inherited or acquired. The new classification system groups the 
previously ‘pure’ or ‘primary’ dystonias into isolated dystonias and ‘dystonia plus’ 
or ‘heredodegenerative’ dystonias into combined dystonia. Hence, by combining 
phenomenology and biological mechanism in the same classification, it becomes 
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easier for diagnostic testing and clinical recognition of dystonia syndromes.  This 
will also help to keep the clinical practice and scientific discoveries in the same 
pace.  
Nevertheless, studying the genetics of dystonia will not only help refine diagnostic 
and reproductive technology applications, but it also contributes greatly to our 
understanding of dystonia and quest for better treatments and a cure.
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Chapter 4. Neuropathology of DYT1 dystonia 
 
4.1. Background 
Neuropathological reports on genetically confirmed DYT1 dystonia are few in 
number and results are inconsistent. The absence of histological confirmation of 
changes in the basal ganglia, cerebral cortex and brainstem has made it even more 
difficult to support the traditional view of dystonia being a basal ganglia disorder. 
The evidence of perinuclear inclusion bodies in some of the neurons of 
pedunculopontine nucleus, the cuneiform nucleus and periaqueductal gray, but not 
in substantia nigra pars compacta, striatum, hippocampus and neocortex in four 
manifesting DYT1 carriers is by far the most interesting finding in the 
neuropathology of DYT1 dystonia (129). However, these findings are not replicated 
till date (Chapter 1, 1.5). 
DYT1 dystonia is caused by a heterozygous three base pair deletion in exon 5 of 
TOR1A gene with autosomal dominant inheritance. It encodes protein torsinA 
which resides in endoplasmic reticulum while the mutant form has been reported 
to reside in the nuclear envelope. The exact function of torsinA is still unknown but 
it is believed to take part in chaperone-like activities. Though DYT1 dystonia is more 
frequently observed in the clinics, the penetrance of the disease is only 30-40%. 
The low penetrance makes it difficult to draw a clinic-genetic-pathological 
correlation. 
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4.2. Aims and Hypothesis 
Hypothesis 
 That the ΔGAG deletion mutation in DYT1 dystonia influence the clinico-
pathological phenotype and include perinuclear inclusions in brainstem, 
which have been previously described (129). 
 The emerging role of cerebellum in dystonia will influence clinico-
pathological phenotype in cerebellum. 
 That a consistent neuropathology such as tau pathology or LBs, can be 
identified amongst seven genetically confirmed cases of DYT1 dystonia. 
Aim 
 To obtain both paraffin fixed and frozen tissues from brain regions of 
interest for genetically confirmed DYT1 cases. 
 To characterize the neuropathology of DYT1 cases. 
 To determine whether there is any corelation between clinical, genetic and 
pathological features.  
 
4.3. Methods 
Cohort 
Ten DYT1 cases were identified by genetic screening (described in Chapter 3) of the 
dystonia cohort. We selected the first seven cases for neuropathological 
examination as brain tissues were not available for the case 8, 11 and 12 (Table 
3.1).  Autopsy specimens of 7 DYT1 confirmed cases were received from the 
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BTBDD. Neurologically normal controls (n=5) were selected from the collection of 
the QSBB.  Clinical details, macroscopic findings and neuropathology reports were 
provided by the respective institutions. To our knowledge, none of the DYT1 cases 
have been previously reported. Formalin fixed, paraffin embedded brain tissue was 
available in all dystonia cases although systematic sampling of multiple regions for 
each case was not possible due to the retrospective nature of the study. Where 
possible the frontal and temporal cortices, striatum, globus pallidus, thalamus, 
subthalamic nucleus, cerebellum, midbrain, pons, and medulla were investigated. 
Brain regions available for study in each case are indicated in Table 2.3 DYT1 and DYT6 
cohorts for neuropathological studyTable 2.3. The midbrain was absent in cases 2 and 3 
and was only partially represented in case 6. The pons including the reticular 
formation was present in all cases except case 6. 
IHC 
Histological staining and and IHC methods carried out are described in detail in 
Chapter 2. In brief, paraffin embedded tissue sections (7 μm) were cut and stained 
using routine methods, including hematoxylin and eosin, Gallyas silver and Luxol 
fast blue/cresyl violet. IHC staining was performed according to a standard avidin-
biotin complex protocol using the following antibodies: ubiquitin (1:200, Dako, 
Ely,UK), tau (1:600, AT8, Autogen Bioclear, Calne, UK); AT100 (1:200, Innogenetics, 
Gent, Belgium), glial fibrillary acidic protein (GFAP; 1:1,000, Dako), Aβ (1:200, 
Dako), α-synuclein (1:50, Novacastra, Newcastle, UK), α-synuclein (1:1000, BD 
Transduction Biolabs, Oxford, UK), p62 (1:100, BD Bioscience, Oxford, UK), CD68 
(1:150, Dako),  and TDP-43 (1:2000, Protein Tech, Manchester, UK). Antibodies to 
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ubiquitin, p62, and tau required pretreatment with pressure cooking in sodium 
citrate buffer, pH 6.0, for 10 minutes before IHC staining. Sections to be used for 
IHC staining with antibodies to α-synuclein and Aβ were treated with formic acid 
for 30 minutes before pressure cooking as described above. For GFAP IHC, 
pretreatment with proteinase K was used. Antibody binding sites were visualized 
using the chromogen diaminobenzidine, and sections were counterstained using 
Mayer's hematoxylin.  
Assessment 
The staining protocol was designed to detect intracellular inclusions as previously 
described in DYT1 dystonia (129). In all cases brain regions including the midbrain 
and pons were stained with antibodies to ubiquitin and p62 to assess the presence 
of intraneuronal inclusions in the periaqueductal grey  matter, pedunculopontine 
nucleus, cuneiform nucleus, and reticular formation (129). Due to limited tissue 
availability the periaqueductal grey matter was not available in all cases (absent in 
cases 2, 3 and 6). The pontine tegmentum was available in all cases except case 6. 
Cases were systematically screened for additional neuropathological changes. 
Using Aβ IHC vascular and parenchymal Aβ deposition was determined in the 
frontal cortex and diffuse and mature plaque load was assessed based on the 
criteria of the Consortium to Establish a Registry for Alzheimer’s Disease 
(CERAD)(304). NFT pathology was determined using tau IHC and staged where 
possible according to the method of Braak and Braak (305). Vascular pathology was 
assessed and tau, ubiquitin, and α-synuclein IHC were performed in selected 
regions to exclude progressive supranuclear palsy, corticobasal degeneration, 
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Parkinson disease and multiple system atrophy as described previously (306). 
Where brainstem LBs were identified cortical LB pathology was also determined 
(307). 
4.4. Results 
Demographics and clinical reports obtained from the respective brainbanks for 
each case is described in detail in Chapter 3 and summarized in Table 4.1 
Table 4.1 Demographics and clinical report of DYT1 cases and controls 
 
Case  Sex  Ethnicity  Phenotype 
Family 
history Age at 
onset, y 
Age at 
death, y 
Cause of death  
1  F American 
Caucasian 
Non-
manifesting  
+ N/A 89 Natural 
2  
F American 
Caucasian 
Non-
manifesting  
+ N/A 87 Stroke 
3  
F American 
Caucasian 
Affected - ~9-10 77 Complications of disorder 
4 F American 
Caucasian 
Non-
manifesting  
+ N/A 90 Stroke 
5 
F American 
Caucasian 
Affected + N/A 90 Natural 
6 
F American 
Caucasian 
Non-
manifesting  
N/A N/A 88 N/A 
7 
M 
American 
Caucasian 
Non-
manifesting  
N/A 
N/A 75 Natural 
C1 M English Control N/A N/A 69 Myocardial infarction 
C2 F English Control N/A N/A 93 Old age 
C3 F English Control N/A N/A 87 Cancer 
C4 F English Control N/A N/A 81 Respiratory tract infection 
C5 F English Control N/A N/A 79 Cancer 
N/A: not available 
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4.4.1. Macroscopic findings 
The macroscopic details were available from the neuropathology reports supplied 
by the brain bank providing the case. In all the DYT1 cases the weight of the unfixed 
brains was in the normal range (315) or mildly reduced (range 1010 – 1200g, data 
available for cases 2-4 and 6). The blood vessels of the circle of Willis showed 
variable atherosclerosis in all cases except case 7. Mild cerebral cortical atrophy 
was evident in case 3 and generalized brain atrophy consistent with age was 
described in case 6. At brain slicing the cortical ribbon was well preserved in all 
cases. The ventricular system was unremarkable in cases 3 and 4 but there was 
moderate dilatation in case 2. Four cases showed cerebral infarction, this affected 
the right middle cerebral artery territory in case 2, frontal white matter in case 3, 
several infarcts of varying age with unspecified distribution in case 5, and multiple 
regions of cerebral white matter, occipital cortex and deep grey nuclei in case 4. 
Case 7 was found to have a diffuse leptomeningeal melanocytoma. Pigmentation of 
the substantia nigra and locus coeruleus was described in cases 2, 3, 4, and 6 where 
it was noted to be normal. 
4.4.2. Histological findings 
A summary of the pathological findings is given in Table 4.2 Examination of the 
midbrain and pons, represented in all cases except cases 6,  using ubiquitin and p62 
IHC showed no evidence of  NCIs of similar distribution and morphology to those 
previously associated with early-onset DYT1 dystonia (129) in the 7 cases and 5 
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controls studied. Moreover a detailed systematic examination of additional brain 
regions did not reveal similar inclusions in other structures.   
DYT1 cases were systematically assessed for other neuropathological 
abnormalities. Neuronal loss was generally inconspicuous in the regions studied. 
There was mild neuronal cell loss in the pigmented neurons of the substantia nigra 
pars compacta of case 1, 4, 5 and 7 and in the locus coeruleus of case 2, 4 and 5. 
Mild to moderate Purkinje cell loss was observed in the cerebellum of all the cases 
(Figure 4.2). Mild to moderate gliosis of the striatum was observed in all the cases 
and also in the substantia nigra of all cases in which it was available for analysis. 
The pontine base showed variable gliosis and this was severe in case 3. Vascular 
pathology and ischemic damage in the form of SVD, CAA and infarction was 
assessed in all cases. Cases 1, 4, 5 and 6 had mild SVD while this was severe in case 
2. CAA was mild in cases 2 and 6 and moderate in case 4. Small areas of infarction 
were observed in 3 cases. In cases 2 and 4 infarcts involved the globus pallidus and 
in case 5 a small infarct was noted in the midbrain tegmentum. Using two different 
α-synuclein antibodies for IHC investigation on multiple regions to assess LB 
pathology, cortical and brainstem Lewy bodies were observed in case 5 and rare 
LBs were observed in substantia nigra of case 7. Braak staging of LB pathology could 
not be performed as only limited brain regions were available. 
Full neuropathological assessment for AD was not possible due to the limited tissue 
available. Sparse diffuse Aβ plaques were noted in the cortex of case 1. In cases 2, 
4, 5 and 6 both diffuse and mature cortical Aβ plaques were present (Figure 4.1). 
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Tau pathology in the form of NFTs and neuropil threads was evident in four cases 
(cases 4, 5, 6 and 7). Formal Braak and Braak staging could not be performed. 
Tufted astrocytes, astrocytic plaques and coiled bodies were not observed. 
No consistent abnormalities were noted in the brain regions available for 
examination in this study including the midbrain, striatum, globus pallidus, 
cerebellum, and pons. Apart from AD and LB pathology as described above, none of 
the cases were found to have neuropathological features of any other 
neurodegenerative disease. In particular, multiple system atrophy, progressive 
supranuclear palsy and corticobasal degeneration were excluded.  
Table 4.3 summarizes the semi-quantitative findings of the histological features of 
the seven DYT1 cases. 
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Table 4.2 Summary of pathological findings in DYT1 cases 
Case 
Brainweight,  
g*  
Infarction 
Aβ pathology 
Tau pathology 
Lewy body 
pathology 
SVD CAA Final neuropathological diagnosis* 
D M 
1 N/A - + - - - + - 
 moderate atherosclerosis of cerebral vessels 
 mild neuronal loss and gliosis in hippocampus between the CA1 region and the subiculum 
 mild loss of Purkinje cells in the cerebellum 
 mineralization of vessel walls in the dentate nucleus 
 non-specific neurodegenerative changes 
2 1110 
globus 
pallidus 
+ + - - +++ + 
 mild cerebral artery atherosclerosis 
 right middle cerebral artery territory subacute infarct 
 possible AD 
3 1200 - - - - - - - 
 mild cortical atrophy 
 small areas of infarction 
 cerebral athero-arterio-arteriolosclerosis, remote frontal white matter infarct 
4 1010 
globus 
pallidus 
+++ ++ 
+ 
(cortex, striatum 
and brainstem) 
- + ++ 
 cerebral artho-arteriosclerosis 
 microinfarcts in cerebral white matter, deep gray nuclei and occipital cortex 
 macro infarct in right posterior internal capsule and pulvinar 
 hippocampal sclerosis 
5 N/A 
midbrain 
tegmentum 
++ ++ 
+ 
(cortex, striatum 
and brainstem) 
++ 
(cortical and 
brainstem) 
+ - 
 diffuse LB disease (a) SN degeneration with LBs (b) neocortical LBs (c)AD neuropathology 
 cerebrovascular disease 
(a)numerous infartcs of different ages (b)atherosclerotic disease  of circle of Willis arteries 
6 1184 - ++ + 
+ 
(cortex, striatum 
and  brainstem) 
- + + 
 brain generalized atrophy 
 focal acute (perimortem) petechial hemorrhages 
 
7 N/A - - - 
+ 
(brainstem) 
+ 
(SN) 
- - 
 melanocytic neoplasm with diffuse leptomeningeal and perineural spread 
- = absent; + = occasional/mild; ++ = moderate; +++ = severe;  N/A-not available; SVD- Small vessel disease ;  CAA- Cerebral amyloid  angiopathy;  SN: Substantia nigra; Aβ : D-diffuse plaques, M-mature plaques;  AD: 
Alzheirmer’s disease; LB: Lewy body; *: Derived from neuropathology report issued by BTDBB 
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Table 4.3  Semi-quantitative summary of neuronal loss (NL), gliosis pathology, Lewy bodies (LB), and Tau pathology in DYT1 cases  
 
Brain regions Case 1 Case 2 Case 3 Case 4 
NL Gliosis Aβ LB Tau NL Gliosis Aβ LB Tau NL Gliosis Aβ LB Tau NL Gliosis Aβ LB Tau 
D M D M D M D M 
Frontal cortex - + + - - - - +++ + + - - - ++ - - - - - ++ ++ + - + 
Temporal cortex - + - - - - - - + + - - - - - - - - - ++ ++ + - - 
Caudate - + N/P - - - ++ N/P - - - + N/P - - - ++ N/P - + 
Putamen - + N/P - - - ++ N/P - - - ++ N/P - - - ++ N/P - ++ 
Globus pallidus - ++ N/P - - - +++ N/P - - N/A N/A N/A N/A N/A - +++ N/P - - 
Thalamus - + N/P - - - - N/P - - N/A N/A N/A N/A N/A - ++ N/P - - 
Subthalamic nucleus - + N/P - - N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Midbrain tegmentum - ++ N/P - N/P N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A - - N/P - + 
Midbrain tectum N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A - - N/P - + 
Reticular formation - ++ N/P - N/P - - N/P - - - - N/P - - - - N/P - + 
Substantia nigra pars compacta + ++ N/P - N/P N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A + ++ N/P - + 
Red nucleus - - N/P - N/P N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Locus coeruleus N/A N/A N/A N/A N/A + - N/P - + - +++ N/P - + + + N/P - + 
Pontine tegmentum - ++ N/P - N/P - - N/P - + - ++ N/P - - - ++ N/P - - 
Pontine base - ++ N/P - N/P - - N/P - - - +++ N/P - - - ++ N/P - - 
XIIth nerve nuclei N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A - + N/P - - 
Dorsal motor nuclei Xth N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A - - N/P - - 
Inferior olive N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A - - N/P - - 
Pyramid N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A - - N/P - - 
Periaqueductal gray N/A N/A N/A N/A N/A - - N/P - - N/A N/A N/A N/A N/A - - N/P - + 
Cerebellum + + N/P N/P - + + N/P N/P - + ++ N/P N/P - + ++ N/P N/P - 
Vermis ++ ++ N/P N/P - N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A + ++ N/P N/P - 
Dentate nucleus + - N/P N/P - - - N/P N/P - - + N/P N/P - - + N/P N/P - 
Key:  - = absent; + = occasional/mild; ++ = moderate; +++ = severe/frequent,  Tau [ - = absent; + = Neurofibrillary tangles/ abnormal neurites/neuropil threads;  Aβ [D: diffuse plaques, M: mature plaques]; N/A: not available; N/P: 
not performed; Assessment: LB- α-syn, Tau- AT8, NL-H&E, Gliosis- GFAP. 
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Table 4.3: Semi-quantitative summary of neuronal loss (NL), gliosis pathology, Lewy bodies (LB), and Tau pathology  in DYT1 cases continued.. 
 
Brain regions Case 5 Case 6 Case 7 
NL Glios
is 
Aβ LB Tau NL Gliosis Aβ LB Tau NL Gliosis Aβ LB Tau 
D M D M D M 
Frontal cortex - + + ++ - + - + ++ + - + - ++ N/P - - 
Temporal cortex - ++ ++ ++ - + - ++ + ++ - + N/A N/A N/A N/A N/A 
Caudate - + N/P - + - ++ N/P - + - + N/P N/P - 
Putamen - ++ N/P - - N/A N/A N/A N/A N/A - + N/P N/P - 
Globus pallidus - ++ N/P - - - - N/P - - - ++ N/P N/P N/P 
Thalamus N/A N/A N/A N/A N/A - + N/P -  N/A N/A N/A N/A N/A 
Subthalamic nucleus N/A N/A N/A N/A N/A - ++ N/P - - N/A N/A N/A N/A N/A 
Midbrain tegmentum + ++ N/P + - N/A N/A N/A N/A N/A - + N/P - N/P 
Midbrain tectum - ++ N/P - + N/A N/A N/A N/A N/A - + N/P - N/P 
Reticular formation - - N/P - - N/A N/A N/A N/A N/A - ++ N/P - - 
Substantia nigra pars compacta + ++ N/P ++ + - ++ N/P - + + ++ N/P + - 
Red nucleus - + N/P - - - + N/P - + - + N/P - N/P 
Locus coeruleus + - N/P ++ - N/A N/A N/A N/A N/A - ++ N/P - + 
Pontine tegmentum - - N/P ++ - N/A N/A N/A N/A N/A - ++ N/P - + 
Pontine base - - N/P - - N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
XIIth nerve nuclei N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Dorsal motor nuclei Xth N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Inferior olive N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Pyramid N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Periaqueductal gray N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Cerebellum ++ ++ N/P N/P - + ++ N/P N/P N/P + ++ N/P - - 
Vermis + ++ N/P N/P - N/A N/A N/A N/A N/A + ++ N/A N/P N/P 
Dentate nucleus - - N/P N/P - - + N/P N/P - - - N/P - - 
Key:  - = absent; + = occasional/mild; ++ = moderate; +++ = severe/frequent,  Tau [ - = absent; + = Neurofibrillary tangles/ abnormal neurites/neuropil threads;  Aβ [D: diffuse plaques, M: mature plaques]; 
N/A: not available; N/P: not performed; Assessment: LB- α-syn, Tau- AT8, NL-H&E, Gliosis- GFAP; CAA- Aβ 
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Figure 4.1 Histological findings in DYT1 cases. Neocortical regions examined and illustrated 
using the frontal cortex showed good preservation of neurons (A) and only mild gliosis (B). Aβ 
immunohistochemistry showed only sparse plaques (C) and mild cerebral amyloid angiopathy 
(D). Scale bar: A-C=60 µm, D=30µm. A-D represents phots from Case 4. 
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Figure 4.2 Histological findings in DYT1 cases. In the cerebellum there was mild Purkinje cell 
depletion (A) with associated gliosis (B) and occasional axonal swellings and torpedo bodies 
(C). Lewy body was observed in temporal cortex (D). A: haematoxylin and eosin; B: GFAP; C: 
Silver stain and D: alpha-synuclein Scale bar: A, D=60 µm, B, C=30µm. A, B and D represent 
photos from Case 4. C represents Case 1. 
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4.5. Discussion 
This study provides a detailed neuropathological assessment of the largest cohort 
of genetically proven DYT1 cases ever evaluated. This is an important contribution 
as there are few neuropathological studies of genetically confirmed DYT1 mutation 
cases in the literature (311). I aimed to to determine whether consistent 
neuropathological features could be identified as a hallmark of the disease and to 
address the question of whether neuronal perinuclear inclusions of the type 
previously associated with early-onset DYT1 dystonia could be confirmed in our 
cohort to be a consistent disease marker (129).  
I described in chapter 3 that all of the cases examined carry a 3-basepair deletion 
(ΔGAG) in exon 5 of the TOR1A gene which is a common mutation in DYT1 dystonia. 
Among the seven cases included in the neuropathology study, two cases (cases 3 
and 5) were symptomatic and five were asymptomatic carriers for DYT1 dystonia 
(cases 1, 2, 4, 6, and 7). Case 3 had a clinical diagnosis of childhood onset slowly 
progressive dystonia and died at age of 77. Case 5 had a clinical diagnosis of 
dystonia and died at the age of 90. Cases 1, 2, 4, 5 and 6 were in good health for 
most of their lives with no chronic neurological disorder. 
Neuropathological studies of dystonia are sparse, partly due to the low availability 
of post-mortem tissue from these patients and the labour intensive nature of the 
exploratory neurological examination of the entire human brain. Only a few studies 
have examined neuropathological abnormalities in a handful of dystonia patients, 
providing limited information regarding the relationship between 
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functional/structural brain changes and underlying neuropathology. Using a series 
of genetically confirmed DYT1 brains it was hoped to identifiy consistent 
neuropathological changes in the disease. Post-mortem human brain tissue was 
used to examine a number of brain regions (basal ganglia, cerebellum, dentate 
nucleus, locus coeruleus, frontal cortex, midbriain, substantia nigra, pons, and 
medulla) although not all regions were available in each case due to the 
retrospective nature of the study. Using a similar IHC approach to that applied in a 
previous neuropathological study of DYT1 dystonia (129) we were unable to 
replicate the finding of ubiquitin positive inclusions in the midbrain and pons with 
the exception of inclusions that were also immunoreactive for tau or α-synuclein, 
representing NFTs and Lewy bodies respectively. We also screened for intracellular 
inclusions in other brain regions and could not demonstrate abnormality other than 
Alzheimer pathology and sparse LB pathology. The remaining pathological features 
identified in the cases were those of gliosis, mild-moderate Purkinje cell depletion, 
CAA, SVD of varying severity and cerebral infarcts. None of these changes can be 
regarded as disease specific and are most likely to be due to the advanced age at 
death of the cases (75-90 years). 
We examined anatomical regions implicated in dystonia and found no pathological 
intracellular inclusions or evidence of more than mild neuronal loss in the caudate, 
putamen, subthalamic nucleus, thalamus, substantia nigra and globus pallidus, 
other than that associated with small infarcts in the latter in two cases (316).  
 P a g e  | 124 
The reason that we failed to replicate the findings of McNaught et al. (129) is 
uncertain. With the exception of case 4 in the McNaught series, who was aged 33 
years at death, the ages of our 2 case series were similar excluding the possibility 
that the inclusions observed are age related. One difference between the two 
studies is that all four cases described by McNaught et al. manifested clinical 
dystonia compared with only two cases in our series, the remaining five cases that 
we investigated were non-manifesting carriers of the gene mutation. If the 
neuronal inclusions are only present in patients with clinical dystonia this may have 
reduced the likelihood that we would have detected inclusions in our cases. An 
alternative explanation would be that different antibodies were used in the two 
studies and this remains a possibility. Given the limitation that only a small amount 
of tissue was available for study we chose ubiquitin and p62 as screening 
antibodies as they target abnormally folded proteins for degradation by the 
proteasome and autophagy respectively. As both are sensitive markers of 
inclusions formed from a wide variety of different proteins in neurodegenerative 
diseases and can recognise proteinaceous inclusions for which the principle protein 
component has not been identified we argued that if DYT1 dystonia is associated 
with intraneuronal inclusions these would be highlighted by one or both of these 
antibodies (317,318). Any inclusions identified could then have been further 
defined using other specific antibodies such as lamin A/C or torsinA and the 
affected neurons would have been immunophenotyped to determine whether 
cholinergic neurons were affected as described in the McNaught study. Assessment 
of cell inclusions using a reliable human specific torsinA antibody would be highly 
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desirable. During the study I characterized 4 different antibodies: torsinA 
(99,129,319), torsinA (TA913)(320), anti-torsinA (ab34540) and torsinA (santacruz s-
20) using western blots, IHC and immunofluorescence (Chapter 5). However, none 
of these was found to be reliable and therefore hindered the further progress of 
this study.  
Despite the limitations of this study due to its retrospective nature and the 
restricted tissue availability our observations  support the previous findings that in 
primary dystonia, there is no overt neurodegeneration or cell loss (311). The 
pathological change of brainstem neuronal inclusions reported in DYT1 dystonia 
(129) was not replicated in our cohort. This study supports the hypothesis that 
dystonia may be a result of dysfunction of a wide variety of cellular pathways but 
these to not give rise to morphological changes identifiable using current methods. 
Hence emphasis should be placed on the need to understand the biochemical and 
cellular pathways involved in dystonia. In this regard, generation of cellular disease 
models using the induction of pluripotent stem (iPS) cells from patient skin 
fibroblast has opened new horizons (321,322). Understanding the cellular pathways 
influenced by particular mutations and the neuronal networks affected may inform 
future neuropathological studies.  
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Chapter 5. Neuropathology of DYT6 cases 
 
5.1. Background 
DYT6 dystonia is caused by the mutation in the coding region of THAP1 (thanatos 
associated protein domain containing, apoptosis associated protein 1) gene 
(137,138). Missense, nonsense and frameshift mutations, spread throughout most 
of the coding portion of the gene, have all been associated with disease. Mutations 
in this gene have been detected in genetically diverse populations throughout the 
world (Chapter 1). To date, penetrance has only been measured in Amish–
Mennonite families, where it appears to be ~60%, but this may not be true of all 
populations or mutations (139). Most mutations are found in the heterozygous 
state, but homozygotes are described (138,323). 
THAP1 protein is thought to be involved in the regulation of transcription and 
hence dysregulated transcription of key genes is thought to be one of the 
mechanism by which THAP1 mutations might cause dystonia. THAP1 protein is also 
known to interact with PAR-4, promoter region of TOR1A/DYT1 and TAF1/DYT3 
gene. 
Neuropathology of DYT6 has not been described in the literature so far. This is the 
first ever neuropathologcal examination carried out in two cases of DYT6 mutation 
human brains. 
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5.2. Aims and Hypothesis 
Hypothesis 
 The mutation and its location in THAP1 gene influence the clinico-
pathological phenotype in a DYT6 case. 
 DYT6 and DYT1 dystonias are forms of primary pure dystonia, hence may 
share the pathology. 
 The perinuclear inclusions described in brainstem for DYT1 dystonia may be 
true for DYT6 dystonia (129). 
 The emerging role of cerebellum in dystonia will influence clinico-
pathological phenotype in cerebellum. 
 Description of a significant pathology in DYT6 may help in treatment of 
DYT6 dystonia since this is the first ever neuropathological examination 
carried out on DYT6 cases to date. 
Aims 
 Characterise neuropathology of DYT6 cases. 
 Investigate clinico-genetic-pathological correlation 
5.3. Methods 
Two DYT6 cases were identified by genetic screening (described in Chapter 2 and 3) 
of the dystonia cohort. To carry out the detailed neuropathological examination, 
tissues for brain regions of interest were requested based on the previous studies 
(129,304,306,307,324). These include brainstem, midbrain, substantia nigra, frontal 
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cortex, motor cortex, cerebellum, dentate nucleus, pons, and medulla. However, 
brain regions studied were largely based on the availability of the tissue at the 
respective brain banks. Histological staining and and IHC methods carried out as 
described in detail in Chapter 2. Antibodies used for IHC include: ubiquitin (1:200, 
Dako, Ely,UK), tau (1:600, AT8, Autogen Bioclear, Calne, UK); AT100 (1:200, 
Innogenetics, Gent, Belgium), glial fibrillary acidic protein (GFAP; 1:1,000, Dako), Aβ 
(1:200, Dako), α-synuclein (1:50, Novacastra, Newcastle, UK), α-synuclein (1:1000, 
BD Transduction Biolabs, Oxford, UK), P62 (1:100, BD Bioscience, Oxford, UK), CD68 
(1:150, Dako) and TDP-43 (1:2000, Protein Tech, Manchester, UK). 
Neuropathological assessment 
A detailed neuropathological study was carried out on both cases for the brain 
regions available. Semi-quantitative assessment of neuronal loss and gliosis was 
performed using haematoxylin and eosin staining and GFAP IHC respectively. The 
midbrain and pons were stained with antibodies to ubiquitin and p62 to assess the 
presence of intraneuronal inclusions in the periaqueductal gray matter, 
pedunculopontine nucleus, cuneiform nucleus and reticular formation where 
available (129). The Aβ cortical plaques were assessed based on CERAD criteria 
(304). Other concomitant pathological conditions including tau, CAA, TDP-43, α-
synuclein pathology and SVD were assessed using published criteria (304,306,325–
327).  
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5.4. Results 
5.4.1. Clinical data 
 Demographic and clinical data are summarized in Table 5.1. 
Case 1 was a Caucasian male with onset of dystonia at the age of 17 which became 
severe. Later in life he developed seizures, chronic obstructive pulmonary disease 
and was thought to have multi-infarct dementia. Genetic testing was negative for 
DYT1 dystonia. He died following two seizures at the age of 71.  
Case 2 was a 59 year old male with clinical diagnosis of dystonia. No further clinical 
details were available.  
  
Table 5.1 Demographic and clinical details of DYT6 cases 
 
Case  Sex  Ethnicity  
Clinical 
diagnosis 
DYT6 
variant 
Age at 
onset, years  
Age at 
death, years  
Cause of 
death 
1 M 
American 
Caucasian 
Dystonia, 
affected 
p.R29Q 17 71 Seizures 
2 M 
American 
Caucasian 
Dystonia, 
affected 
p.S21F N/A 59 N/A 
N/A: not available 
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5.4.2. Genetics 
Case 1 had a single heterozygous mutation, p.R29Q in the coding region of THAP1. 
The mutation variant is predicted to be damaging using prediction software 
(Mutation taster-score: 43, Polyphen -score: 0.867 and SIFT-score: 0.004). This 
mutation has previously been described as pathogenic in DYT6 (312,313). 
Case 2 had a novel heterozygous variant p. S21F, predicted to be disease causing 
(Mutation taster-score: 155, Polyphen-score: 0.981 and SIFT-score: 0.01. The amino 
acids involved in each case are conserved across several species (Figure 5.1). 
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Figure 5.1 Mutations in THAP1 gene considered in this study. Diagram showing conservation of the amino acids and the nucleotides of concern across different species 
in exon 1 of THAP1, c. 62C>T/ p. S21F and in exon 2 of THAP1, c. 86G>A / p. R29Q (the affected bases and codons are shown in boldface and red, respectively).  
Species  
Human  G  T  T  T  C  T  T  T  C  C  A  C  A  A  G  T  T  T  C  C  T  C  T  T  A  C  T  C  G  A  C  C  C  
 -  V  -  -  S  -  -  F  -  -  H  -  -  K  -  -  F  -  -  P  -  -  L  -  -  T  -  -  R  -  -  P  -  
Chimpanzee  G  T  T  T  C  T  T  T  C  C  A  C  A  A  G  T  T  T  C  C  T  C  T  T  A  C  T  C  G  A  C  C  C  
 -  V  -  -  S  -  -  F  -  -  H  -  -  K  -  -  F  -  -  P  -  -  L  -  -  T  -  -  R  -  -  P  -  
Gorilla  G  T  T  T  C  T  T  T  C  C  A  C  A  A  G  T  T  T  C  C  T  C  T  T  A  C  T  C  G  A  C  C  C  
 -  V  -  -  S  -  -  F  -  -  H  -  -  K  -  -  F  -  -  P  -  -  L  -  -  T  -  -  R  -  -  P  -  
Mouse  G  T  C  T  C  C  T  T  C  C  A  C  A  A  G  T  T  T  C  C  T  C  T  T  A  C  T  C  G  C  C  C  C  
 -  V  -  -  S  -  -  F  -  -  H  -  -  K  -  -  F  -  -  P  -  -  L  -  -  T  -  -  R  -  -  P  -  
Chicken  A  T  C  T  C  T  T  T  C  C  A  C  A  A  G  T  T  T  C  C  T  T  T  G  A  C  C  A  G  G  C  C  C  
 -  I  -  -  S  -  -  F  -  -  H  -  -  K  -  -  F  -  -  P  -  -  L  -  -  T  -  -  R  -  -  P  -  
Zebrafish  A  T  C  T  C  C  T  T  C  C  A  C  A  A  G  T  T  T  C  C  G  C  T  G  G  C  A  C  G  G  C  C  G  
 -  I  -  -  S  -  -  F  -  -  H  -  -  K  -  -  F  -  -  P  -  -  L  -  -  A  -  -  R  -  -  P  -  
Xenopus  A  T  C  T  C  T  T  T  T  C  A  C  A  A  G  T  T  T  C  C  C  C  T  T  A  A  A  C  G  C  C  C  G  
 -  I  -  -  S  -  -  F  -  -  H  -  -  K  -  -  F  -  -  P  -  -  L  -  -  K  -  -  R  -  -  P  -  
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5.4.3. Neuropathological assessment 
A summary of the pathological findings is given in Table 5.2 with details of the 
regional histological assessment provided in Table 5.3. 
Macroscopic findings 
Macroscopic findings were derived from the report provided by the BTDBB for case 
1 and by direct observation of the brain slices provided for case 2. In case 1 mild to 
moderate generalised cerebral atrophy was described. The blood vessels of circle of 
Willis showed moderate atherosclerosis with no vascular anomalies. The cortical 
ribbon was of slightly reduced thickness and the hippocampal formation was mildly 
atrophic. Patchy areas of acute ischemia were observed in the deep gray matter 
structures but there was no evidence of established vascular lesions.  
Case 2 showed no macroscopic abnormalities. The cortical ribbon, caudate, 
putamen, thalamus, subthalamic nucleus, globus pallidus, hippocampus, 
cerebellum, pons and medulla were all unremarkable. There were no focal lesions 
and no brain atrophy was observed.  
Histology 
In case 1 the cortex, cerebellum, dentate nucleus, basal ganglia, substantia nigra 
and medulla were well preserved with no detectable neuronal loss with the 
exception of mild Purkinje cell depletion. There was mild to moderate gliosis in 
several brain regions (Figure 5.2).   Aβ deposits were most frequent in the frontal 
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cortex where there were frequent diffuse and sparse mature plaques. There was 
also mild cerebral amyloid angiopathy. Tau pathology of Alzheimer type 
(neurofibrillary tangles, neuropil threads and abnormal neurites) was mild in the 
temporal cortex but was not observed in subcortical regions. Formal analysis of the 
Aβ Thal phase and Braak and Braak tau staging was not possible due to the limited 
regions available for examination. There was no α-synuclein pathology in the form 
of either Lewy bodies or glial cytoplasmic inclusions and no TDP-43 immunoreactive 
inclusions were found. There was mild small vessel disease but no further evidence 
of vascular lesions. We sought to identify pathological neuronal cytoplasmic 
inclusions in the midbrain and pons as described previously in DYT1 dystonia cases 
using ubiquitin and p62 IHC, however, such inclusions were not identified.  
In case 2 no neuronal loss was observed expect for mild loss of pigmented neurons 
in the substantia nigra and mild Purkinje cell depletion. Gliosis was restricted to the 
cerebellar cortex where it was of mild degree. Alzheimer pathology in the form of 
cortical Aβ deposition was observed in the parietal cortex where there were sparse 
diffuse deposits. There was moderate cerebral amyloid angiopathy in the parietal 
lobe. No tau immunoreactive inclusions were found in any region. Careful 
examination of the midbrain and pons showed no p62 or ubiquitin labelled 
neuronal cytoplasmic inclusions. No α-synuclein or TDP-43 pathology was found 
and there was no evidence of small vessel disease.  
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Table 5.2 Summary of neuropathological findings in DYT6 cases 
Case Macroscopic features 
 
Aβ Tau Lewy  
body 
SVD CAA TDP-43  
D M 
1 
Mild-moderate cerebral atrophy* 
Mild cortical and hippocampal 
atrophy* 
Patchy acute ischemic lesions * 
+++ + + - 
+ + 
- 
2 
 
No abnormalities* + + - - - ++ - 
- = absent; + = mild; ++ = moderate; +++ = severe; SVD- Small vessel disease ;  CAA- Cerebral 
amyloid angiopathy;  D-diffuse, M-mature;   *: Derived from neuropathology report issued by 
BTDBB for case 1 and QSBB for case 2 
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Figure 5.2 Histological findings in DYT6 cases. Sparse mature and frequent diffuse plaques were 
observed in frontal cortex (A) with moderate cerebral amyloid angiopathy in the parietal lobe 
(B). In the cerebellum there was mild Purkinje cell depletion and associated gliosis (C). Mild 
cortical gliosis was observed in cerebellum (D). A and B: Aβ IHC; C: alpha-internexin and D: GFAP. 
A=20, B=50,  C and D=60 µm, A-B represent photos from Case 1 and C-D represents Case 2.  
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 Table 5.3: Semi-quantitative summary of neuropathological changes in DYT6 cases 
 
Case 1 Case 2 
Regions Neuronal loss 
 
Gliosis Aβ Lewy bodies 
 
Tau CAA TDP43 Neuronal loss Gliosis Aβ Lewy bodies Tau CAA TDP43 
 
D M D M 
Cortex                 
Frontal - + +++ + - - + N/P - - N/P N/P N/P N/P N/P N/P 
Motor N/A N/A N/A N/A N/A N/A N/A - - N/P N/P N/P N/P N/P 
Temporal - + + - - + + N/P - - - - N/P - N/P N/P 
Parietal N/A N/A N/A N/A N/A N/A N/A - - + -  - ++ N/P 
Hippocampal formation N/A N/A N/A N/A N/A N/A N/A - - N/P - - N/P N/P 
Caudate - - N/P N/P - N/P - - - N/P N/P - N/P - 
Putamen - + N/P N/P - N/P - - - N/P N/P - N/P - 
Globus pallidus - + N/P N/P - N/P - - - N/P N/P - N/P - 
Thalamus N/A N/A N/A N/A N/A N/A N/A - - N/P N/P - N/P N/P 
Subthalamic nucleus N/A N/A N/A N/A N/A N/A N/A - - N/P - - N/P N/P 
Substantia nigra N/A N/A N/A N/A N/A N/A N/A + - - - - N/P N/P 
Locus coeruleus N/A N/A N/A N/A N/A N/A N/A - - N/P - N/P N/P N/P 
Pontine nuclei N/A N/A N/A N/A N/A N/A N/A - - N/P - N/P N/P N/P 
Dorsal motor nucleus of vagus - ++ N/P - - N/P N/P N/A N/A N/A N/A N/A N/A N/A 
Twelfth nerve nucleus - ++ N/P - - N/P N/P - - N/P - N/P N/P N/P 
Inferior olive - ++ N/P - - N/P N/P - - N/P - N/P N/P N/P 
Cerebellar Purkinje cells + + N/P N/P - N/P N/P + + N/P N/P - N/P N/P 
Dentate nucleus - + N/P N/P - N/P N/P - - N/P N/P - N/P N/P 
Key:  - = absent; + = mild; ++ = moderate; +++ = severe; D: diffuse plaques; M: mature plaques; N/A: not available; N/P: not performed; CAA: cerebral amyloid angiopathy 
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5.5. Discussion 
The molecular genetics of primary dystonia syndromes have been the object of 
extensive analysis and a number of genes associated with autosomal dominant 
inheritance have now been identified. Despite these genetic advances which shed 
light on the disease pathogenesis there are few neuropathological descriptions of 
isolated dystonia in the literature and the neuropathology of DYT6 has not 
previously been described. In this study we undertook detailed neuropathological 
assessment of two DYT6 cases with confirmed THPA1 mutations and could find no 
disease specific morphological abnormalities. 
 Both cases had missense mutations in the THAP1 domain of THAP1 resulting in 
different amino acid changes, p. R29Q (312,313) and a novel mutation p. S21F 
respectively. In the latter case, a pathogenic mutation in this codon due to a 
different nucleotide change has previously been reported (159). The heterogeneity 
in the clinical spectrum of DYT6 dystonia is growing owing to the number of THAP1 
mutations reported in literature since the gene discovery. This has made it difficult 
to establish a genotype-phenotype correlation in terms of clinical phenotypes 
reported for each DYT6 case in literature. However, functional studies were more 
successful in demonstrating the mutation effect. Mutations in the THAP1 domain 
are thought to interrupt DNA binding causing transcriptional dysregulation of 
THAP1 target genes (328). A functional  study on a THAP1 case with a frameshift 
mutation in NLS region of THAP1 demonstrated impaired nuclear import of mutant 
THAP1 in vitro(329);  THAP1 is reported to interact with the promoters of TOR1A 
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(148) and TAF1, implicated in DYT3 dystonia (156) and recently THAP1 has been 
reported to autoregulate its own expression (330).  Hence, studies of biochemical 
and cellular mechanisms may provide a link to abnormal motor control in DYT6 
dystonia.  
Our neuropathological investigation of these DYT6 cases utilised a similar 
immunohistochemical approach to that previously applied in DYT1-related dystonia 
cases (129) and adult-onset dystonia cases (125) with the specific aim of 
determining whether brainstem neuronal cytoplasmic inclusions are a common 
hallmark of isolated dystonias. We were unable to identify such inclusions in our 
study and, indeed, we found no neuropathological features that could be regarded 
as specific to dystonia in either case(129). As basal ganglia dysfunction gives rise to 
dystonia we examined these regions in detail but no significant pathological 
changes were found. Neurodegenerative diseases such as Parkinson’s disease, 
progressive supranuclear palsy and corticobasal degeneration, which may 
sometimes present with dystonic symptoms, were excluded by detailed 
neuropathologic examination. 
This study adds further evidence that morphological abnormalities detectable using 
current neuropathological techniques are not features of isolated dystonias and 
indicate that future advances in our understanding of the pathogenesis of group of 
diseases is more likely to come from biochemical and molecular biology studies. In 
this context, iPS cells may provide a good understanding of the cellular pathways 
and biochemical activities of the gene /protein under consideration. However, it 
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may be challenging to apply the results of such studies in a controlled setting to the 
clinical diseases. 
5.6. Antibody optimization 
5.6.1. Problem 
The problems with the commercial antibodies is not unheard of (331). The quality 
control has been of utmost importance since we are in the era of off-the-shelf 
molecular and cellular biology. The list of commercially available antibodies for the 
protein of interest is long. However, the process of optimising any antibody to 
specifically detect your protein of interest within the correct conditions is arduous 
and frequently unsuccessful. 
Primary dystonia genes, TOR1A and THAP1 were known since 1997 and 2007 
respectively. However, good quality antibodies which are human specific for 
respective genes are difficult to obtain. This is partly due to the unavailability of 
brain tissues of interest to carry out tests by respective companies and as well, 
these proteins are poorly characterized.  
Four different TOR1A antibodies were tested: rabbit polyclonal TOR1A (ab34540), 
mouse monoclonal TOR1A (sc-373915), rabbit monoclonal TOR1A (kindly given to 
brainbank in 2007), rabbit polyclonal TOR1A (TA913 kindly given by Dr Angrez lab). 
For THAP1, a rabbit polyclonal THAP1 (Proteintech) was tested. 
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Optimization conditions for IHC included: 
 Different primary antibodies as listed above 
 Different blocking solution: 1% and 10% milk, 5% BSA 
 Different pre-treatments: formic acid/citrate buffer /proteinease k  
 Different primary antibody incubation period: overnight/ an hour 
 Different primary antibody dilutions: 1:10, 1:100, 1:500, 1:800, 1:1000, 1:5000 
 Different staining material: frozen / paraffin embedded brain tissues 
 Different  species: human / mouse 
 Other variations : tissues from control and affected individuals 
Optimization for Immunoflourescence included 
 Different paraffin embedded tissues : mouse / human 
 Different secondary antibodies: goat / mouse /rabbit 
Optimization for Western blot included 
 Different species lysates: human, mouse, neuroblastoma cells 
 Different primary antibody concentration: 1:100, 1:500, 1:800, 1:1000 
 Different blocking solution : 1% milk, 5% BSA 
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5.6.2. Results 
    
 
Figure 5.3 Immunohistochemical optimization of the TOR1A and THAP1 antibodies in 
normal human controls. Panel A, B and C represents three different TOR1A antibodies 
tested in this study. Each of the antibodies gave high background and stained whole of the 
nucleus (shown by arrows). Panel D represents THAP1 antibody tested.  
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Figure 5.4  Immunofluorescence staining of TOR1A antibody in wildtype mouse (left panel) and 
human (right panel) paraffin-fixed tissues. Staining is with high background and the whole nucleus 
is stained making it difficult to localise the nuclear protein. Arrows showing stained nucleus. 
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Figure 5.5 Antibody optimization. (a) represents western blots of three TOR1A antibodies for 
human and mouse lysates (a) TOR1a (abcam) showed TOR1A band at about 38kda in mouse but 
not in human (B) TOR1A (santacruz) did not show specific band (C) TOR1A-TA193 showed a fuzzy 
band for human but not for mouse. (b) represents western blots for a THAP1 antibody tested 
where bands were observed at various sizes in mouse lysate but did not work with human brain 
lysate.
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The non-specific staining in both IHC and IF were observed (Figure 5.3). By WB, 
non-specific bands were observed in human brain lysates, however specific bands 
at the predicted molecular weight of THAP1 (25kda) and TOR1A (38kda) were 
detected in both mouse and cell lysates. The presence of non-specific bands in WB 
and a high background in IHC and IF for human brain samples meant that we could 
not be confident that any staining which we were detecting by IHC was specific and 
thus was the reason to stop pursuing staining using the above antibodies in our 
cohort. 
5.6.3. Discussion 
The use of IHC is ubiquitous in neuroscience. A list of antibodies for the protein of 
interest is available commercially. Antibodies that work are extremely valuable 
research tools. However, the search for such antibodies is made quite difficult by 
two different problems; the good antibody problem, the bad technique problem. 
 Despite cellular studies on torsinA and THAP1 proteins the exact function of the 
protein is still unknown. Also there is mismatched information on whether torsinA 
is nuclear or cytoplasmic protein which makes it difficult to test our hypothesis on 
humans in the IHC studies. Published reports which used TOR1A antibodies for 
immunofluorescence did not use human samples, further published reports which 
used the THAP1 antibodies used neither human or cellular samples. Hence, the first 
problem, “the good antibody problem” is that production of a good antibody is a 
difficult and a time consuming process and many researchers may not possess the 
skill necessary to make good antibodies or the time to make project specific 
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antibodies. During project conception, only one THAP1 antibody was available 
commercially which is tested here.  The commercial antibodies available for torsinA 
and THAP1 are not tested on humans due to the unavailability of the 
affected/control human brains though are predicted to work on human. The IHC 
studies on human TOR1A cases published used their own lab-specific TOR1A 
antibodies. Two of these antibodies were kindly given to us to use in this project. 
Hence, the second problem, “the bad technique problem” is that a good antibody 
may not “work” in all of the various antibody-based assays. This may occur because 
the antibody cannot detect its target in a particular type of assay (e.g. the antibody 
target may become denatured in formalin fixation, thus formalin fixation is a bad 
technique for this antibody).  Alternatively, incorrect technique (or a bad 
technique) in an assay may interfere with the antibody binding to its target. Also, 
lot to lot variation in antibodies may alter protein conformation in different 
regions, expression below the level of detection. Also sometimes it is hard to 
replicate findings from other groups as they may use subtly different techniques 
which they do not fully describe in their papers. 
Antibody characterization is the first step in any scientific projects. We ran WB with 
several protocol variations to characterize the protein of interest. TOR1A and 
THAP1 proteins are expected at of 38kda and 25kda, respectively. However, several 
nonspecific bands were observed and after running several WBs we were unable 
reach to a reasonable level of assurance that an antibody is actually recognizing 
what it is supposed to. However, the same antibodies, TOR1A (abcam) and TOR1A 
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(santacruz) provide an acceptable level of assurance with mouse brain tissue. Same 
is the case with THAP1 antibody. TA913 antibody is lab specific and is published as 
recognizing human TOR1A only (320). The WB result assured us as well as it did not 
recognize mouse but human TOR1A. However, this batch of antibody was not 
affinity purified and did not produce a strong band. Affinity purified TA913 was out 
of stock. 
In parallel, variations in IHC and IF were carried out on fresh and fixed tissues of 
human and wild type mouse. High background caused by both non-specific staining 
and by non-specific secondary antibody binding made it difficult to describe the 
expression pattern of proteins in both human and mouse tissues.  
 The possible problem with the antibodies tested above is that they are likely to 
cross react with a number of different homologous proteins. For example, torsinB 
has 80% homology with torsinA and is reported to colocalise in humans CNS (100). 
Both proteins showed cytoplasmic distribution but torsinB was also perinuclear in 
some neurons. After several communications with the company the immunogen 
sequence was available for TOR1A (abcam): CKTVFTKLDYYLDD. NCBI BLAST of the 
immunogen sequence showed no significant homology to other torsin family 
members, including TOR1B.  However, sequence alignment of the orthologs 
showed it was not exact match for human (highlighted region in the alignment 
below). Hence the lack of exact match of the immunogen sequence may be one of 
the reasons for the problems we have faced with the antibody.  
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The exact immunogen sequence for TorsinA (santacruz) was not available. 
However, the datasheet provides information on cross reaction to lesser extent 
with TorsinB. This explanation does not help much for researchers as the lab data 
provided in the datasheet showed no trace of torsinB in WB. 
Orthologs Immunogen sequence (319-332aa) 
Human CKTVFTKLDYYYDD  
Mouse                    CKTVFTKLDYYLDD 
Rat                 CKTVFTKLDYYLDD 
Monkeys             CKTVFTKLDYYYDD 
  
           Figure 5.6 Alingment of the orthologs for the immunogen in TOR1A antibody (abcam). 
Hence, the integrity of this neuropathological study was being threatened by the 
proliferation of poorly characterized antibodies that produce artifactual staining 
pattern. 
5.7. DYT6 and DYT1 interaction 
5.7.1. Background  
In vitro studies have shown that THAP1 physically interacts with TOR1A and 
represses torsinA expression by binding to the TOR1A promoter; this interaction is 
abolished by pathogenic mutations, leading to a decreased repression (149). 
However, this effect was not observed in fibroblasts from DYT1 patients. Thus it 
was likely that the interaction is possible in CNS only.  
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5.7.2. Aims and Hypothesis 
Hypothesis 
 There is a direct interaction between causative genes of DYT1 and DYT6 
primary dystonia 
  The dystonia gene TOR1A is repressed by the transcription factor THAP1 
   The THAP1-TOR1A interaction is restricted to CNS in humans 
Aims 
 To obtain frozen brain tissues for brain regions of interest 
 Define interaction using qPCR 
5.7.3. Results 
A total of 6 DYT1, 2 DYT6 and 5 control cases were included in this study. These 
cases were genetically confirmed for the mutations in DYT1 and DYT6 genes. In 
DYT1 cohort, all the cases have p.303-/Glu304 mutation in TOR1A/DYT1 gene. Two 
cases included in DYT6 cohort have p.Arg29Gln and p.Ser21Phe mutations in 
THAP1/DYT6 gene respectively and both are in zinc-dependent THAP domain (1-81 
amino acids) of the THAP1 protein. 
To validate the efficiency of the primers and qPCR reaction standard curve was 
generated. Keeping in consideration that there is no best match, primers for genes 
of interest (TOR1A, THAP1), and housekeeping genes (GAPDH, ACTB, RPLP0, UBC) 
were chosen to take forward as their efficiency matched to an agreeable level.  
To determine whether THAP1 modulates TOR1A expression or vice-versa in human, 
we analysed TOR1A mRNA and THAP1 mRNA levels in 6 DYT1 cases, 2 DYT6 cases, 
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normalised against 5 controls in brain regions. The availability of the brain regions 
vary in each case. Brain regions sampled for was based on the previous study and 
included cerebellum (Cbl), frontal cortex (Ftx), superior temporal gyrus (Gyrus), 
basal ganglia (BG), midbrain (MB), global pallidus (GP), putamen (Pu), caudate 
(Cau), pons, medulla (Med) and hippocampus (Hip). Brain regions included in the 
study was also based on the brain regions available for research for each case. 
Cases were normalized using reference genes (GAPDH, ACTB, RPLP0, UBC) and 
calibrated against age and sex matched healthy controls (calibrator). 
Normalised expression of TOR1A and THAP1 is ubiquitous in brain regions studied 
in controls, DYT1 and DYT6 cases (Figure 3.2). In controls, expression level of TOR1A 
is higher than THAP1 in the brain regions studied. Expression of these two genes is 
lower in the DYT1 and DYT6 cases compared to controls except in few brain 
regions. Student’s t-test revealed a significant difference in TOR1A and THAP1 
expression in putamen (0.023, p<0.05) of DYT6 cohort only. No significant 
difference in expression of the two genes was observed in other brain regions 
Table 5.4 Student’s t-test (p<0.05), p values to compare the difference in expression 
of TOR1A and THAP1 in each brain regions of  DYT1 and DYT6 cohorts 
 
Brain regions p values TOR1A vs THAP1  
(Statistical significant p value defined as < 0.05) 
DYT1 cohort DYT6 cohort 
Frontal cortex 0.58 0.59 
Superior temporal gyrus 0.13 0.19 
Global pallidus 0.65 0.65 
Putamen 0.19 0.023 
Cerebellum w/dentate nuc. 0.82 0.64 
Midbrain/S. Nigra 0.26 0.8 
Medulla 0.6 0.12 
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studied in both cohorts. No significant pattern of THAP1 and TOR1A was observed 
in both cohorts. 
 
Figure 5.7 Mean normalized copy number of THAP1 and TOR1A gene expression in controls. 
 
In DYT6 case 1 and 2, THAP1 expression is lower compared to controls in the brain 
regions studied but expression was higher than in controls in globus pallidus and 
cerebellum of case 1. In both DYT6 cases, there is a marked increase in TOR1A 
expression in putamen compared to the controls. However similar pattern of genes 
expression was observed in an asymptomatic DYT1 case (case 6). Hence, it is 
difficult to conclude that the interaction is centered in putamen of DYT6 cohort. A 
3bp mutation in TOR1A is described as a loss of function. Our data suggests that 
though loss of function, TOR1A expression is higher than normal in some CNS 
regions; globus pallidus, midbrain, pons, putamen. The lack of a consistent pattern 
of expression of these genes makes it difficult to pinpoint a region for interaction 
and thus supports the heterogeneity observed in primary dystonia. 
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 Figure 5.8 THAP1 and TOR1A expression in DYT6 patients. In putamen of both cases with decrease 
in expression of THAP1, there is a marked increase in expression of TOR1A. Student’s t-test reveals a 
significant difference in expression compared to the controls (0.023, p<0.05).  
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Figure 5.9 THAP1 and TOR1A expression in DYT1 and DYT6 patients. The expression pattern doesnot 
follow a consistent pattern. 
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5.7.4. Discussion 
The low penetrance of THAP1 and TOR1A mutations has often been related to the 
phenotypic heterogeneity of the primary pure dystonia. A possible role of THAP1 as 
a genetic modifier in DYT1 dystonia has been recently suggested as THAP1 was 
shown to bind to TOR1A promoter (148) and repress transcription of torsin A (149). 
The functional link between the two gene products suggesting the mechanism of 
transcriptional dysregulation as a cause of primary dystonia provided a 
breakthrough in understanding the primary pure dystonia. However, both studies 
failed to show the effect in vivo and the TOR1A modification was moderate in vitro. 
Genetic screening of the sequence variations in the THAP1 gene and also the 
THAP1-binding sites of the TOR1A-promoter questioned the THAP1 as a genetic 
modifier of DYT1 dystonia (332). 
Our study aimed to address the possibility that dystonia being a CNS disorder, 
THAP1-TOR1A interaction may be centered within specific regions in CNS. TOR1A 
and THAP1 gene expression is ubiquitous in the brain regions included in this study 
(Figure 1.5, Figure 1.6). Our results suggested a significant difference in expression 
of THAP1 and TOR1A in putamen of DYT6 cohort, normalised against the healthy 
controls.  
The basal ganglia traditionally have been implicated in human dystonia by studies 
showing correlations between dystonia and imaging or pathological evidence for 
basal ganglia dysfunction. The basal ganglia and especially the putamen are most 
frequently implicated among patients with dystonia and overt lesions in structural 
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imaging studies (35,36,333). Even when overt lesions cannot be identified, 
functional imaging studies such as fMRI or PET often reveal areas of abnormal 
activity in the basal ganglia for many types of dystonia (39,334). In primates, focal 
destructive lesions of the posterior putamen has been reported to cause dystonia 
(59). In putamen of the two DYT6 cases, there is a marked increase in TOR1A 
expression when THAP1 expression decreased, compared to the control. This data 
matches the previous finding that THAP1 may act as a repressor. In DYT6 cases, 
when THAP1 is mutated, TOR1A is excessively expressed. However, similar pattern 
of THAP1 and TOR1A expression was also observed in a DYT1 asymptomatic case 
(case 6). Hence, a possibility that THAP1 not only represses TOR1A but a similar 
effect vice-versa is also possible. However, lack of a significant pattern among all 
the DYT1 cases makes it difficult to draw a conclusion. Another possibility is that a 
third modifier is necessary to make the effect pathogenic.   
THAP1 has been shown to bind to the promoter region of a TAF1 transcript (156). 
TAF1 gene has been linked to another form of primary dystonia (adult onset X-
linked dystonia parkinsonism) which is clinically very different (335,336). Hence it 
will be interesting to see if THAP1 and TAF1 gene show any potential functional link 
to associate with the clinical phenotype presented for each dystonia type. 
Our data suggest a possible link between THAP1 and TOR1A in putamen of DYT6 
cohort and a possible role of THAP1 gene as a repressor. However, similar pattern 
was observed in a DYT1 case, asymptomatic. There was no specific expression 
pattern of THAP1 and TOR1A genes in the brain regions studied. Hence, it is difficult 
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to pinpoint putamen as a brain region for THAP1 and TOR1A interaction and if 
repression is a feature of THAP1 gene.  Furthermore, a better understanding of 
THAP1 and TOR1A protein function and cellular pathogenicity may address the 
interaction more precisely.  
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Chapter 6. Genetics of Primary plus dystonia, Dopa-responsive 
dystonia (DYT5) 
 
6.1. Background  
Mutations in the GCH1 gene are associated with childhood onset, autosomal 
dominant hereditary DRD (170). Correct diagnosis of DRD is crucial, given the 
potential for complete recovery once treated with L-dopa. The majority of DRD 
associated mutations lie within the coding region of the GCH1 gene, but three 
additional single nucleotide sequence substitutions have been reported within the 
5’ untranslated (5’UTR) region of the mRNA. One subject had 2 mutations, -39C>T 
and -132C>T and another had a single mutation, -22 C>T. One family of 
Irish/French-Canadian ethnicity with DRD was studied where -22 C>T mutation 
segregate in the family with disease affected status (181,186). This makes it likely 
that the -22 C>T mutation is pathogenic and results in DRD.  
6.2. Methods 
Sanger sequencing was carried out as described in Chapter 2 for the coding regions 
and the 5’UTR of the GCH1 gene. 
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6.3. Aims and Hypothesis 
Hypothesis 
 Noncoding mutations in the 5’ upstream region of GCH1 gene are 
pathogenic in DYT5 dystonia 
 Coding and noncoding mutations in GCH1 gene may be observed in primary 
torsion dystonia due to some shared clinical phenotype 
Aims 
 To obtain DNA from DRD cases with no mutations reported in coding 
regions of the GCH1 gene 
 Screen dystonia cohort (described in chapter 2) for the coding and 
noncoding mutations in GCH1 gene. 
 Investigate the clinico-genetic correlation 
6.4. Results 
Of the total 192 clinically diagnosed DRD cases negative for mutations in the coding 
regions of GCH1 gene, two noncoding point mutations, -39C>T and -132C>T were 
observed in the 5’ UTR region. Both mutations were present in each of the cases.  
Case 1 is a 21 year old Portuguese male clinically presenting as a recessive 
hereditary spastic paraplegia. He had mild disability during primary school and 
slowly progressed. At age of 15 he developed gait disturbance and became more 
forgetful. MR brain scan showed patchy signal change in the subcortical white 
matter with atrophy of the corpus callosum. He had very mild ptosis but also slight 
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exophthalmos. He had severe spasticity in both lower limbs but no weakness. There 
was no dystonia. He has an elder brother who is affected but his parents are well 
and not related. The elder brother had a partial transient response to levodopa. 
Case 2 is a 25 year old Tunisian female. At the age of three weaknesses, 
unsteadiness and walking difficulties in both legs were noticed and progressed 
slowly. By the age of 14 her right arm became more affected than the left, her back 
was sore and tilted to the left. Over the years jerky movements affected her right 
hand and her trunk. Levodopa which had a dramatic initiation response but after a 
couple of years the effect wear off. She had mild distal dystonia of the right arm 
and slight dystonia at the left side.There was no dystonia of the face but her speech 
is slightly dystonic. Her lower limbs show only slight dystonia. Tendon jerks were 
reduced and symmetrical.  Eye movements were normal. There was no known 
family history of dystonia and the parents are not related. She has a sister who is 
well. 
6.5. Discussion 
Human disease can result from single nucleotide polymorphisms that affect any 
step of its finely tuned regulatory system. However, the absence of mutations in 
the coding region or the splice sites in some classic cases of DRD has been observed 
(185,337). It has also been suggested that autosomal recessively inherited 
mutations of the tyrosine hydroxylase gene might also casue DRD (338), but genetic 
heterogeneity cannot explain the absence of GCH1 mutations in families with 
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autosomal dominantly inherited DRD and linkage to the GCH1 locus. Hence, genetic 
analysis beyond the coding regions of the GCH1 gene is necessary. 
Three different mutations have been described in the 5’ untranslated region (UTR) 
of the GCH1 gene in literature. We report two cases with both mutations, -39C>T 
and -132C>T in the 5’ UTR of GCH1 gene. 5’ UTR in other genes suggest that this 
region of the gene is important in the regulation of gene expression and that 
sequence change changes in this particular region of the gene can lead to 
decreased enzyme activity of the gene product (181). 
Both cases were with childhood onset, slowly progressive, no family history of 
dystonia, non-consanguineous parents and the effect of levodopa not sustained. 
The first case is clinically a recessive HSP case and since DRD can mimic HSP a trial 
of levodopa was given where the effect was not sustained. His brother is affected 
but the mutations are not segregated. Hence, the pathogenicity of these non-
coding mutations in 5’ UTR of GCH1 gene is less likely. In second case, though 
clinically dystonic symptoms are reported, the levodopa response was not 
sustained. Hence the non-coding mutations in GCH1 gene cannot be directly 
associated with the disease phenotype. Deep brain stimulation of the internal part 
of globus pallidus has been considered as a next step.   
In particular for diseases linked to non-coding substitutions, functional assays are 
required to establish a link between the substitution and the disease phenotype. 
The -39C>T and -132C>T substitutions were identified as co-existing in cis in a single 
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subject with DRD, making it impossible to independently determine hereditary 
disease association for each substitution (187). The negligible effects on luciferase 
activity for -39C>T and -132C>T substitutions in a single DRD patient was reported  
when tested either individually or combined into a single reporter construct (187). 
However, functional study on -22 C>T mutation showed reduced translational 
efficiency and likely leading to reduced wild type GCH1 protein levels, underlying 
manifestation of DRD.  
Nevertheless from this study we conclude that the effect of two non-coding 
mutations in the 5’UTR of GCH1 gene described in above two cases is not 
significant to underline the manifestation of DRD. 
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Chapter 7. Genetics of spinocerebellar ataxia (SCA8) 
 
7.1. Background 
SCA8 is a dominantly inherited, slowly progressive neurodegenerative disorder 
caused by a CTG/CAG repeat expansion. The mutation for SCA8 was initially 
identified in 1999 as a CTG/CAG expansion mapping to chromosome 13q21 (197). 
Initial sequence analysis of the SCA8 CTG/CAG repeat region identified no likely 
open reading frames in the CTG or CAG direction, but it was demonstrated that the 
SCA8 repeat mutation was transcribed in the CTG direction and that transcripts 
containing the CAG repeat were primarily expressed in the CNS and especially in 
the cerebellum (197). The SCA8 repeat is conserved in chimpanzees, gorillas, and 
orang-utans but the genomic region containing the SCA8 repeat is not conserved in 
the mouse (200–202).  
Clinically SCA8 presents as an ataxia with slow progression that largely spares 
brainstem and cerebral function (197,206–209,213,214). Disease progression is 
relatively slow with significantly limited mobility occurring approximately 20 years 
after the initial symptoms but does not shorten life. Moderate to severely affected 
patients present with dysarthric speech and commonly manifest oculomotor 
deficits (206,213,215). Severely affected individuals can present with hypereflexia 
and occasionally present with mild myoclonic finger and arm jerks. Mild sensory 
loss is observed as indicated by decreased vibratory perception (206,213). 
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The precise number of the pathogenic (CTG)n repeat is technically difficult to 
determine. This study will use a division of alleles in four classes:  the small normal 
alleles (≤ 39 CTA/CTG repeats), the intermediate alleles (40-84 CTA/CTG repeats), 
large expanded alleles (85-400 CTA/CTG repeats), and very large expanded alleles 
(≥400 CTA/CTG repeats) (339). 
7.2. Aims and Hypothesis 
Hypothesis 
 The (CTG)n repeat length determines the disease pathogenesis in SCA8. 
Aims 
 To determine SCA8 repeat size in a cohort of ataxia cases and normal 
controls. 
 To determine if repeat size length is statistically significant to the disease 
pathogenesis. 
7.3. Methods 
Fragment analysis was carried out to analyse the SCA8 repeat alleles as described in 
Chapter 2. 
7.4. Results 
The study group comprised 630 cases of clinically diagnosed sporadic ataxia 
patients, 631 English controls and 1148 of diversity controls. 
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The distribution of the number of SCA8 repeats are shown in table 1. Very large 
expanded alleles (≥400 CTA/CTG repeats) were not observed in cases and controls. 
In clinically diagnosed ataxia patient cohort of 630 cases, large expanded SCA8 
alleles (>84 CTA/CTG repeats) were noted in 6 (0.95%) cases, intermediate SCA8 
alleles (40-84 CTA/CTG repeats) were noted in 6 (0.95%) and 618 (98.1%) cases 
were in the the small normal SCA8 repeat allele (≤ 39 CTA/CTG repeats) range.  In 
the English control cohorts of 631 individuals, we identified an individual (0.16%) 
with a large expanded SCA8 allele, 5 (0.79%) individuals with intermediate alleles 
and 625 (99.04%) individuals in small normal allele range. In diversity control 
cohort of 1148 individuals, we identified 3 individuals (0.27%) with a large 
expanded SCA8 allele, 23 (2%) individuals with intermediate alleles and 1122 
(97.7%) individuals in small normal allele range. Student’s t-test showed there is no 
significant difference in SCA8 repeat expansion length between the diversity 
controls and the patients group at 0.05 level of significance (p= 0.192). However, 
occurrence of SCA8 repeat expansion in patients compared with English controls 
showed a significant difference at 0.05 level of significance (p= 0.018). Clinical data 
is summarized in the Table 7.1. 
In diversity control cohort, cases with repeat expansion 84 are, case 1 (repeat 
genotypes 22/87) is a female of Chinese origin, case 2 (repeat genotypes 22/95) is a 
male of Pakistani origin, and case 3 (repeat genotypes 22/88) is a female of Middle 
Eastern origin (Israel). 
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Figure 7.1 Distribution of SCA8 repeats expansion in ataxia cases and controls. 
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Table 7.1  Clinical details of cases with SCA8 repeat expansion in the range of 85-399 repeats 
along with two cases in the borderline. 
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Clinical diagnosis 
1 45F 28/87 - + - + + + Late onset cerebellar degeneration 
2 63F 22/91 - + - + - - Progressive Parkinsons syndrome 
3 43F 27/95 - - - + + + Idiopathic cerebellar ataxia with 
pyramidal signs 
4 36F 27/96 - + + + + + Early onset spinocerebellar ataxia 
5  67F 22/97 - - - - - - Craniocervical Dystonia, 
Blepharospasm 
6 43M 22/103 + + - + - + Inherited ataxia 
7 59F 24/83 - + + + + + Multi-system atrophy (MSA) 
8 44F 24/84 - + + + + + Extrapyramidal signs probable MSA 
 P a g e  | 165 
Case 1 (SCA8 repeats 28/87) is a 45 year old female with idiopathic early onset 
cerebellar ataxia. She has subcortical slow speech with dysarthria. She has broken 
pursuit eye movements and gaze evoked nystagmus. She has finger nose and heel 
shin ataxia. She mobilises with a stick and her gait is ataxic. Tests for SCA 1-7, 12, 
17, ataxia telangiectasia mutated (ATM), ataxia with oculomotor apraxia type 1 
(AOA1) and ataxia with oculomotor apraxia type 2 (AOA2) were normal. 
Case 2 (SCA8 repeats 22/91) is a 63 year old female with atypical Parkinsonism and 
no family history. She has progressive dysarthria and dysphonia and recurrent falls 
since 2006. There was a slight restriction of upward gaze, intermittent upbeat 
nystagmus bilaterally. She had spastic dysarthria and slow tongue movement. Her 
gait was slow, stooped and broad-based with poor-arm swing and turning. Over the 
two years she developed neck stiffness, a decline in her dexterity and a slowing of 
movement. She is imbalanced and occasionally has urinary incontinence. Brain MRI 
showed volume loss of the cerebral peduncles, pons, cerebellum, superior colliculi, 
frontal and temporal lobes. A DaTscan showed nigrostriatal degeneration. 
Case 3 (SCA8 repeats 27/95) is a 43 year old female with clinical diagnosis of 
idiopathic cerebellar ataxia with pyramidal signs. She started to notice bumping 
into objects at the age of 38 and her balance became progressively worse. She had 
mild broad-based gait and gaze evoked nystagmus. There was no dysarthria and no 
limb ataxia. Tests were negative for SCA 1, 2, 3, 6, 7, 12, 17, AOA1, AOA2, and 
friedreich’s ataxia (FRDA). 
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Case 4 (SCA8 repeats 27/96) is a 30 year old female with clinical diagnosis of early 
onset spinocerebellar ataxia. She had tremor of the head, jerky pursuit, gaze-
evoked nystgamus and slight frontalis overreactivity. Saccades were slow and there 
was ataxia of in her upper and lower limbs. She had dysarthric speech pattern and 
bilateral horizontal nystgmus and jerky pursuit movements. Cerebellar signs were 
present on finger-nose testing and heel-knee-shin testing. Gait was broad based 
and only able to perform tandem walk. Tests were negative for SCA1, 2, 3, 6, and 7 
and ATM. 
Case 5 (SCA8 repeats 22/97) is a 67 year old female with clinical diagnosis of cranial 
cervical dystonia in addition to belpharospasm. She has restricted movements of 
the neck and had torticollis to the right and occasional rectrocollis.  
Case 6 (SCA8 repeats 22/103) is a 40 year old male with inherited autosomal 
dominant cerebellar ataxia. He had experienced balance problems and on 
examination had mild broad-based gait with trunkal stiffness. He had a slightly 
asymmetric face and nystagmus. Speech was slightly slurred. In upper limbs, tone 
and power were normal with coordination showing dysmetria, dysdiadokinesia and 
intention tremor. Lower limbs were normal with mild dysmetria in the heel-to-shin 
test. A brain MRI showed severe atrophy of both cerebellar hemisphere and the 
vermis. 
Case 7 (SCA8 repeats 24/83) is a 45 year female with multiple system atrophy 
(MSA).  She had gradually deteriorating ataxia and bladder incontinence because of 
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MSA. Her gait deteriorated such that she needed frame to walk and now she is 
wheelchair bound. There were no problems with the vision, hearing, memory, 
blackouts or numbness or pins and needles in the limbs. She had occasional 
swallowing difficulty and bladder incontinence. Neurological examination revealed 
an ataxic dysarthria and finger-nose and heel-shin ataxia in the arms and legs. 
There was bilateral first-degree nystagmus and no clear cognitive deficit. A brain 
MRI showed atrophy of cerebellum and brainstem but little of the supratentorial 
structures and ‘hot-cross-bun’ changes in the brainstem, consistent with a 
diagnosis of MSA. 
Case 8 (SCA8 repeats 24/84) is a 40 year old female with probable diagnosis of 
MSA. She showed clinical symptoms of slowly progressive cerebellar ataxia for 
three years, late-onset and acquired. In 2008, she had a mildly ataxia gait and 
limbs. She had increasing difficulties with balance, slurred speech, writing and 
problems with focus over the last two years. She had gaze instability due to 
nystagmus. A brain MRI showed a degree of mild cerebellar atrophy and vermian 
volume loss. Tests for SCA1, 2, 3, 6, 7 and FRDA were negative. 
7.5. Discussion 
The genetics underlying SCA8 is complex and not yet finally understood. SCA8 was 
the first published repeat expansion SCA (CAG or CTG) in an untranslated region. It 
is characterized by repeat instability and with no correlation between repeat length 
and penetrance. There is no anticipation observed and penetrance is reduced as 
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the expansion can also be found in healthy individuals. Thus, the diagnosis remains 
controversial (204).  
Potentially pathogenic alleles contain 85 or more combined CTA/CTG repeats. 
However, repeats of this size are surprisingly frequent in the general population 
and also occur in asymptomatic relatives of ataxia individuals 
(197,204,206,211,340). The complex pattern of inheritance has resulted in 
unaffected carriers commonly having repeat sizes that exceed the pathogenic 
threshold making it difficult to ascertain clear ranges for pathogenic expansion 
(199,208). SCA8 may rarely coexist with SCA6 (339) or SCA1 (341) which makes it 
difficult to assign symptoms to a specific entity. 
This study examined the length of SCA8 repeats in English ataxia patients, English 
controls and in diversity (from 25 different countries) controls. Alleles with >84 
SCA8 repeats are potentially pathogenic and in the ataxia cohort investigated, 6 out 
of 631 cases were in this range. However, a case out of 631 English controls and 3 
cases out of 1148 individuals in diversity control cohort were also in the potentially 
pathogenic range table .The range of SCA8 large alleles observed is not much 
different from that reported in the literature. The significant difference (p= 0.018) 
in occurrence of SCA8 repeat expansions in ataxia patients compared with English 
controls but not with the diversity controls (p=0.192) suggests that the 
pathogenicity of SCA8 repeat expansion is not only dependent on the repeat size 
but also on the population, environment and the genetic modifiers. Another 
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possibility is that the individuals with a large repeat expansion in ataxia cohort, 
English cohort and Diversity cohort may have shared the common founder. Hence, 
SCA8 sizes among affected and unaffected expansion carriers can be shorter or 
longer than the pathogenic threshold MN-A family defined in literature but the 
pathogenicity may also be influenced by other genetic modifiers. These data 
demonstrate that the presence of a SCA8 expansion cannot be used to predict 
whether or not an asymptomatic individual will develop ataxia as the control cases 
were asymptomatic at the time of study. 
The six cases with SCA8 repeat expansion ≥85 repeats were characterized by high 
frequencies of gait ataxia, ataxic dysarthria, limb dysmetria, and gaze-evoked 
nystagmus. Pyramidal tract signs and reduced vibratory sense are observed less 
frequently. Other neurological signs are rare or absent. The clinical features of the 
SCA8 can be summarized as relatively pure cerebellar ataxia. The disease 
progression is typically very slow. When available, MRI scans showed cerebellar 
atrophy. However, two cases with SCA8 repeat in the large intermiediate range, 83 
and 84 respectively, are in the borderline of the marked pathogenic ranges and 
were also looked into. They showed all the above clinical criteria. The brain MRI in 
one case showed features consistent with diagnosis of MSA and another case was 
diagnosed as MSA. Hence, SCA8 expansion may be a susceptibility factor for MSA. 
This data suggests that SCA8 repeat expansion length should not be the sole 
method of for diagnostic purposes.  
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The disease status in the MN-A family have supported the hypothesis that CTG/CAG 
repeat length is directly associated with ataxia (197,206) but was not true in other 
ethnicities. In our cohort, the largest SCA8 repeat allele was 103 in an inherited 
ataxia case but repeat length of 97 was found in a dystonia case with no other 
clinical symptoms of SCA8 described above. 96 repeat length was observed in early 
onset spinocerebellar ataxia case with the clinical symptoms of SCA8. The 
expanded allele ranged from 87-103 repeats and this is quite a narrow range to 
determine if the penetrance is directly related to the repeat length. Also, alleles in 
the pathogenic repeat length expansion range were observed in control population, 
the reduced penetrance of SCA8 is the most difficult genetic feature of the disease 
to understand. 
Although the risk of developing ataxia is dependent on the size of the expansion 
and probably also on other factors that affect the penetrance of the mutation, 
neither family history nor the expansion repeat size can be used to accurately 
predict which offspring will develop symptoms of the disease. The length of the 
repeat tract does not correlate with the age of onset, severity, symptoms, or 
progression of the disease. Hence, along with the clinical symptoms, neurologic 
assessment, including neuroimaging (brain MRI or CT) and assessment of family 
pedigree is essential to establish a clinical prognosis. 
Although next generation sequencing (NGS) is a very powerful diagnostic tool in 
genetic studies, there are also limitations in particular in the diagnostics of repeat 
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expansion SCAs. NGS are currently relatively poor in their ability to identify 
stretches of repetitive DNA sequence. It does currently not qualify for detection of 
these types of mutations. This weakness of NGS also reduces the chances to 
discover new repeat expansion SCAs in a research setting.  
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Chapter 8. Neuropathology of BPAN 
 
8.1. Background 
Neurodegeneration with brain iron accumulation (NBIA) is a group of inherited 
neurological disorders in which iron accumulates in the basal ganglia resulting in 
progressive dystonia, spasticity, Parkinsonism, neuropsychiatric abnormalities, and 
optic atrophy or retinal degeneration. Nine types and their associated genes are 
recognized. The age of onset ranges from infancy to late adulthood; the rate of 
progression varies. Cognitive decline occurs in some subtypes, but more often 
cognition is relatively spared. Cerebellar atrophy is a frequent finding in some 
subtypes. Recently, de novo mutations in a WDR45 gene was identified causing a 
phenotypically distinct X-linked dominant form of NBIA, named BPAN (229). 
WDR45 encodes a beta-propeller protein that serves a putative role in autophagy, a 
lysosomal process to degrade cellular components that is thought to be defective in 
many neurodegenerative disorders (244). Neuropathological features reported on a 
case of BPAN included positive iron staining in substantia nigra and globus pallidus 
with is a hallmark feature of NBIA. Axonal spheroids and tau-positive NFTs were 
reported but no amyloid-β plaques or LBs were observed (237). 
In this chapter we will discuss Beta-propeller protein associated neurodegeneration 
(BPAN) and neuroacanthocytosis. 
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8.2. Aims and Hypothesis 
Hypothesis 
 Iron accumulation in basal ganglia is a feature of BPAN. 
 Tau pathology as described in a case of BPAN is a consistent feature of the 
disorder. 
 Delineation of tau-isoforms may determine similarities to other diseases. 
 Beta-propeller protein participates in autophagy. 
Aims 
 To carry out a detailed neuropathological study of a case with mutation in 
WDR45. 
 To carry our tau-blotting to determine the tau isoforms present. 
 To investigate autophagy in a case of BPAN. 
8.3. Methods 
Paraffin blocks representing multiple brain regions from a post mortem case of 
BPAN were obtained from QSBB and investigated using routine histological staining 
and IHC methods as described in Chapter 2. Antibodies used for IHC included: 
ubiquitin (1:200, Dako, Ely,UK), tau (1:600, AT8, Autogen Bioclear, Calne, UK); 
AT100 (1:200, Innogenetics, Gent, Belgium), glial fibrillary acidic protein (GFAP; 
1:1,000, Dako), Aβ (1:200, Dako), α-synuclein (1:50, Novacastra, Newcastle, UK), α-
synuclein (1:1000, BD Transduction Biolabs, Oxford, UK), P62 (1:100, BD Bioscience, 
Oxford, UK), CD68 (1:150, Dako) and TDP-43 (1:2000, Protein Tech, Manchester, 
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UK). Neuropathological assessment of neuronal loss, gliosis and concomitant 
pathologies (tau, Aβ, LBs, CAA, TDP-43, and SVD) were carried out in a semi-
quantitative manner according to published criteria (304–307). A score scale of 0 - 
+3 was used to indicate increasing pathology. 
WB (as described in Chapter 2) was carried out to delineate the tau isoforms 
present and to investigate disturbances in autophagy by WB on LCI and LCII.  
8.4. Results 
8.4.1. Genetics 
The case had a de novo mutation in the exon 9 of WDR45, c.694_703del, 
p.Leu232Alafs*53. The genetics and clinical history of this case have been 
previously published as case number HH84 (229,237). 
8.4.2. Clinical details 
The case was a female 51 years of age at death. She showed features of learning 
disability, mental retardation and progressive gait abnormalities since childhood.  
By the age of 13, she was moved to a special school for handicapped children. Her 
movement disorder symptoms started deteriorating significantly at the age of 29 
with slowing of gait and reduction of arm-swing whilst walking. Her condition 
deteriorated and she developed dystonic features during her thirties. She 
developed behavioural difficulties with social withdrawal, self-mutilative 
tendencies and depression throughout the years. Disturbed sleep with early 
morning awakening occurred and the behavioural problems became more and 
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more prominent. There was reduced spontaneous speech and communication as 
well as reduced attention span. In the late stages of her disease, she was 
wheelchair-bound, had urinary and faecal incontinence and was totally dependent 
on the activities of daily living (ADL)-score. Family history was negative. 
On examination she showed predominant extra-pyramidal symptoms with 
significant bradykinesia, hypomimia and hypophonia with signs of mild cerebellar 
disturbance. She had a bilateral grasp reflex. Her eye movements were normal. 
Brain imaging revealed generalised brain atrophy and bilateral generalised 
mineralisation of the globus pallidus. The globus pallidus and substantia nigra 
showed changes thought to represent iron deposition. Blood count revealed 
microcytic hypochromic anemia, normal platelets, white-cell count, negative 
acanthocytes, normal lactate and pyruvate.  
8.4.3. Macroscopic findings 
The macroscopic details were available from the neuropathology reports supplied 
by the QSBB. The brain weighed 1,117g. External examination of the left half of the 
brain showed frontal atrophy with preservation of parietal, temporal and occipital 
lobes. Coronal slices revealed mild dilatation of the frontal horn of the lateral 
ventricle and patchy thinning of the cortical ribbon in the frontal lobe. In the 
occipital cortex an area of cavitation with the appearance of an old infarct involved 
the primary visual cortex.  White matter in the anterior frontal and temporal lobes 
showed mild atrophy.  The globus pallidus was reduced in size with blurring of the 
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distinction between internal and external parts and showed dark discolouration 
anteriorly (Figure 1A, arrow).  The caudate and putamen appeared normal.  The 
thalamus and hippocampus showed mild atrophy and there was moderate 
reduction in bulk of the amygdala. There was marked abnormality of the substantia 
nigra which showed brown discolouration and had a gelatinous texture throughout 
(Figure 1B, double arrow).  The locus coeruleus was indiscernible (Figure 1B, 
arrow).  The medulla and cerebellum appeared normal. 
 
 
                  
 
Figure 8.1 A coronal slice at the level of the 
anterior commissure shows atrophy and dark 
discolouration of the globus pallidus (A, arrow). 
There was loss of pigment in the locus 
coeruleus which was indiscernible (B, arrow). 
The substantia nigra was markedly abnormal 
with brown discolouration and a gelatinous 
texture (B, double arrow). 
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8.4.4. Histological findings 
Histological examination showed mild superficial vacuolation in anterior frontal, 
temporal and parietal cortices.  A full thickness cortical infarct with cavitation, 
infiltration of macrophages and surrounding gliosis was confirmed in the visual 
cortex. Neuronal loss was mild in neocortical regions (frontal, temporal, parietal, 
Table 2) and occasional swollen neurons were identified using αB-crystallin 
immunohistochemistry. Luxol fast blue staining confirmed good myelin 
preservation in the subcortical white matter. There was no cortical iron deposition 
identified using Perl’s stain.  
Neuronal populations in the hippocampus, amygdala, striatum, thalamus and 
subthalamic nucleus were well preserved. Examination of the globus pallidus 
showed extensive mineralisation of vessels including arteries, veins and capillaries.  
Perl’s staining for iron was positive in areas of mineralisation and also in scattered 
cells with macrophage morphology.  GFAP IHC showed marked gliosis of the globus 
pallidus and there was also an increase in CD68 immunoreactive microglia.  No 
axonal swellings were identified using antibodies recognising neurofilaments.  
Examination of the midbrain showed very severe loss of pigmented neurons in the 
substantia nigra accompanied by gliosis, macrophage infiltration and marked 
deposition of Perl’s positive pigment. Numerous axonal swellings were present and 
were highlighted with IHC for amyloid precursor protein (APP), neurofilament 
cocktail, SMI31 and ubiquitin.  Occasional swellings were α-internexin-positive 
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however, most were unstained in this preparation.  In the pons the locus coeruleus 
showed mild neuronal loss, the pontine nuclei were well preserved. In the medulla 
the Xth and XIIth cranial nerve nuclei as well as the inferior olivary nucleus were 
well preserved.  Axonal swellings were observed in the gracile and cuneate nuclei. 
The cerebellum showed mild Purkinje cell depletion with good preservation of the 
dentate nucleus and hemispheric myelin.  There was no Aβ deposition in the 
hippocampus or neocortex. No α-synuclein pathology was found in brainstem or 
limbic regions and there was no TDP-43 pathology in limbic structures. 
Tau pathology was extensive in the form of neurofibrillary tangles, pre-tangles and 
neuropil threads affecting cortical regions, white matter, deep grey nuclei, 
hippocampus, amygdala, brainstem structures and the cerebellum. Very rare coiled 
bodies were present in the sub-cortical white matter but there was no 
accumulation of tau in astrocytes. The type of tau pathology and semi-quantitative 
analysis of the tau burden in different brain regions is summarised in Table 2.  
Isoform specific antibodies demonstrated the expression of both 3- and 4-repeat 
tau isoforms. Immunoreactivity for AT100, which recognises Alzheimer–type paired 
helical filament tau, was also demonstrated.  NFTs and neuropil threads are also 
identified using Gallyas silver staining further confirming the presence of fibrillary 
tau.   
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Figure 8.2 Histological findings in frontal cortex of BPAN case. Mild neuronal loss and vacuolation 
(A) with swollen neurons were observed (B). Tau pathology was extensive in the form of 
neurofibrillary tangles, pre-tangles and neuropil threads (C-D) and also showed immunoreactivty 
for Alzheimer–type paired helical filament tau (E). Good myelin preservation was observed in the 
subcortical white matter with fibres radiating towards cortex (F). Scale bar: A= 100µm, B-C 
&E=50 µm, D=25 µm and F=260 µm. A: H&E; B: αβ crystalline; C: AT8; D: Gallyas stain; E: AT100 
and F: Luxol fast blue. 
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Figure 8.3 Histological findings in midbrain. Examination of the midbrain showed severe loss of 
pigmented neurons in the substantia nigra accompanied by gliosis, axonal swellings (A and D) 
and marked deposition of iron (B). Tau pathology was positive with NFTs and threads (C). Scale 
bar: A and C=50 µm, B and D=25 µm. A=H&E; B=Perl’s stain; C=AT8 and D=phosphorylated 
SMI31 neurofilament. 
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Figure 8.4 Histological findings in globus pallidus (top panel) and hippocampus (bottom 
panel). Examination of the globus pallidus showed extensive mineralisation of vessels 
including arteries, veins and capillaries (A) and iron deposition in the areas of 
mineralisation (B). Examination of the hippocampus showed extensive tau pathology in the 
form of neurofibrillary tangles, pre-tangles and neuropil threads (C). D represents tau 
pathology in CA1 region. Scale bar in A represents: A=50 µm, B=100, C =525 µm and D=25 
µm. A=H&E; B= Perl’s stain; C and D= AT8 IHC. 
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Figure 8.5 Tau deposition. Extensive tau pathology was observed in the form of neurofibrillary 
tangles, pretangles and threads and was of Alzheirmer-type tau deposition. Gallyas silver 
impregnation demonstrated the presence of fibrillar protein (A). Support for Alzheimer-type tau 
deposition was provided using the AT100 antibody, recognising tau phosphorylated at Thr212 and 
Ser214 with paired helical filament conformation, which labelled a proportion of NFTs (B) and by 
isoform specific antibodies, which showed a mixture of 3- repeat (C) and 4-repeat (D) tau isoforms. 
Scale bar in A represents: A,C-D= 25 µm and B= 50 µm.  
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Table 8.1 Summary of neuronal loss and semi-quantitative assessment of tau pathology in 
different brain regions 
 
  Tau pathology 
 
Neuronal loss Threads Pre-tangles Neurofibrillary tangles 
Cortex      
Frontal + +++ - ++ 
Temporal + +++ - ++ 
Parietal + +++ - ++ 
Occipital Infarct visual cortex + - - 
Cingulate - +++ - +++ 
Sub-cortical white 
matter 
    
Frontal N/A + N/A N/A 
Temporal N/A + N/A N/A 
Parietal N/A + N/A N/A 
Occipital N/A + N/A N/A 
Cingulate N/A ++ N/A N/A 
Amygdala - +++ - +++ 
Hippocampus     
Dentate fascia - + - ++ 
CA4 - ++ + ++ 
CA3 - ++ - ++ 
CA2 - ++ - ++ 
CA1 - +++ + +++ 
Subiculum - +++ + +++ 
Entorhinal cortex - +++ + +++ 
Transentorhinal cortex - +++ + +++ 
Caudate - +++ + ++ 
Putamen - ++ + ++ 
Globus pallidus + ++ - + 
Meynert + +++ - +++ 
Thalamus - ++ - ++ 
Subthalamic nucleus - ++ - ++ 
Substantia nigra +++ ++ - + 
Locus coeruleus + ++ - + 
Pontine tegmentum - ++ - ++ 
Pontine nuclei - + - + 
Dorsal motor nucleus of 
vagus 
- + - + 
Twelfth nerve nucleus - + - - 
Inferior olive - + - - 
Gracile nucleus - + - - 
Cuneate nucleus - + - - 
Cerebellar Purkinje cells + - - - 
Cerebellar white matter N/A - N/A N/A 
Dentate nucleus - + - + 
N/A: not available 
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8.4.5. Immunoblots 
Tau blots:  
      
 
 
 
  
Figure 8.6 Immunoblotting of non-dephosphorylated (left) and dephosphorylated 
tangle (right) preparations of Pick’s disease (PiD), Alzheimer’s disease (AD) and WDR45 
case. WB of non-dephosphorylated tangle extractions showed the classical triplet band 
as observed in AD cases (i.e. 3R+4R). When dephosphorylated, the isoform composition 
is almost identical to the AD with 0N3R, 0N4R, 1N3R and 1N4R tau-isoforms. 
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Tau blotting of the tangle preparations of WDR45 case showed the classical triplet 
band as observed in Alzheimer’s disease (i.e. 3R + 4R). When dephosphorylated, 
the isoform composition is almost identical to the AD with 0N3R, 0N4R, 1N3R and 
1N4R tau-isoforms. 
8.4.6. Autophagosome associated light chain 3 (LC3) blots 
 
Figure 8.7 Immunoblotting of frontal cortical homogenates from the mutation case 
and three neurologically normal cases showing LC3I (~18kDa) and LC3II (~16kDa) levels 
(upper panel). Beta-actin loading control is shown in the bottom panel.  
The mutation case shows higher autophagosome associated light chain 3 (LC3)-II 
formation compared to three control cases.  This implies higher levels of 
autophagic flux in the mutation case compared to the three age and sex matched 
control cases.  
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8.5. Discussion 
This report describes genetic, clinical and corresponding pathological details of a 
case with a mutation in WDR45 gene. De novo mutations in the WDR45 gene have 
been linked to a subset of NBIA cases, currently known as BPAN and the only X-
linked NBIA described in literature. The case is a 51 years old female with disease 
onset in childhood. The clinical pattern of the case studied here matches to other 
BPAN cases described which are characterized by global developmental delay and 
intellectual deficiency in early childhood followed by further neurological and 
cognitive regression in late adolescence or early adulthood, with parkinsonism, 
dystonia, and sometimes ocular defects and sleep perturbation (229,237,342).  
Exome sequencing revealed a de novo mutation in exon 9 of WDR45, c.694_703del, 
p.Leu232Alafs*53 and the mutation in the case and clinical history had been 
previously published (229). 
Consistent with the reports of significant basal ganglia pathology observed in 
neuroimaging for BPAN cases, iron deposition in the globus pallidus and substantia 
nigra was evident on brain imaging of this case. Macroscopic examination of the 
brain suggested atrophy and dark discolouration of the globus pallidus and a 
markedly abnormal substantia nigra with brown discolouration and a gelatinous 
texture throughout. The major pathological findings in this case were severe 
neuronal loss with gliosis affecting the substantia nigra, iron deposition in the 
substantia nigra and globus pallidus, axonal swellings in the substantia nigra, gracile 
nucleus and cuneate nucleus and very extensive phospho-tau deposition. Tau 
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pathology was in the form of neurofibrillary tangles, pre-tangles and neuropil 
threads and histological studies indicated that many of the tau immunoreactive 
structures contained fibrillary protein (Gallyas silver positive and AT100 
immunoreactive) and contained both 3-and 4-repeat tau isoforms similar to the tau 
deposits of Alzheimer’s disease. This finding was confirmed by immunoblotting of 
non-dephosphorylated tangle extractions which showed the classical triplet band 
as observed in AD cases (i.e. 3R+4R). When dephosphorylated, the tau isoform 
composition is almost identical to the AD case with 0N3R, 0N4R, 1N3R and 1N4R 
tau-isoforms.  Tau pathology was described in BPAN in a post-mortem case in 
literature but not well documented. The detailed description of the tau pathology 
and the tau isoform composition adds significantly to the neuropathological 
findings previously described. 
A link between tau pathology, autophagy impairment, and neurodegeneration has 
been suggested (343). Impairment of protein degradation pathways such as 
autophagy is emerging as a pathological phenomenon in neurodegenerative 
diseases, including Alzheimer’s, Huntington’s and Parkinson’s diseases (343). The 
autophagy pathway is the main degradation route for long-lived proteins, damaged 
organelles and protein aggregates. It is a highly regulated process, characterized by 
the formation of double- or multi-membrane vesicles (autophagosomes) that 
sequester portions of cytosol, which are then delivered for degradation following 
fusion with lysosomes (343) . However, there is accumulating evidence that protein 
misfolding disorders involve specific defects in particular steps of the autophagy 
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process and manipulation of the autophagy in neurodegenerative disease may have 
unpredictable outcomes.  
The WDR45 gene belongs to the large family of WD40 repeat protein and is one of 
the four mammalian homologs of yeast Atg18, an important regulator of 
autophagy. Its involvement in autophagy has been documented in yeast and 
mammalian cells, where it interacts with ATG2 (244), and in C. elegans, where its 
deletion leads to accumulation of early autophagosomes (245). In lymphoblast cell 
lines from BPAN patients, the amount of protein is clearly reduced and 
autophagosome formation is hindered at an early stage as shown by the 
accumulation of LC3-II protein and its co-localization with ATG9A in enlarged 
membrane structures (236). This suggests that the mutant protein is structurally 
unstable and undergoes degradation. These abnormal intracellular structures 
stained for ATG9A and LC3s, an autophagosome marker which suggests improper 
autophagosome formation. Accumulation of LC3-II protein was also observed in 
immunoblot from the brain tissue of our WDR45 case, where LC3-II accumulation is 
higher compared to the three normal controls. This implies higher level of 
autophagic flux in the mutation case compared with controls as previously 
observed in patient lymphoblasts.  
The complexity and multifactorial nature of the neurodegenerative diseases related 
to iron dysregulation suggests multiple interventions are necessary.  For example, 
treatments for iron accumulation (using iron chelating therapies) are beneficial for 
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neuroprotection but they may impair cell repair processes (344). When cells are 
stressed or injured, the autophagic process is induced to clear damaged cellular 
components and by-products of the stress response. Defective autophagy would 
leave damaged cells compromised and at risk of perpetuating further damage to 
neighbouring cells. This cascade, when occurring in post-mitotic tissue such as 
brain, would present clinically with neurological deterioration after a threshold of 
cellular functional impairment is exceeded. But the precise mechanism by which 
the beta-propeller protein that is encoded by WDR45 serves the autophagic 
process remains to be elucidated.  
In conclusion, significant basal ganglia pathology was observed on histology and 
immunohistochemistry. The major pathological findings in this case were severe 
neuronal loss with gliosis affecting the substantia nigra, iron deposition in the 
substantia nigra and globus pallidus, axonal swellings in the substantia nigra, gracile 
nucleus and cuneate nucleus and very extensive phospho-tau deposition. Tau 
isoforms were similar as tau deposits observed in AD cases. The higher autophagy 
reflux observed in LC3 immunoblotting is consistent with the understanding that 
the WDR45 protein participates in autophagy. Though the precise steps in 
autophagy are not known yet, BPAN provides a direct link between autophagy and 
neurodegeneration. It would be interesting to elucidate the role of iron in this 
mechanism. 
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8.6. Neuropathology of Neuroacanthocytosis 
8.6.1. Background 
NA encompasses a group of genetically heterogeneous disorders characterized by 
neurologic signs and symptoms associated with acanthocytosis, an abnormality of 
red blood cells (246). The autosomal recessive type, called chorea-acanthocytosis 
(ChAc), is the most common form of NA and is linked to the mutations in VPS13A 
gene (251,252,254,255) mapped to chromosome 9q21 and consists of 73 exons 
encoding chroein (255,256). The degeneration of the basal ganglia is a consistent 
feature of NA disorder. On autopsy of NA cases, the cerebral cortex appears 
unaffected.  
8.6.2. Aims and Hypothesis 
Hypothesis 
 The degeneration of the basal ganglia is a consistent feature of NA.   
Aim 
 To review and characterise the neuropathology of an archival, previously 
published NA case using modern methods. 
8.6.3. Methods 
Paraffin blocks representing multiple brain regions from a post mortem case of NA 
were obtained from QSBB and investigated using routine histological and 
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immunohistochemical methods as described in Chapter 2. Details of this case had 
previously been published (case 13 and case 2 respectively)(345,346) but analysis 
using current IHC techniques had never been performed. 
Clinical details and macroscopic description of the brain were obtained from the 
records of the QSBB. Antibodies used for IHC include: ubiquitin (1:200, Dako, 
Ely,UK), tau (1:600, AT8, Autogen Bioclear, Calne, UK); AT100 (1:200, Innogenetics, 
Gent, Belgium), glial fibrillary acidic protein (GFAP; 1:1,000, Dako), Aβ (1:200, 
Dako), α-synuclein (1:50, Novacastra, Newcastle, UK), α-synuclein (1:1000, BD 
Transduction Biolabs, Oxford, UK), P62 (1:100, BD Bioscience, Oxford, UK), CD68 
(1:150, Dako) and TDP-43 (1:2000, Protein Tech, Manchester, UK). 
8.6.4. Results 
The patient was a 56 year old Caucasian male. He was treated for depression aged 
26 and showed behaviour disturbance, personality change and cognitive 
impairment. He developed progressive generalized chorea from the age of 44 years 
when on drug treatment. He was admitted to a psychiatric hospital aged 47 years 
and remained a resident there. He had two generalised tonic-clonic seizures aged 
50 and 51 years. On examination aged 51 years, his verbal and performance IQ’s 
were below his estimated average level. There was a mild impairment of saccadic 
and smooth pursuit eye movements, facial impassivity with mild orofacial 
dyskinesia, occasional blepharospasm and a brisk jaw reflex. Chorea was mild and 
generalized while the patient was on Sulpiride and tetrabenazine with additional 
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severe Parkinsonism and a lurching gait. The small muscles on his hands and feet 
were wasted, tendon reflexes were absent, plantar responses was flexor and 
vibration sense was impaired distally. His Parkinsonism had not resolved three 
months after withdrawal of medication. Laboratory data revealed slightly elevated 
serum creatine kinase level (261 IU/1) and acanthocytes (30%) in peripheral blood. 
Computerised tomography (CT) scan showed mild cerebral and caudate atrophy. 
Electroencephalography (EEG), standard automated perimetry (SAP) and Motor 
Nerve Conduction Velocities (MNCV) were normal, but MAP’s were small and there 
was evidence of denervation on electromyography (EMG). He had a daughter who 
is asymptomatic.  
The macroscopic appearances were in keeping with the clinical diagnosis of NA. At 
autopsy, the fixed brain weighed 1505 grams.  The leptomeninges were thin. There 
was no evidence of herniation at the base. Basal vessels showed a few plaques of 
non-occlusive atheroma. Cranial nerves appeared normal. The caudate nucleus, 
putamen and pallidum were atrophic with brown pigmentation throughout these 
nuclei. The ventricular surface of caudate was concave. The lateral ventricles were 
moderately dilated. Pigmentation of substantia nigra and locus coeruleus was well 
preserved. The pons, medulla and cerebellum were unremarkable.  
Microscopically, neuronal loss and astrocytic gliosis were severe in the caudate 
nucleus and putamen. The globus pallidus was also gliotic but neuronal loss was not 
apparent (Figure 8.1). The thalamus was moderately gliotic but neurons were well 
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preserved. There was mild gliosis and neuronal loss in the substantia nigra and 
locus coeruleus. In the cerebellum, mild Purkinje cell loss was observed in 
cerebellar hemisphere and moderate gliosis was observed in the Bergmann layers 
and white matter. There were occasional empty baskets but no torpedoes.  Diffuse 
iron deposition was detected in the caudate and putamen using Perl’s stain. Tau 
pathology in the form of neurofibrillary tangles and neuropil threads corresponding 
to Braak and Braak stage I was observed in CA1, entorhinal and transentorhinal 
cortex of hippocampus.  A single ubiquitin positive intraneuronal inclusion of 
uncertain nature and significance was observed in the subiculum. Sparse diffuse Aβ 
deposits were observed in cortical regions (frontal, temporal, occipital and 
cingulate) and sparse diffuse plaques in transentorhinal cortex of hippocampus. 
Small vessel disease and cerebral amyloid angiopathy were absent. There was no α-
synuclein or TDP-43 pathology in brainstem or limbic regions respectively. 
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Figure 8.8 Histological findings in hippocampus of neuroacanthocytosis case. Tau pathology in the 
form of neurofibrillary tangles and neuropil threads was observed in CA1, entorhinal and 
transentorhinal cortex (A). Sparse diffuse plaques were observed in transentorhinal cortex (B). 
Scale bar represents 30µm. A: AT8 IHC and B: Aβ IHC. 
 
 
 P a g e  | 195 
 
 
Figure 8.9 Histological findings in caudate (top panel) 
and putamen (bottom panel) of neuroacanthocytosis 
case. Neuronal loss and astrocytic gliosis were severe 
in the caudate nucleus and putamen with iron 
accumulation. Scale bar: A= 60µm, B-F=30 µm. A and 
D: H&E; B and E: GFAP IHC and C and F: Perl’s stain. 
 P a g e  | 196 
 
Table 8.2 Semiquantitative analysis of the IHC stains in a Neuroacanthocytosis case 
 
Regions 
Neuronal 
loss 
Gliosis Tau 
α-
syn 
Aβ Iron 
deposit
-ion 
CAA SVD 
Phospo 
TDP-43 D M 
Cortex    
  
 
 
 
 
  
Frontal - - - - + - - - - - 
Motor - - - - - - - - - - 
Temporal - - - - + - - - - - 
Parietal N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Occipital - - - - ++ - - - - - 
Cingulate - - - - ++ - - - - - 
Insular N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Amygdala - ++ - - - - - - - - 
Hippocampus 
  
  
 
 
 
 
  
Dentate fascia - - - - - - - - - - 
CA4 - - - - - - - - - - 
CA3 - - - - - - - - - - 
CA2 - - - - - - - - - - 
CA1 - - + - - - - - - - 
Subiculum - - + - - - - - - - 
Entorhinal cortex - 
 
+ - - - - - - - 
Transentorhinal 
cortex 
- - + - + 
- 
- - - - 
Caudate +++ +++ - - - - + - - - 
Putamen +++ +++ - - - - + - - - 
Globus pallidus - +++ - - - - - - - - 
Thalamus - - - - - - - - - - 
Subthalamic nucleus - - - - - - - - - - 
Red nucleus - - - - - - - - - - 
IIIrd nerve nucleus N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Substantia nigra + - - - - - - - - - 
Locus coeruleus + - - - - - - - - - 
Pontine nuclei - - - - - - - - - - 
Pontine base white 
matter 
- - - - - - - - - - 
Dorsal motor nucleus 
of vagus 
- - - - - - - - - - 
Twelfth nerve nucleus - - - - - - - - - - 
Inferior olive - - - - - - - - - - 
Cerebellar 
hemisphere Purkinje 
cells 
+ - - - - - - - - - 
Cerebellar 
hemisphere white 
matter 
- ++ - - - - - - - - 
Dentate nucleus - - - - - - - - - - 
N/A: not applicable; -: absent; +: sparse/mild; ++: moderate; +++: severe;  D: diffuse; M: mature; CAA: cerebral amyloid 
angiopathy; SVD: small vessel disease 
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8.6.5. Discussion 
The neuropathological features of clinically diagnosed ChAc reported previously 
include marked atrophy, neuronal loss and gliosis of the caudate nucleus and 
putamen (259,345–351). Chorea is a major clinical feature of  AR and AD ChAc but 
also occurs in HD (352), dentatorubropallidoluysian atrophy (352), HD like-2 
(353,354), neuroferritinopathy (232,355) and pantothenate kinase-associated 
neurodegeneration (222).  
Marked atrophy, neuronal loss and gliosis of the striatum and globus pallidus 
observed in this case is similar to the previous findings in AR and AD-ChAc with 
mutation in VPS13A gene (259,347). Iron accumulation in the brain is a hallmark 
not only in NBIA diseases but is also found in PD and AD (243), and in Huntington's 
disease (356). Iron deposition in the striatum was observed in this case with Perl’s 
positive stain. MRI has demonstrated iron deposition   in the globus pallidus, 
substantia nigra, and red nucleus  along with caudate and putamen in an AR-ChAc 
case (357). This feature was linked to the "eye-of-the-tiger" sign described in PKAN 
and a common pathway responsible for clinical manifestations in both these 
neuroacanthocytosis syndromes, ChAc and PKAN.  
The loss of chorein expression has been suggested as a diagnostic feature of ChAc. 
Experiments using a gene-targeted mouse model of AR-ChAc revealed an increased 
level of gene expression of gephyrin, which is known to be a GABAA receptor-
anchoring protein, in comparison to the wild type controls. Hence, chorein 
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functional loss may lead to a compensatory upregulation of gephyrin and GABRG2 
in the pathologic condition in ChAc (262,358,359). 
The occurrence of acanthocytes is not known and is very likely due to a distinct 
primary cause in each syndrome depending on the respective gene defect. The 
ChAc-associated protein VPS13A apparently plays a role in vesicle tethering along 
the recycling or late endosomal (RE/LE) pathway; late endosomes/lysosomes will 
eventually fuse with autophagosomes to autolysosomes (262). Absence or 
dysfunction of VPS13A may thus interfere with autolysosomal degradation of cargo 
and may lead to accumulation of aggregates. The protrusions and thorns of 
acanthocytes could perhaps be viewed as an arrested state among a multitude of 
continuously changing states of membrane deformation, thus potentially providing 
insights into basic mechanisms of cell biology (262). To determine the 
pathomechanisms underlying the neuropathology of AR-ChAc, further studies of 
ChAc brains are necessary, including analyses of the expression of chorein and 
related molecules.  
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Chapter 9. Lewy bodies (LBs) in Lysosomal storage disorders 
(LSDs) 
 
9.1. Background 
Inherited metabolic disorders which have been linked to lysosomal dysfunction 
belong to a family of diseases identified as sphingolipidoses, a class of LSDs. The 
main members of sphingolipidoses are NPC, Krabbe disease, Gaucher disease, 
Fabry disease, Tay-Sachs disease, Sandhoff diasease and metachromatic 
leukodystrophy. Lysosome is central to the autophagy process, it is not 
unreasonable to assume this pathway is integral in protecting against 
neurodegeneration. LSDs occurring due to the enzyme dysfunction in ceramide 
pathway also develop LB pathology, for example, NPC, Krabbe disease, and 
Gaucher disease. Hence, a possibility is that LSDs, GM1, Tay-Sachs disease, Sandhoff 
disease, Fabry disease and metachromatic leukodystrophy which occur due to the 
enzyme dysfunction in the ceramide pathway may mimic the LB pathology. 
9.2. Aims and Hypothesis 
Hypothesis 
 That LB pathology may be a common feature in the LSDs due to the enzyme 
dysfunction in the ceramide pathway. 
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Aim 
  To assess LB pathology in the LSDs cases (GM1, Tay-Sachs disease, Sandhoff 
disease, Fabry disease and metachromatic leukodystrophy). 
9.3. Methods 
Paraffin blocks (frontal cortex, hippocampus, substantia nigra, pons) for LSDs, 
Leukodystrophy metachromatic, Sandhoff disease, Fabry's disease, Tay-Sachs 
disease, and Gangliosidosis GM1 were obtained from BTDBB and investigated using 
routine histological staining and IHC methods as described in Chapter 2. Antibodies 
used for IHC include: ubiquitin (1:200, Dako, Ely, UK), α-synuclein (1:50, Novacastra, 
Newcastle, UK), α-synuclein (1:1000, BD Transduction Biolabs, Oxford, UK) and P62 
(1:100, BD Bioscience, Oxford, UK). 
9.4. Results 
9.4.1. Clinical data 
Demographics and clinical history are summarized in Table 9.1. 
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Table 9.1 Summary of demographics and clinical data for LSD cases 
Cases 
UMD# 
Sex Ethnicity 
Age at onset, 
years 
Age  at death, 
years 
Clinical diagnosis and neuropathological data* 
1231 M Caucasian 14 60 Leukodystrophy, Metachromatic 
1814 M Caucasian N/A 1 
Sandhoff Disease 
 lost developmental milestones at 13 months 
 macular cherry red spot in both eyes, myopic astigmatism 
4299 M Caucasian 38 50 
Fabry's Disease 
 ruptured basilar aneurysm - subarachnoid hemorrhage, severe brain edema and acute hypoxic 
ischemic encephalopathy 
 neuronal storage and small remote cerebral infarcts 
5094 M Caucasian 3 27 
Tay-Sachs Disease 
 learning difficulties, increased agitation, developmental regression and behaviour difficulties 
 moderate cerebellar atrophy, cerebellar degeneration with storage 
5384 M Caucasian 7 19 
Gangliosidosis, GM1 
 low beta-galactosidase activity 
 slow course of neurodegeneration and seizures 
 global cerebral atrophy (i) neuronal cytoplasmic storage material positive for Luxol fast blue (ii) 
ultrastructural evidence of myelin and few zebra bodies (iii) extensive cortical neuronal loss, 
mild to moderate gliosis, moderate white matter gliosis  
5596 F Caucasian N/A 1 Gangliosidosis, GM1 
N/a: not available, *Derived from the neuropathological report available from BTDBB 
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Case 1, Leukodystrophy, Metachromatic – The case is a Caucasian male 60 years 
old at death. The disease onset was at the age of 14. No further clinical history was 
available. 
Case 2, Sandhoff disease – The case is a Caucasian male 1 year old at death. His 
chromosomal analysis was normal but had very low lysosomal enzyme 
(hexosaminidase A) activity. Opthalmologic examination reported macular cherry 
red spot in both eyes and myopic astigmatism. At 13 months old he lost all the 
developmental milestones achieved. He died from the complications of the 
disorder. Detailed neuropathological examination report was not available but was 
consistent with the presentation of the Sandhoff disease. 
Case 3, Fabry’s disease – The case is a Caucasian male 50 years old diagnosed with 
Fabry’s disease at the age of 38. Neuropathological examination revealed ruptured 
basilar aneurysm causing subarachnoid hemorrhage, severe brain edema and acute 
hypoxic ischemic encephalopathy. Neuronal storage and small remote cerebral 
infarcts were reported. 
Case 4, Tay-Sachs disease - The case is a Caucasian female 27 years old at death 
with a history of late onset Tay - Sachs disease who had mycolonus, behavioural 
problems and seizure like activity. Her presentation was at age 3 when she had 
coordination problems and was diagnosed at age 11. Genetic studies revealed a 
late-onset genetic mutation in father and an unsual mutation in the mother. She 
had learning difficulties and at age 17 she had increased agitation, developmental 
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regression and behaviour difficulties. MRI suggested moderate cerebellar atrophy 
which is consistent with the parent’s clinical history of GM2 deficiency. 
Neuropathological examination of the brain confirmed the diagnosis of GM2 
gangliosidosis. The cerebrum and cerebellum were atrophic and there was 
neuronal and glial storage. The neuronal storage was most severe in the deep gray 
nuclei than in the cerebral cortex. 
Case 5, Gangliosidosis- GM1 – The case is Caucasian male 19 years old at death. He 
was diagnosed with type 2 GM1 gangliosidosis by enzyme testing at the age of 7. 
He developed a slow course of neurodegeneration and seizures. He had no acute 
illines surrounding his death. Neuropathological examination of the brain 
confirmed the clinical diagnosis. The brain weighed 679g (expected 980g) showing 
global cerebral atrophy. Extensive cortical neuronal loss was reported along with 
mild-moderate gliosis of the cortex and the white matter. Neuronal cytoplasmic 
storage materials were positive for Luxol fast blue. 
Case 6, Gangliosidosis- GM1 – The case is Caucasian female 1 year old at death. 
She died from complications of the disorder. No further medical history was 
available. 
9.4.2. Neuropathology  
Using two different α-synuclein antibodies for IHC investigation on all tissues 
sections available for the five LSD cases no cortical or brainstem LBs could be 
identified. 
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Case 1, Leukodystrophy, Metachromatic – Frontal cortex and hippocampus were 
well preserved. There was mild neuronal cell loss in substantia nigra and locus 
coeruleus. LB pathology was negative. 
Case 2, Sandhoff disease – Cortex was well preserved but white matter was pale. 
There was mild neuronal cell loss in hippocampus. Neuronal storage in cells was 
observed in the granule cell layer. LB pathology was negative. 
Case 3, Fabry’s disease – Frontal cortex was well preserved. LB pathology was 
negative. 
Case 4, Tay Sachs disease – Swollen granule cells with neuronal storage were 
observed in hippocampus. LB pathology was negative.  
Case 5, Gangliosidosis- GM1 – there was mild neuronal cell loss in the frontal 
cortex with swollen neurons. The hippocampus was well preserved. Substantia 
nigra showed loss of pigmentation in the neuronal cells. LB pathology was negative. 
Case 6, Gangliosidosis- GM1 – There was mild neuronal loss in the frontal cortex. 
LB pathology was negative. 
9.5. Discussion 
Deposition of filmentous α-synuclein in the neuronal or glial cytoplasm is a 
common pathological feature of many neurological diseases, such as PD, dementia 
with LBs, multiple system atrophy and NBIA. Animal models developed in mice and 
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flies have shown that the overexpression of α-synuclein leads to the formation of 
both filamentous and granular aggregates. It has been shown that that cells are 
capable of clearing preformed α-synuclein aggregates via the lysosomal 
degradation pathway (360), blocking this pathway causes the accumulation of the 
α-synuclein aggregates in cells. It is suggested that once formed, the α-synuclein 
inclusions are refractory to clearance (361). The link between lysosomal 
malfunction has been associated with age-related neurodegenerative disorders and 
inhibition of the lysosomal enzymes leads to features such as protein deposition, 
synaptic loss and neuronal death (361). Lysosomes are a critical component for all 
forms of autophagy and auto-phagy-mediated clearance of damaged proteins is 
particularly important for neuronal survival. Impaired autophagy is observed in 
patients with LSDs (362). LSDs comprise mainly of sphingolipidoses, are a group of 
monogenic inherited diseases caused by defects in the proteins involved in the 
lysosomal sphingolipid degradation, with subsequent accumulation of non-
degradable storage material in one or more organs (273).  
The hypothesis that if LSDs, NPC, Gaucher disease and Krabbe disease in the 
ceramide pathway have shown LB pathology, other LSDs along the pathway 
impinging on to ceramide may mimic the pathology. However, neuropathological 
study of a case each of GM1 gangliosidosis, Tay-Sachs disease, Sandhoff disease, 
Fabry disease and metachromatic leukodystrophy was negative for alpha-synuclein 
deposition. The reasons could be (a) the LSDs we included in this study are not 
directly impinging on to the ceramide where as LSDs which are related to α-
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synuclein deposition in the literature (Gaucher disease, NPC and Krabbe disease) 
are directly related or impinging on to free ceramide synthesis (Figure 1.10). In 
Gaucher, NPC and Krabbe diseases, the role of the respective metabolic enzyme 
defect appears to be more crucial for LB formation and these enzymes produce the 
free ceramide. Hence LB formation may be a response to the direct stress in 
ceramide synthesis. (b) The life span necessary for LB formation may not be 
sufficient.  The age in the cohort varied from 1 to 60 years old at death. In NPC 
cases, classic LBs were observed in cases as young as 23 years old at death. Cases 
below that age showed diffuse immunoreactivity with threads and dots and pre-LBs 
scattered (283). However, neurodegenerative diseases with tau-based inclusions 
have been shown to increase the α-synuclein inclusions and tau pathology has been 
described in NPC cases (283,363). Hence, the GM1 gangliosidosis and Sandhoff 
cases aged 1 at death may not have enough life span to develop LBs. The absence 
of LBs in the other cases aged 19, 27, 50 and 60 years at death can also be 
attributed to the age factors as in normal human controls LBs tend to appear after 
60 years old. However, in the latter two cases, if LBs are the hallmark of their 
respective diseases pre-LBs or diffuse α-synuclein immunoreactivity in the 
predicted brain regions would have been expected. Hence, this study concludes 
that LBs cannot be considered as a hallmark of all LSDs with enzyme defects in the 
ceramide pathway.   
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Chapter 10. Sumary and future directions 
 
Neuropathology has been the key in understanding the aetiologyl of many 
neurological disorders such as AD, PD, frontotemporal degeneration and cerebellar 
ataxias. Dystonia shares many clinical features with these conditions but research 
in general, has been unrewarding in providing information on disease processes. 
Neuropathological studies in dystonia cases are few in number and only limited 
morphological abnormalities have been described. The aim of this project was to 
understand the neuropathology of rare genetic neurological disorders, in particular 
dystonia. To address this, we designed experiments to explain the following 
questions: 
 Do perinuclear neuronal inclusions represent a hallmark lesion in primary 
pure dystonia, DYT1 and DYT6? 
 Does a common theme in the pathogenesis of primary dystonia exist? 
 Does interaction takes place between the two primary dystonia genes in 
human CNS? 
 Are non-coding mutations important in understanding disease pathology 
(with an example of primary plus dystonia, DYT5 cohort)? 
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 Can we draw the relationship between the repeat lengths and disease 
pathogenesis in secondary dystonia (with an example of SCA8 repeats in 
ataxia cohort)? 
 Does WDR45 gene provide a link between neurodegeneration and 
autophagy (with an example of secondary dystonia, BPAN)? 
 Can we expect common disease pathology for disorders in a common 
pathway (with an example of LSDs in ceramide pathway)? 
The work performed in this thesis, I have: 
 Determined that primary pure dystonia cases lack a neuropathological 
hallmark and that the perinuclear neuronal cytoplasmic inclusions are not a 
consistent feature of the disorder.  
 Demonstrated that the interaction between two primary dystonia genes 
may exist in basal ganglia but the cohort is too small to draw a firm 
conclusion. 
 Identified the importance of understanding the pathogeneity of genetic 
mutations or repeat lengths. In DRD, non-coding mutations in 5’UTR of 
GCH1 needs consideration but it is important to understand the functional 
aspects of the mutation before giving a ‘disease causing’ status. Repeat 
lengths in SCA8 may provide a basis to determine the affected individuals 
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but it should not be the only way to determine the disease in genetic 
testing.  
 Determined that autophagy is directly linked to neurodegeneration in a case 
of BPAN. 
 Demonstrated that even a small change may contribute to the disease 
pathology and that a common pathology may not exist for disorders due to 
enzyme dysfunction in the same pathway. 
When I began this project, there were limited neuropathological reports available 
for the DYT1 cases. In addition, the first report demonstrating the perinuclear 
inclusion in DYT1 cases (129) was published 10 years ago. Between the first paper 
and when I began to investigate the neuropathology of DYT1 cases, no other 
pathological reports are available for DYT1 cases. The neuropathology of DYT6 case 
is the first ever detailed neuropathological investigation carried out to our 
knowledge. Therefore, the work in this thesis contributes to the field of dystonia. 
10.1. Summary for primary pure dystonias (DYT1 and DYT6)  
There is accumulating evidence for genetic and clinical heterogeneity in primary 
dystonia. There has been an unprecedented advance in our understanding of the 
primary and secondary dystonia syndromes with the speed of genetic discoveries. 
However, many of the new genes identified have yet to be independently 
confirmed and their prevalence as a cause of dystonia is as yet unclear to avoid 
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duplication. For example, mutations in PRRT2 were identified as the cause of PKD 
and defined as a locus, DYT10. However, mutation in the gene was also found in 
the family used to define DYT19 which is a separate form of PKD, suggesting that 
the initial linkage in this family was incorrect and DYT19 is in fact synonymous with 
DYT10 (364). Owing to the serious shortcomings with assigning the DYTn loci based 
on statistical associations (314), the new classification system highlights the 
importance of biological phenomena in understanding the disorders. By combining 
phenomenology and biological mechanism in the same classification, it becomes 
easier for diagnostic testing and clinical recognition of dystonia syndromes.  This 
will also help to keep the clinical practice and scientific discoveries at the same 
pace. The findings in this thesis will contribute towards classifying primary pure 
dystonia cases, DYT1 and DYT6 based on etiology.  
Neuropathological studies in dystonia are sparse, partly due to the low availability 
of post-mortem tissue from these patients and the labour intensive nature of 
exploratory neurological examination of the entire human brain. This study 
documents a series of neuropathological findings from the largest cohort of 
genetically confirmed primary pure dystonia (DYT1-7 cases and DYT6-2 cases) cases 
ever evaluated. Using the immunohistochemical staining battery NFTs, LBs, beta-
amyloid plaques, SVD, CAA, neuronal loss, gliosis and axonal swellings noted in 
both cohorts of DYT1 and DYT6 cases, respectively are comparable to the age and 
sex matched human control brains and observed in symptomatic and non-
manifestating carriers as well. No consistent abnormality or perinuclear inclusions 
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previously described was detected to link directly to the pathogenicity of the 
disease in brain regions implicated. The absence of neurodegeneration in primary 
dystonia, as well as observations that lesions of brain regions other than the basal 
ganglia can lead to secondary dystonia, have led to the concept of dystonia as a 
neuro-functional disorder. This study supports the notion that dystonia is a motor 
system disorder rather than a disease of a particular motor structure.  
The increasing knowledge of proteins whose mutant forms cause dystonia has 
implicated a large number of neurobiological pathways that lead to dystonic 
movements. A number of themes have emerged that have been identified from 
abnormal transcription and cell cycle because of the nuclear effects of dystonia 
genes to endoplasmic reticulum dysfunction and synaptic abnormalities (365). The 
EFNS dystonia classification system (13) put these dystonia genes (TOR1A, THAP1, 
CIZ1, TUBB4, or GNAL) in one class of primary pure dystonia. Hence it seems right 
to seek common pathways that may represent targets for therapeutic strategies for 
this movement disorder. However, it may also lead to oversimplification in the 
search for unifying mechanisms. Most cases of dystonia are primary and not 
associated with neuronal death. Thus the pathogenic mechanisms may be subtle 
and only cause relatively mild defects in the relevant pathways, leading to 
abnormal processing of the motor command within the CNS. A common pathology 
for dystonias classified based on the clinical characteristics and statistical 
significance is not always possible as understanding the biological phenomenon is 
an important aspect in any disorder. The current dystonia classification system may 
 P a g e  | 212 
provide new insights into the disorders by combining the clinical and etiological 
characteristics of dystonia. For neuropathological diagnostics of dystonia,  it is not 
only necessary to have a good understanding of the functional anatomy of the 
basal ganglia, but also of a wider network view that includes other structures 
(amongst others the cerebellum). In case of primary dystonia, subtle changes in the 
brain need consideration and traditional neuropathological methods may not be 
sufficient to identify those changes. Hence, there is a need to develop experimental 
procedures to quantify or analyse these changes. 
Protein-protein interactions (PPI) operate at every level of cellular function and are 
involved in almost all cellular processes. The correct identification of these 
interactions is important to systematically understand the roles played by cellular 
proteins in diverse biological functions. Consequently, the prediction of PPI has 
emerged recently as an important element in the fields of bioinformatics and 
systems biology. In DYT6 cases, a significant difference in the expression of TOR1A 
and THAP1 was observed in putamen of a DYT6 cohort supporting the hypothesis 
that THAP1 represses the expression of TOR1A in CNS. However, we also should 
keep in consideration the surrounding proteins THAP1 and TOR1A are likely to 
interact with and that these proteins may act as modifiers. THAP1 has been shown 
to bind to the promoter region of a TAF1 transcript and it will be interesting to see 
if THAP1 and TAF1 gene show any potential functional link to associate with the 
clinical phenotype presented for each dystonia type. TorsinA has been shown as 
having a close association with α-synuclein in LBs (366) where presence of torsinA 
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in LBs can be a consequence of its role in identifying and interacting with abnormal 
proteins that must be cleared by the cell. Furthermore, a better understanding of 
THAP1 and TOR1A protein function and cellular pathogenicity may address the 
interaction more precisely to improve our understanding of diseases and can also 
serve as the basis for new therapeutic approaches. 
Limitations 
The main limitation of the neuropathological investigation in dystonia has been the 
availability of the post-mortem cases. Hence it would be ideal to increase the 
number of cases. However, the drawback is more clinical. The low penetrance of 
primary dystonia genes may leave the cases undiagnosed as the symptoms can be 
mild. This calls for widening the clinical sprectrum to qualify for genetic testing of 
DYT1 and DYT6.  
The other limitation working with the post-mortem cases is the availability of the 
brain regions of interest and this hinders the systematic sampling across the cohort. 
Also the dystonia cohort studied here consisted of cases received from three 
brainbanks (QSBB, HBB, BTDBB). Each brainbank has its own brain sectioning 
protocol. Therefore, brain regions available for each case varied and were in 
variable plane of section. Hence, robust comparision of the neuropathological 
findings across the cohort was not possible. 
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The main drawback of the neuropathological study was the unavailability of torsinA 
and THAP1 antibodies to assess the presence or absence of the torsinA/THAP1 
positive inclusions (discussed in detail in Chapter 5). Optimizing new antibodies is 
always a challenge but reliable human specific antibodies would have given this 
project a new dimension.  
The limitation of using the post-mortem tissue for expression analysis is the 
preservation of the RNA quality. SYBR green is a cheap and efficient method for 
analysing the mRNA expression. However, the reliability and accuracy has often 
been questioned.  
10.2. Summary for non-coding 5’UTR mutation in DYT5 dystonia 
Medical research has primarily focused on protein-coding variants, due to the 
difficulty of interpreting non-coding mutations. As technologies evolved over the 
past century, genetic studies are not limited to studying Mendelian disorders and 
can tackle more complex phenotypes.  For example, genome-wide association 
studies (GWAS) have provided genome-wide information about the genetic basis of 
the complex disease across unrelated individuals for common variants associated 
with complex disease and diverse molecular phenotype (367,368).   
In this regard, the hypothesis for this project was established; if the non-coding 
mutations in the 5’UTR of the GCH1 gene (181) underlie the clinical manifestation. 
The cohort consisted of clinically categorized DRD5 cases with GCH1 mutation 
spectrum negative for GCH1 coding mutations. Two unrelated cases were identified 
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with both -39C>T and -132C>T mutations in the 5’ UTR of GCH1. However, one of 
the cases has an affected sibling without these mutations (described in detail in 
Chapter 6). Functional study identified negligible effect of two mutations (181). 
Hence, in the DRD cohort studied, there is not enough evidence to conclude that 
the two non-coding variants underlie the disease manifestation.  
Study of evolutionary conservation, functional genomics, sequence motifs, and 
molecular quantitative trait loci are important in predicting a function of a non-
coding variant and relating it to the disease. The list of non-coding variants 
implicated in human disease will expand from GWAS and whole-genome 
sequencing technologies. However, there is a need to integrate the genomic data 
with the functional maps to implicate the pathways and proteins interacting 
thereby. This will help to replicate the protein interactions experimentally in the 
scientific laboratories and analyse the pathogenicity of the non-coding variants 
underlying complex diseases. 
Limitation 
The unavailability of the recent clinical details for the siblings considered in this 
study has restricted the current prognosis.  
10.3. Summary for SCA8 
SCA8 was the first repeat expansion (CAG or CTG) identified in an untranslated 
region. Potentially pathogenic alleles contain 85 or more combined CTA/CTG 
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repeats. However, repeats of this size are surprisingly frequent in the general 
population and also occur in asymptomatic relatives of ataxia individuals 
(197,204,206,211,340). In the ataxia cohort investigated, the significant difference 
(p= 0.018) in the occurrence of SCA8 repeat expansions in ataxia patients compared 
with English controls but not with the diversity controls (p= 0.192) suggests that the 
pathogenicity of SCA8 repeat expansion is not only dependent on the repeat size 
but also on the population, environment and the genetic modifiers. 
 The complex pattern of inheritance has resulted in unaffected carriers commonly 
having repeat sizes that exceed the pathogenic threshold making it difficult to 
ascertain clear ranges for pathogenic expansion (199,208). SCA8 may rarely coexist 
with SCA6 (339) or SCA1 (341) which makes it difficult to assign symptoms to a 
specific entity. These data demonstrate that the presence of a SCA8 expansion 
cannot be used to predict whether or not an asymptomatic individual will develop 
ataxia as the control cases were asymptomatic at the time of study. 
However, two cases with SCA8 repeat in the large intermiediate range, 83 and 84 
respectively, are in the borderline of the marked pathogenic ranges and were also 
looked into. They showed all the above clinical criteria for SCA8. The brain MRI in 
one case showed features consistent with diagnosis of MSA and another case was 
diagnosed as MSA. Hence, SCA8 expansion may be a susceptibility factor for MSA. 
This data suggests that SCA8 repeat expansion length should not be the sole 
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method for diagnostic purposes and patients with progressive cerebellar ataxia 
may develop other neurodegenerative disease with time.  
10.4. Summary for BPAN 
This study reports a 51 years old female with a de novo mutation in exon 9 of 
WDR45. The disease onset was in childhood characterized by global developmental 
delay and intellectual deficiency in early childhood then followed by further 
neurological and cognitive regression in late adolescence or early adulthood, with 
dystonia, and sometimes ocular defects and sleep perturbation. The clinical pattern 
of the case studied here matches to other BPAN cases described (229,237,342). 
BPAN is the only X-linked NBIA described in literature with de novo mutations in the 
WDR45 gene causing loss of function of the encoded protein; even though the gene 
is at the chromosome X, males and females present the same clinical phenotype, 
which seems to be due to somatic mosaicism or skewing of the X chromosome 
inactivation (229).   
PKAN and PLAN are the most common forms of NBIA disorders and PKAN alone 
accounts for 50% of the all NBIA disorders (342). In PKAN the pathology of the 
disease was almost exclusively located in the CNS and particularly in the globus 
pallidus represented by reactive astrocytes, numerous large and granular 
spheroids, axonal swellings and iron accumulation (223). In PLAN cases, cerebellar 
cortical atrophy has been a consistent feature in MRI. Iron accumulation in the 
globus pallidus can be the main feature in atypical cases but is not a consistent 
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feature in the infantile cases (342).  Neuropathological changes have been reported 
throughtout the CNS, with tau pathology, diffuse α-synuclein positive-LBs in 
neocortex, depletion of cerebellar granular and Purkinje cells, and numerous axonal 
swellings and spheroid bodies (342).  
Neuropathologically, BPAN and PKAN have similarities with the following 
characteristics: (a) iron accumulation in basal ganglia is a similar and consistent 
feature (b) neither are synucleinopathies and (c) tau pathology is present in both. 
However, BPAN differentiates from PKAN by predominance of substantia nigra iron 
over that seen in globus pallidus which is reverse in the latter and in PLAN iron 
accumulates more equally in these structures. In BPAN the substantia nigra is 
discoloured but in PKAN the globus pallidus is discoloured. The tau pathology 
observed in BPAN resembles that observed in AD cases (ie. 3R and 4R repeats). 
However, a close relationship has been suggested between PLAN and PD. 
BPAN may provide a link between tau pathology, autophagy impairment, and 
neurodegeneration. This study supports the involvement of beta–propeller protein 
(encoded by WDR45  gene) in autophagy as has been documented in yeast and 
mammalian cells (245). The increased accumulation of LC3-II protein in brain tissue 
of the BPAN case compared to the three control cases implies that the 
autophagosome formation is hindered. However, the role of iron in this process is 
yet to be understood.   
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The autophagic process is induced to clear damaged cellular components and by-
products of the stress response by cells. Defective autophagy would leave damaged 
cells compromised and at risk of perpetuating further damage to neighbouring 
cells. In brain, neurological deterioration is inevitable after a threshold of cellular 
functional impairment is exceeded. But the precise mechanism by which the beta-
propeller protein that is encoded by WDR45 serves the autophagic process remains 
to be elucidated.  
In conclusion, significant basal ganglia pathology was observed on neuroimaging, 
histology and IHC. The extensive phospo-tau pathology observed were similar as 
tau deposits reported in AD cases. The higher autophagy flux indicated by the LC3 
blot suggests that the WDR45 protein participates in autophagy. Though the 
precise steps in autophagy are not known yet, BPAN provides a direct link between 
autophagy and neurodegeneration. It would be interesting to elucidate the role of 
iron in this mechanism. 
NA 
PKAN may be classified as NBIA and NA syndromes as both brain iron accumulation 
and acanthocytes are found (262). However, in the BPAN case studied acanthocytes 
were not reported. Cell membrane research may shed light upon the significance of 
the erythrocyte abnormality, and upon possible connections between PKAN and 
NA. 
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10.5. Summary for LSDs and LBs 
A great deal of attention has been focused on the assignment of the genetic locus 
on the clinical basis. However, to identify the pathways of pathogenicity for a given 
disorder, arguably, one should start by analyzing the genetics of disease based on 
pathology. The pathological studies are more likely helpful in finding a common 
pathway if there is a common pathology rather than common clinical 
characteristics. In this regard, LSDs sharing a role in the ceramide metabolism are 
discussed based on Figure 1.9. 
The hypothesis that if LSDs (NPC disease, Gaucher disease and Krabbe disease) due 
to mutations encoding enzyme components in the ceramide pathway have LB 
pathology, other LSDs associated with further components of the same pathway 
impinging on ceramide may result in similar pathological changes. Alpha-synuclein 
immunohistochemical staining of a case each of GM1 gangliosidosis, Tay-Sach 
disease, Sandhoff disease, Fabry disease and metachromatic leukodystrophy was 
negative for alpha-synuclein deposition.  
This study concludes that diseases with gene defects influencing the same pathway 
may not result in similar pathology. As in the ceramide pathway, metabolic 
enzymes defective for each of the diseases have a role in breaking down 
monosaccharides into simpler forms but are not involved directly in producing free 
ceramide except in NPC, Gaucher and Krabbe disease. This puts an emphasis on a 
role of free ceramide in LB formation and that LBs are a response to the stress 
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created by the free ceramide in the cells. If LB pathology is the hallmark of the 
disease, it may only become apparent in those dying at advanced age. In NPC cases, 
α-synuclein immunoreactivity has been observed in a case as young as 3 years old. 
However, neurodegenerative diseases with tau-based inclusions have been shown 
to increase the α-synuclein inclusions and tau has been described in NPC cases 
(283,363). 
The overall level of ceramides in a cell is a balance between the need for 
sphingosine and sphingosine derivatives, such as sphingosine-1-phosphate, and the 
sphingomyelins. With respect to the sphingomyelins they serve a dual purpose of 
being important membrane phospholipids and as a reservoir for ceramides. In the 
nervous system, neurons are polarized cells and their normal functions, such as 
neuronal connectivity and synaptic transmission rely on selective trafficking of 
molecules across plasma membrane.  Small changes in the molecular structure of 
ceramide can regulate its biological function and can contribute in development of 
age-related, neurological and neuroinflammatory disease (369,370). The 
abundance of sphingolipids on neural cellular membranes makes them a potent 
regulator of brain homeostasis.  
10.6. Conclusion 
Statistical significance is not sufficient to link a disorder with the genetic mutation. 
Establishing the pathogenesis bears relevance not only to researchers but also to 
the clinicians. There are pathological and shared mechanisms which overlap with 
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dystonia and other common neurological disorders such as tau, α-synucleinopathy 
and autophagy. For example, torsinA shows a close relationship with α-synuclein in 
LBs; LBs are a result of the stress created by defective enzyme in free ceramide 
synthesis; in BPAN, defective autophagy may result in tau accumulation; and 
autophagic flux may produce acanthocytic protrusion in NA. Hence, understanding 
the cellular pathology of these shared mechanisms may provide some insights into 
pathogenesis of each disorder. 
10.7. Future directions 
In this thesis, I investigated genetics and neuropathology of primary (DYT1, DYT6, 
DYT5) and secondary (SCA8, BPAN, NA, LSDs) dystonias. Given the obstacles 
encountered, one might question whether it is worthwhile to further investigate 
for pathological hallmarks in primary dystonia. This thesis provides a basis for the 
absence of a pathological hallmark in primary pure dystonia. However, it also 
highlights that the current histological and IHC methods are not sufficient to 
identify the subtle changes in the brain leading to neurodegeneration. What is 
important in the future is to take time and design species-specific antibodies and 
experiments to identify and quantify these subtle changes in the brain.  To 
investigate the PPI it is important to understand the function of the protein under 
consideration. The ultrastructural localization and function of torsinA and THAP1 
are not known yet. Hence, cellular characteristic and pathology of these proteins 
should be of prior concern.  
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A recent technology that has opened new horizons in the generation of cellular 
disease models in the induction of pluripotent stem (iPS) cells from patient skin 
fibroblast (321,322). The resultant iPS cells were shown to behave similar to human 
embryonic system (hES) cells  in terms of biomarker expression and differentiation 
potential but retained any mutations present in the genome of the donor cell (371), 
which makes them suitable for modelling of genetic diseases.  This technology 
offers breaking down a complex genetic disease involving multiple brain areas into 
its constituent neurons and studying their particular pathology. A cellular pathology 
resultant from the particular mutation is essential to understand, as cells and their 
interactions are the key determinant of the motor output and may provide a link 
for the genetic defect to the observed motor symptoms. However, high level of 
control in the in vitro system can lead to observations being artefacts of culture 
conditions and not true features of the disease. Hence, cellular pathology should be 
integrated with the clinical, molecular and pathological presentations of the genetic 
disorder to provide a therapeutic approach.  
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Publications associated with this thesis 
 Paudel R, Hardy J, Revesz T, Holton JL, Houlden H. Review: genetics and 
neuropathology of primary pure dystonia. Neuropathol Appl Neurobiol. 
2012 Oct;38(6):520–34. 
 Paudel R, Kiely A, Li A, Lashley T, Bandopadhyay R, Hardy J, Jinnah HA, 
Bhatia K, Houlden H, Holton JL. Neuropathological features of genetically 
confirmed DYT1 dystonia: investigating disease-specific inclusions. Acta 
Neuropathol Commun. 2014 Nov 18;2(1):159. 
 Neuropathology of genetically confirmed DYT6. Ready to submit. 
 Neuropathology of a BPAN case. (Drafting) 
 SCA8 repeats in ataxia patients (Drafting) 
Co-authored publications during this time 
 Pure cerebellar ataxia in an Indian consanguineous family caused by a novel 
homozygous mutation in PNPLA6 (Drafting). 
 Houlden H, Schneider SA, Paudel R, Melchers A, Schwingenschuh P, 
Edwards M, et al. THAP1 mutations (DYT6) are an additional cause of early-
onset dystonia. Neurology. 2010 Mar 8; 74 (10):846–50. 
 Kruer MC, Salih MA, Mooney C, Alzahrani J, Elmalik SA, Kabiraj MM, Khan 
AO, Paudel R, Houlden H, Azzedine H, Alkuraya F. C19orf12 mutation leads 
to a pallido-pyramidal syndrome. Gene. 2014 Mar 10;537 (2):352-6. 
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 Xiromerisiou G, Houlden H, Scarmeas N, Stamelou M, Kara E, Hardy J, Lees 
AJ, Korlipara P, Limousin P, Paudel R, Hadjigeorgiou GM, Bhatia KP. THAP1 
mutations and dystonia phenotypes: genotype phenotype correlations. Mov 
Disord. 2012 Sep 1;27 (10):1290-4. 
 Kruer MC, Paudel R, Wagoner W, Sanford L, Kara E, Gregory A, Foltynie T, 
Lees A, Bhatia K, Hardy J, Hayflick SJ, Houlden H.Analysis of ATP13A2 in large 
neurodegeneration with brain iron accumulation (NBIA) and dystonia-
parkinsonism cohorts. Neurosci Lett. 2012 Aug 8;523 (1):35-8. 
 Hersheson J, Mencacci NE, Davis M, MacDonald N, Trabzuni D, Ryten M, 
Pittman A, Paudel R, Kara E, Fawcett K, Plagnol V, Bhatia KP, Medlar AJ, 
Stanescu HC, Hardy J, Kleta R, Wood NW, Houlden H. Mutations in the 
autoregulatory domain of β-tubulin 4a cause hereditary dystonia. Ann 
Neurol. 2013 Apr;73 (4):546-53. 
 Koutsis G, Pemble S, Sweeney MG, Paudel R, Wood NW, Panas M, Kladi A, 
Houlden H. Analysis of spinocerebellar ataxias due to expanded triplet 
repeats in Greek patients with cerebellar ataxia. J Neurol Sci. 2012 Jul 
15;318 (1-2):178-80.  
 Li A, Paudel R, Johnson R, Courtney R, Lees AJ, Holton JL, Hardy J, Revesz T, 
Houlden H. Pantothenate kinase-associated neurodegeneration is not a 
synucleinopathy. Neuropathol Appl Neurobiol. 2012 Mar 15. 
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